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Krithika Rajaram  
A STUDY OF HOST-CHLAMYDIAL INTERACTIONS MEDIATED BY 
INTERFERON-GAMMA AND NITRIC OXIDE  
 
 The host response towards chlamydial infection mobilizes elements of 
both innate and adaptive immunity, culminating in the production of the Th1 
cytokine interferon-gamma (IFN-γ). IFN-γ induces a variety of anti-chlamydial 
programs, many of which are unique to either humans or mice. Consequently, 
the human pathogen Chlamydia trachomatis and its near-identical murine relative 
C. muridarum have evolved to survive and cause disease in their respective 
hosts. Understanding the mechanisms that contribute to chlamydial niche 
specificity will facilitate the creation of improved mouse models for the study of 
human chlamydial disease. To this end, we examined a small chlamydial 
genomic region of extreme divergence called the Plasticity Zone (PZ) in C. 
muridarum for its alleged roles in host specificity and virulence. Using a newly 
adapted reverse genetic technique, we determined that much of the PZ is in fact 
dispensable in the murine genital tract. We concomitantly embarked on a screen 
for C. muridarum mutants that were no longer resistant to IFN-γ and uncovered a 
gain-of-function mutation in an ORF outside the PZ that led to dramatic 
attenuation in mice.  
 IFN-γ is secreted by multiple cell types including macrophages, which 
participate in  innate as well as adaptive immune responses. IFNγ-dependent and 
-independent defense mechanisms mounted by macrophages contribute 
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significantly to bacterial clearance. Specifically, the amount of nitric oxide (NO) 
produced by macrophages in response to different infectious doses determines 
infection outcome in mice. We discovered that the in vivo regulation of infection 
by NO is also replicated in cell culture. Murine macrophage cell lines infected at 
high multiplicities of infection cause chlamydial death because of a massive NO 
response that is triggered by elevated levels of reactive oxygen species (ROS) 
and lysosomal cathepsin B activity. 
 Taken together, our work elucidates the mechanisms behind important 
host and chlamydial defense strategies, offering insight into the evolutionary 
adaptations that are a consequence of the relentless host-pathogen arms race.  
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CHAPTER 1 
INTRODUCTION 
Now, here, you see, it takes all the running you can do, just 
to keep in the same place. The Red Queen in Lewis 
Carroll’s Alice in Wonderland. 
 
 
 About 2 billion years ago, seas of bacteria witnessed the arrival of 
predatory eukaryotes that immediately imposed upon them an enormous 
evolutionary challenge. Protozoan ancestors drove their prey to acquire or evolve 
genes that allowed survival within the predator and sometimes even exploitation 
of the new host, thus paving the way for the emergence of intracellular bacteria. 
The genomes of both host and intracellular bacterium have since been 
continually shaped by their association. Microorganisms of the phylum 
Chlamydiae are obligate intracellular bacteria that have their beginnings in the 
cytoplasm of primordial amoebae. While many of them still maintain 
endosymbiotic relationships with free-living amoebae, the best-known chlamydial 
species are important pathogens of humans and animals. In this chapter, I will 
introduce prominent members of the Chlamydiae, their exclusive lifestyle within 
eukaryotic cells, and the defense and counter-defense strategies evolved by the 
host and pathogen, respectively. 
 
1.1 A brief history of Chlamydiae 
 Chlamydia trachomatis bears the distinction of being the first identified 
species of the phylum Chlamydiae. Originally discovered as the causative agent 
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of a blinding disease called trachoma, C. trachomatis has since also been 
recognized as a leading cause of human sexually transmitted disease (STD). 
The earliest mention of trachoma dates back to ancient China in 2600 B.C. and 
was discussed in the Hippocratic Corpus around 5 B.C. (1). By the nineteenth 
century, the disease was pandemic in the New World and Europe. However, the 
agent of trachoma was identified only in 1907 when Halberstaedter and 
Prowazek, on a scientific expedition in Java, discovered inclusion bodies within 
the cytoplasm of conjunctival epithelial cells from apes and humans with 
trachoma. In the following years, similar inclusion bodies were observed in 
patients suffering from urogenital infections, thus linking trachoma and sexually 
transmitted disease. Due to its small size and inability to grow outside of living 
cells, Chlamydia trachomatis was thought to be a virus for several decades. The 
discovery that it contained both DNA and RNA and was susceptible to antibiotics 
in the 1960s led to its reclassification as a bacterium (1).  
 The sequencing revolution in the 1990s brought with it an explosion of 
data with many sequences bearing considerable similarity to C. trachomatis (Fig.  
1.1) (2, 3). The number of chlamydial families has increased from 1 to 8 in the 
last two decades. 16S rRNA phylogenetic analysis of chlamydial species 
revealed that these organisms are a deeply branching group within the 
phylogenetic tree of eubacteria, with only very remote relationships to other taxa 
(3). Chlamydia-like organisms have been recovered from various hosts including 
protists, birds, fish, reptiles and mammals. Regardless of origin, all characterized 
species appear to lead strict intracellular lifestyles. 
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1.2 Chlamydia trachomatis and its relatives  
 C. trachomatis is grouped into 15 serovars based on antigenic variation of 
the major outer membrane protein (MOMP) (4). The serovars exhibit unique 
tissue tropisms and varying disease presentation (5). Ocular serovars A - C are 
endemic in developing regions of the world where poor hygiene and poverty 
prevail. Repeat infections of the conjunctival epithelium can lead to scarring of 
the eye and trichiasis, and the resulting corneal damage can cause blindness. 
Infection of columnar epithelial cells in the genital tract by sexually transmitted 
serovars D - K can be asymptomatic or can lead to urethritis, cervicitis and 
epididymitis. Complications in women typically arise from untreated or persistent 
infections and reinfections to cause pelvic inflammatory disease (PID). Patients 
with PID are at increased risk for infertility, miscarriage and ectopic pregnancy. 
Serovars L1 – L3 are also sexually transmitted, but can invade the mucosal 
epithelia to attack lymphatic tissues resulting in a serious, systemic disease 
referred to as lymphogranuloma venereum (LGV) (5). Laboratory studies of C. 
trachomatis infections often employ primate models, or alternatively, utilize the C. 
trachomatis mouse agent of pneumonitis, recently renamed C. muridarum, in a 
mouse genital tract (GT) model of infection (6). Chlamydia pneumoniae is 
another ubiquitous pathogen that is a common cause of human and animal 
respiratory infections and is increasingly associated with a number of chronic 
illnesses including asthma, chronic obstructive pulmonary disease (COPD), 
atherosclerosis and Alzheimer’s disease (7). On rare occasions, other species of 
Chlamydia that are primarily animal pathogens, such as C. psittaci and C. 
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abortus, can be zoonotically transmitted to humans. C. psittaci, acquired from 
feral birds and domestic poultry, can cause life-threatening pulmonary respiratory 
infections (8) and is classified as a CDC biothreat agent.  
 
1.3 Intracellular life of Chlamydia 
1.3.1 Developmental cycle 
 All recognized Chlamydia spp. exhibit a biphasic developmental cycle 
(Fig. 1.2) where the organism alternates between the elementary body (EB) and 
the reticulate body (RB) (Fig. 1.3) (9). The EB are small, extracellular infectious 
particles protected by a cysteine-rich protein coat. They have a highly condensed 
nucleus and were long thought to be metabolically inactive. Recent studies have 
challenged this dogma by demonstrating that EB are capable of moderate levels 
of respiratory activity and glucose metabolism (3, 10). To establish an 
intracellular infection, unknown EB ligands bind to receptors on target epithelial 
cells to facilitate endocytosis of the pathogen. Upon entry, the EB-containing 
phagosome dissociates from the endocytic pathway and remains in the cytosol 
as a parasitophorous vacuole referred to as an ‘inclusion’. At 2 to 3 hours post 
infection, the EB begins its transformation into the larger, reticulate body 
concomitant with decondensation of the chromosome and reduction of the outer 
membrane disulfide bonds. During the replicative stage, RB undergo repeated 
divisions by binary fission while decorating the inclusion membrane with 
chlamydial proteins that are presumably involved in nutrient trafficking and 
immune evasion. At around 18 to 24 hours post infection, the RB begin their 
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differentiation to EB. The cellular signals that initiate these developmental 
transitions have not been identified. Between 24 to 48 hours depending on the 
chlamydial species, the mature inclusion primarily contains EB. The EB escape 
the host cell either by rupturing the inclusion and host cell membranes, or by 
extrusion of the inclusion, and they then proceed to infect neighboring cells (9).  
 
1.3.2 Subversion of host metabolism 
 Chlamydiae modulate multiple host cellular pathways in order to secure 
their residence in the cytosol. Entry into host cells is facilitated by the recruitment 
of host actin cytoskeleton or alternatively by lipid raft-mediated processes (11-
13). Within the first several minutes, chlamydial endosomes are stripped of early 
endocytic markers and they avoid fusion with the phagolysosomal trafficking 
pathway (14). Many of these initial events are mediated by EB proteins that are 
translocated into the host cytosol upon invasion (13). Among the early effectors 
are a subset of chlamydial inclusion membrane proteins (Incs) that localize to the 
nascent inclusion membrane via a Type III secretion system-dependent 
mechanism (14). The inclusion utilizes host microtubules to migrate to the 
perinuclear region where its proximity to the host secretory system allows it to 
exploit a rich supply of host nutrients (15). To support the growing inclusion, 
chlamydiae acquire several host lipids by recruiting lipid-laden vesicles and lipid 
droplets to the inclusion and possibly via IncD interaction with the cytosolic lipid 
transfer protein (CERT) (16, 17). Chlamydia also appears to depend on 
lysosomal protein degradation for amino acids (18). Electron microscopic 
 6 
 
observation has revealed that chlamydial inclusions also associate with 
mitochondria (19). The pathogens have limited ATP synthesizing capabilities and 
might acquire mitochondrial ATP to supplement their energy requirements (2). 
Chlamydia spp. are incapable of de novo nucleotide synthesis and contain 
ATP/ADP translocases that facilitate the transport of host dNTPs across the 
chlamydial cell membrane (20). dNTPs are converted into other nucleotide 
intermediates by chlamydial ribonucleotide reductase and salvage enzymes (21). 
 
1.3.3 Host response to chlamydial infection 
 Regardless of host tissue or chlamydial species, the epithelial cell is a 
primary target of chlamydial infection. The epithelial cell barrier is equipped with 
an array of innate defense mechanisms and can detect chlamydial products by 
means of pattern recognition receptors (PRRs) located on the cell surface and in 
the cytosol. Chlamydial ligands of these PRR include lipopolysaccharide (LPS), 
heat shock protein 60 (Hsp60), macrophage infectivity potentiator (Mip), MOMP 
and chlamydial nucleic acid metabolites (22-25). PRR-ligand interaction triggers 
a cellular signaling cascade that culminates in the activation of NF-κβ, IRF3 or 
mitogen activated protein kinase (MAPK) pathways (26, 27). The ensuing 
production of inflammatory cytokines and Type I interferons facilitates the 
recruitment of neutrophils and macrophages to the site of infection. These innate 
responders drive tissue-damaging inflammation while also inducing adaptive 
immunity. The complete resolution of chlamydial infection usually depends on the 
 7 
 
production of the pro-inflammatory cytokine IFN-γ by innate cells and CD4+ Th1 
cells (28).  
 Interestingly, many of the anti-chlamydial responses induced by IFN-γ 
appear to be host-specific. IFN-γ in human cells upregulates the expression of 
indoleamine 2, 3-deoxygenase (IDO), a host enzyme that depletes intracellular 
pools of tryptophan by catalyzing the first step in its degradation to N-
formylkynurenine. It was observed that the treatment of human cell lines with 
IFN-γ completely inhibited the development of Chlamydia spp. (29). Growth could 
be restored to sexually transmitted serovars of C. trachomatis, but not ocular 
strains or C. muridarum, by the addition of exogenous indole (30, 31). That this 
pro-survival adaptation was specific to C. trachomatis STD strains suggested that 
tryptophan starvation was induced by IFN-γ in the female urogenital tract. Vaginal 
microbiome studies have revealed that patients with chlamydial STD have 
abnormally high levels of indole-producing bacteria that presumably supply C. 
trachomatis with this essential intermediate (32). The IFN-γ-mediated IDO 
response is also conserved in guinea pigs. The guinea pig-adapted species 
Chlamydia caviae, like genital C. trachomatis, is completely refractory to the 
effects of IFN-γ in human cells (33).  
 In murine cells, IFN-γ does not induce IDO upon chlamydial infection. 
Instead, it stimulates defense mechanisms that target C. trachomatis while 
leaving mouse-adapted C. muridarum largely unaffected (30). The observed in 
vitro susceptibility of C. trachomatis to IFN-γ is reflected in its rapid resolution 
from genital tract infections of mice. In contrast, C. muridarum is more virulent in 
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the mouse model and much of its clearance is executed by an IFN-γ-independent 
mechanism (28). Why C. trachomatis and C. muridarum display such remarkable 
differences in their susceptibilities to murine IFN-γ is unknown. Unlike the 
primarily IDO-dependent inhibition of chlamydiae in human cells, it appears that 
multiple IFN-γ-regulated pathways contribute to pathogen destruction in murine 
cells. This includes the production of nitric oxide (NO) by inducible nitric oxide 
synthase (iNOS), an enzyme that is highly upregulated in response to IFN-γ and 
chlamydial infection in murine epithelial cells and macrophages. In the absence 
of NO, chlamydiae persist in IFN-γ-treated cell lines and mice (34, 35). Apart from 
a failure to prevent chlamydial dissemination, iNOS -/- mice also exhibit excessive 
pathology. However, the addition of an iNOS inhibitor to IFN-γ-treated murine 
cells did not rescue C. trachomatis growth, implying that other effector 
mechanisms contributed to chlamydial species-specific inhibition (30). A 
microarray gene expression study of murine cells treated with IFN-γ discovered a 
cluster of upregulated genes that encoded GTPases of the Guanylate Binding 
Protein (GBP) and the Immunity Related GTPase (IRG) families (30). GBP and 
IRG proteins bind to the phagosomal membranes of many pathogens including 
Toxoplasma gondii and Mycobacterium tuberculosis. Once they are docked on 
the phagosome surface, the GTPases orchestrate the recruitment of various 
immune effectors including autophagic components and NADPH oxidase (36). 
Several IRG proteins including Irga6 and Irgb10 localize specifically to C. 
trachomatis inclusions to facilitate their elimination from murine epithelial cells 
(30, 37, 38). These studies suggest that the coordinated action of several IRGs, 
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nitric oxide and other unidentified mechanisms might be necessary for the 
prompt resolution of C. trachomatis infection from the mouse genital tract. It was 
recently revealed that unlike C. muridarum, clearance of C. trachomatis infection 
from the mouse GT can be achieved entirely by innate immune responses (39). 
The distinct behaviors of chlamydiae that naturally infect mice and humans has 
called into question the suitability of the mouse model for the study of adaptive 
immunity and vaccine development (28, 39). These difficulties might be partially 
overcome by genetically engineering humanized mice that lack mouse-specific 
anti-chlamydial pathways (40). Identification and characterization of mouse 
defense mechanisms is thus critical for improved investigation of human genital 
chlamydial disease in mice.  
 Several studies examining C. pneumoniae lung infections in human 
patients and mice have revealed that the organisms are not restricted to 
epithelia, but can infect and disseminate via monocytes and macrophages (7). 
While chlamydial growth within macrophages is severely limited and species 
dependent (41, 42), their survival as persistent, viable forms in these mobile cell 
populations can facilitate their transfer to more permissive endothelial and 
epithelial cells in distant sites of the host. In spite of their role in assisting the 
systemic spread of C. pneumoniae, macrophages are required for the eventual 
resolution of murine lung infection (43). Aside from IFN-γ secretion, macrophages 
are potent producers of oxidative radicals via iNOS and the phagocyte NADPH 
oxidase (phox) pathways. By direct association with the phagosomal membrane, 
phox can deliver reactive oxygen species (ROS) to bacteria within the 
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phagosome, thereby minimizing damage to the host. NO can interact with ROS 
to produce reactive nitrogen species (RNS) such as ONOO–, NO2, and N2O3 
(44). ROS and RNS act upon a variety of bacterial targets including thiols, lipids, 
DNA and enzyme metal centers. The importance of macrophage-derived NO in 
mice was confirmed in a recent study where the ability to limit C. psittaci-
mediated respiratory disease was dependent on the amount of NO produced by 
the macrophages (45).  
   
1.3.4 Chlamydial adaptations to counter host immunity 
 Comparative genome sequence analysis of diverse chlamydial species 
revealed a remarkable degree of genetic conservation (46). Various serovars of 
C. trachomatis and C. muridarum were found to differ by less than 1% in gene 
content (47). This meant that only a handful of genes and single nucleotide 
polymorphisms (SNPs) dictate differences in host/tissue specificity and disease 
sequelae. It has been hypothesized that differential host immune responses 
govern biological and pathological phenotypes of Chlamydia, and that species-
specific chlamydial genes and alleles may have evolved to combat the defenses 
mounted by their respective hosts (46, 48).  
 Among genes with a high degree of polymorphism are ompA (MOMP) and 
a family of genes encoding polymorphic membrane proteins (pmp) (2, 49). 
MOMP, a cysteine-rich surface protein, is also the most abundant protein present 
in EB and RB. Multiple studies have suggested that MOMP plays a role in 
attachment at the chlamydial-host interface (50, 51). Infectivity potential and 
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tissue tropism have also been ascribed to MOMP (52, 53). However, a large 
phylogenetic analysis of MOMP sequences from various serovars and isolates of 
C. trachomatis found no correlation between MOMP and chlamydial phenotypes 
(54). Thus, the variations observed in MOMP may have simply accumulated in 
response to host immune selection.  
 Chlamydia spp. possess varying numbers of pmp genes, ranging from 9 in 
C. trachomatis to 21 in C. pneumoniae (55). Many roles have been attributed to 
chlamydial Pmps including host cell entry, virulence and tissue tropism (56). 
Support for a role in antigenic variation was provided by a recent study that 
discovered variable expression of Pmps within subpopulations of chlamydial 
inclusions (57).  
 Inclusion membrane protein genes (inc), described in an earlier section, 
also belong to a polymorphic multigene family that arose by gene duplication 
(14). Variations in the Incs helped to separate C. trachomatis isolates into ocular, 
genital and LGV biovars (58). Many Incs have roles in inclusion fusion and 
trafficking as well as lipid transport (17, 59).  
 Finally, a small hypervariable region referred to as the ‘plasticity zone’ 
(PZ) has been identified near the replication terminus in all sequenced 
Chlamydia spp. (2, 46, 60). In the following section, I will briefly describe the 
various genes and gene families encoded by the PZ.  
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1.3.5 The Plasticity Zone 
The chlamydial plasticity zone contains a collection of poorly conserved 
genes encoding incomplete metabolic pathways, pseudogenes and 
uncharacterized ORFs (Fig. 1.4) (46). Understanding why certain PZ genes have 
been left intact in one species but have been lost from another could provide 
insight into the distinct host selective pressures that Chlamydia spp. encounter in 
their unique niches. For instance, several species possess a tryptophan 
biosynthesis (trp) operon in the PZ that allows them to evade IDO-mediated 
tryptophan starvation in their host cells. C. trachomatis STD serovars contain a 
partial trp operon (trpRBA) that encodes a functional tryptophan synthase. This 
enzyme catalyzes the final step in tryptophan synthesis by utilizing indole as a 
substrate. In contrast, IDO-susceptible ocular serovars have accumulated 
inactivating mutations in trpA and cannot synthesize tryptophan from indole (Fig. 
1.5) (31).   
Why ocular strains of C. trachomatis have lost tryptophan synthase is a 
subject of much speculation (31). Unlike the female urogenital tract which 
supports an abundant indole-producing microflora, the more sterile environment 
of ocular tissues may not be able to supply chlamydiae with exogenous indole. 
An indole-poor niche would offer little reason for ocular strains to retain functional 
tryptophan synthase. That the mouse pathogen C. muridarum lacks a trp operon 
is explained by the absence of an IDO response in murine epithelial cells (30, 
47). Finally, C. caviae, C. felis and C. pecorum contain an almost complete trp 
operon (trpABFCDR, kynU, prsA) which should theoretically allow these 
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organisms to convert host kynurenine to tryptophan via several intermediate 
steps (46, 61, 62). Interestingly, the trp gene cluster in C. pecorum is situated 
outside the PZ, but whether the location of the operon bears any significance in 
terms of its function or regulation is unknown.  
While the trp operon offers a compelling argument for the role of the PZ in 
mediating tropism, the function of other PZ ORFs is unclear. A family of putative 
cyotoxins has generated considerable interest because of their homology to 
clostridial toxin TcdB and E. coli Efa1/LifA (Fig. 1.6 A) (63, 64). The cytotoxin 
ORFs are either present as full length copies in several chlamydial species or 
have undergone frameshifts and deletions as observed in different strains of C. 
trachomatis and are completely absent from C. pneumoniae and C. abortus 
genomes (60). Elementary bodies of C. muridarum and C. trachomatis serovar D 
are cytotoxic in cultured cells and induce dramatic alterations in actin cytoskeletal 
morphology. However, cells infected with EB of C. trachomatis serovar L2 display 
no cytotoxicity. These results correlate with the presence of three intact cytotoxin 
genes in C. muridarum (tc0437–tc0439), a partial ORF (ct166) in C. trachomatis 
serovar D and an almost complete deletion of the toxin ORFs in serovar L2 (Fig. 
1.6 B) (64). Comparison of a representative C. muridarum cytotoxin TC0438 with 
TcdB and Efa1/LifA shows that the three proteins are of similar length and share 
a UDP glucose-binding domain as well as a glucosyltransferase domain (Fig. 1.6 
A) (63). TcdB and Efa/LifA toxins utilize UDP-glucose as a substrate to inactivate 
Rho/Ras GTPases by glucosylation (65). The yersinial YopT cysteine protease 
domain (CPD) present in TC0438 and Efa1/LifA also inactivates Rho GTPases 
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by proteolytic cleavage. Active Rho/Ras GTPases regulate cytoskeletal dynamics 
by directly or indirectly affecting the polymerization of F-actin (66). The actin 
rearrangements observed in cells infected with cytotoxic EB suggest that 
chlamydial toxins also target Rho/Ras GTPases. In support of this, a recent study 
showed that ectopic expression of CT166 in HeLa cells induced cytoskeletal 
collapse in a Rac1 GTPase-dependent manner (67). CT166 lacks the YopT 
motif, implying that the observed cytotoxicity is likely mediated by the UDP 
glucose-binding and glucosyltransferase domains. Neither of these domains are 
retained in the truncated C. trachomatis serovar L2 cytotoxin ORF. Whether the 
chlamydial cytotoxins promote virulence and confer niche-specific advantages 
has not yet been determined.   
A guaBA-add operon predicted to encode enzymes that catalyze the 
interconversion of AMP and GMP has been retained by C. muridarum, C. psittaci 
and C. felis. C. pneumoniae human strains contain inactivating mutations in guaB 
and the operon is entirely absent from animal isolates of C. pneumoniae and C. 
trachomatis. Similarly, C. abortus contains only a guaB pseudogene (60). 
Presence of this nucleotide synthesis pathway in only some Chlamydia spp. 
could indicate that purine nucleotides are a limiting nutrient in certain niches. This 
idea is supported by the observation that guaB and guaA null mutants of other 
pathogenic organisms including F. tularensis, B. burgdorferi and S. typhimurium 
are severely attenuated in mice (68-70).  
Multiple phospholipase D (PLD) homologs are present in the PZs of C. 
trachomatis, C. muridarum and C. pecorum (61, 71). All pzPLDs contain HKD 
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(His-Lys-Asp) catalytic motifs that have shown to be important for their 
localization to vesicular membranes (72). The recent finding that CT156, a C. 
trachomatis pzPLD, associates with lipid droplets near the chlamydial inclusion 
implicates the PLDs in lipid acquisition and modification (16). Finally, many 
chlamydial PZs encode a protein with homology to eukaryotic membrane attack 
complex/perforin (MACPF) domains (71, 73). In eukaryotes, MAC and perforin 
(PF) perform critical functions in defense against microbial invaders. 
Components of the complement cascade (C5b, C6, C7, C8 and C9) form a lytic 
pore called the MAC on the surface of bacteria and protozoan parasites. Perforin, 
produced by cytotoxic T lymphocytes and natural killer cells, similarly lyses 
bacterial membranes by pore formation (74). Proteins containing MACPF 
domains have been found in many species of bacteria and function as virulence 
factors that promote host cell invasion. While a role for chlamydial MACPF has 
not been defined, their pore-forming capability could facilitate chlamydial exit 
from cells. Furthermore, these proteins might block host complement function by 
molecular mimickry (71).  
In addition to the ORFs described here, chlamydial PZs encode other 
conserved and unique proteins of unknown function. Characterization of the PZ 
and its alleged roles in chlamydial infection and pathogenesis might reveal novel 
cognate host immune responses as well as improve our understanding of 
chlamydial biology.  
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1.4 Genetics in Chlamydia 
 Molecular dissection of the interactions between chlamydiae and their host 
cells has been hindered by a lack of genetic tools. The inability of chlamydiae to 
replicate in axenic media combined with their complex developmental cycle has 
rendered many traditional genetic methods unusable (75). The field has therefore 
relied heavily on comparative genomics between reference and clinical 
chlamydial strains to find correlations between species-specific alleles and 
pathogenesis (31, 60). Analysis of sequences from different reference serovars 
of C. trachomatis revealed frequent occurrence of horizontal DNA transfer 
between chlamydiae (56, 76). Extensive recombination events that have since 
been described in multiple clinical strains does not appear to be restricted to 
genomic ‘hot spots’ and is rather promiscuous (77). DeMars et al. and others 
applied these observations to cell culture infections and successfully generated 
intraspecies and interspecies recombinants between different antibiotic-resistant 
strains (78-80). Recombined regions appear to vary greatly in size, ranging from 
less than 15 bp to several thousand bp (80) (unpublished observations). Lateral 
gene transfer has since been used in combination with chemical mutagenesis 
methods to backcross mutants to a wild-type genome (81).  
 The use of ethyl methanesulfonate (EMS) as a chemical mutagen has 
gained popularity in chlamydial research in recent years (81, 82). The mutation 
rate elicited by EMS treatment can be approximated by calculating the frequency 
of rifampin-resistant chlamydial mutants recovered in response to different doses 
of the mutagen. EMS-generated mutant chlamydial libraries have been utilized in 
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both forward and reverse genetic approaches. Kari et al. established a reverse 
genetic system in chlamydiae by borrowing a technique from plant biologists 
called Targeting Induced Local Lesions IN Genomes (TILLING) (82). TILLING 
combines EMS mutagenesis with a PCR based screen to isolate induced point 
mutations within genes of interest. Chlamydial RB are exposed to an optimized 
dose of EMS and the surviving population is arrayed in 96-well plates in pools of 
roughly 10 EB per well. After a few passages in cell culture, the final harvest is 
subjected to genome extraction and PCR amplification for a 1kb region from the 
gene of interest. PCR products are then incubated briefly with the mismatch-
specific endonuclease CEL1. The presence of multiple alleles in a given 
subpopulation leads to the formation of PCR heterodimers that are recognized 
and cleaved by CEL1. Wells containing a mixture of wild type and mutant alleles 
can be identified by gel electrophoretic separation of the digested PCR products. 
The nature of the mutation is finally determined by capillary sequencing and 
desired mutants are isolated from corresponding wells in storage plates by 
plaque cloning. As proof of principle, Kari et al. employed TILLING to recover a 
trpB null mutant of C. trachomatis serovar D that could no longer utilize indole 
(82).  
 Many chlamydial genes are poorly annotated or have no assigned 
function, making forward genetic approaches invaluable in the identification of 
new pathway components. In a recent study, Nguyen and Valdivia screened an 
EMS-generated mutant C. trachomatis library to identify mutants with abnormal 
glycogen metabolism and defective type II secretion (81). Phenotypic screens 
 18 
 
have also been launched in our laboratory to identify chlamydial genes involved 
in development and immune resistance. The generation of single nucleotide 
polymorphisms by EMS mutagenesis has advantages over insertional gene 
inactivation in that gain-of-function mutants and conditional mutants can be 
recovered. However, a significant limitation of EMS when used at higher doses is 
that mutations in close proximity to one another on a genome may not be 
resolved by backcrossing, thus making it difficult to link phenotype to genotype.   
 Numerous attempts to transform chlamydiae were met with little success 
until a few years ago when Binet and Maurelli generated recombinants of C. 
psittaci with mutated 16S rRNA alleles by electroporation (83). Wang et al. 
further advanced chlamydial transformation techniques by optimization of a 
simple calcium chloride protocol. An E. coli shuttle vector carrying the 
endogenous chlamydial plasmid and a β-lactamase gene was used to transform 
C. trachomatis serovar L2 EB under penicillin selection (84). The transformation 
procedure has since been reproduced by several groups with various strains and 
species of Chlamydia (85-87). Chlamydial transformation has also been used 
successfully in conjunction with a technology called TargeTronTM to inactivate 
genes (88). TargeTronTM employs mobile group II introns that insert themselves 
into specific DNA sequences by means of an RNA: protein recognition complex. 
By altering the RNA target sequence to match sequences within the gene of 
interest, the intron can be re-targeted to insert itself in specific sites. Finally, a 
dendrimer-based approach that delivers DNA complexed with highly-branched 
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polymers to cells has been shown to efficiently transform chlamydiae and can 
also knock-down target gene expression (89, 90).  
 The rapid advances in chlamydial genetics over the past decade have 
already enabled researchers to investigate questions that were previously 
impossible to explore. Whereas past research focused on manipulation of the 
host to determine its impact on chlamydial survival, the field can now directly 
examine chlamydial gene function and its contribution to infection and disease.  
 
1.5 Summary and Thesis Overview 
 Reductive evolutionary processes that forced Chlamydiae to lead obligate 
intracellular lives caused the pathogens to shed the bulk of their ancestral 
genome, leaving intact only the most vital machineries. Different chlamydial 
species have fine-tuned this small core genome to combat the defenses mounted 
by their respective hosts. Understanding how different hosts respond to 
chlamydiae and how the pathogens in turn have evolved host-specific 
adaptations has been the primary focus of my research.  
 To this end, we investigated a small, variable genomic region within the 
mouse pathogen C. muridarum in Chapter 2. Referred to as the ‘plasticity zone’, 
the locus is present in all chlamydial species and is hypothesized to play 
important roles in niche adaptation and evasion of host defenses. By employing a 
newly available reverse genetic tool, we found that much of the PZ appears to be 
dispensible in vitro as well as in a murine genital tract model of infection.  
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 In Chapter 3, we conducted a forward genetic screen to determine why C. 
muridarum, but not C. trachomatis, is resistant to IFN-γ in murine cells. We 
identified a gain-of-function mutation within a small putative C. muridarum 
membrane protein that resulted in increased IFN-γ susceptibility. Inactivation of 
the mutated protein rescued the mutant in IFN-γ-treated cell lines as well as in 
the murine genital tract.   
 Finally, a serendipitous observation lead to the investigation of 
macrophage innate responses against C. muridarum in Chapter 4. We 
discovered that the ability of C. muridarum to survive within cells of the RAW 
264.7 macrophage line depended on the multiplicity of infection. An iNOS-
dependent mechanism was crucial for restriction of chlamydial growth in 
macrophages at higher infectious doses. Reactive oxygen species and lysosomal 
cathepsin B were found to modulate iNOS expression.  
 A brief discussion of our results and how they impact our current 
understanding of chlamydial-host interactions is presented in Chapter 5. We 
identify future research questions for the continued exploration of host and 
chlamydial adaptations.  
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Fig. 1.1. 16S rRNA phylogenetic tree of identified members within the 
phylum Chlamydiae. Different families are distinguished by color coding (Figure 
reproduced from Horn, 2008).  
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Fig. 1.2. Developmental cycle of Chlamydia. The diagram illustrates the 
invasion of a eukaryotic cell by an elementary body (EB). All intracellular forms of 
Chlamydia are enveloped by a lipid membrane called the inclusion. The EB 
differentiates into a bigger reticulate body (RB) that undergoes several rounds of 
multiplication. Towards the end of the cycle, RB differentiate into EB. EB are 
released from the host cell by lysis or extrusion.  
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Fig. 1.3. Electron microscope images of C. psittaci developmental forms. 
(A) Chlamydial inclusion packed with RB at 24 hours post infection in the 
cytoplasm of L cells. Several RB are in the midst of binary fission. (B) EB, RB 
and intermediate forms in an inclusion at 48 hours post infection. Magnification: 
16,000X (Images reproduced from Matsumoto and Manire, 1970 (91)).  
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Figure 1.4. Map of plasticity zones from different species of Chlamydia. The 
plasticity zones (PZ) typically extend from dsbB or disulfide bond formation 
protein (brown) to MACPF (red). Other PZ genes are color-coded as follows: 
Phospholipase D, green; cytotoxin, yellow; nucleotide interconversion, orange; 
tryptophan synthesis, purple; oppA or ABC transporter, navy blue; tgt or queuine 
tRNA-ribosyl transferase, light blue; hypothetical, gray.  
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Fig. 1.5. Mutations in the trpRBA operon of C. trachomatis. A 1 bp deletion in 
the trpA gene of C. trachomatis ocular serovars results in a nonfunctional TrpA 
protein. All sequenced genital serovars encode a functional tryptophan synthase 
that contain serovar-specific polymorphisms in trpA. (Figure reproduced from 
Caldwell et al., 2003).  
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Fig.1.6. Distribution of active domains in chlamydial cytotoxins. (A)  Full-
length C. muridarum putative cytotoxin TC0438 and E. coli Efa1/LifA contain a 
UDP-glucose binding domain (*), a glucosyltransferase domain (°) and a YopT 
cysteine protease domain (CPD). CPD is absent from Clostridium difficile TcdB. 
(B) Schematic diagram of TC0438 aligned to homologous regions from all 15 
serovars of C. trachomatis. C. trachomatis genital serovars D – K contain UDP-
glucose binding domains (*) and glucosyltransferase domains (°). CPD is absent 
from serovars J and K due to frameshift mutations and from other C. trachomatis 
serovars due to deletion mutations. Ocular serovars A – C possess only the 
UDP-glucose binding domain. LGV serovars L1 – L3 lack all three domains. 
(Figure modified from Carlson et al., 2004).  
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2.1 Abstract 
 
 Pathogenically diverse Chlamydia spp. can have surprisingly similar 
genomes. C. trachomatis isolates that cause trachoma, sexually transmitted 
genital tract infections (chlamydia) and invasive lymphogranuloma venereum 
(LGV), and the murine strain C. muridarum share 99% of their gene content. A 
region of high genomic diversity between Chlamydia spp. termed the Plasticity 
Zone (PZ) may encode niche-specific virulence determinants that dictate 
pathogenic diversity. We hypothesized that PZ genes might mediate the greater 
virulence and IFN-γ resistance of C. muridarum compared to C. trachomatis in 
the murine genital tract. To test this hypothesis, we isolated and characterized a 
series of C. muridarum PZ nonsense mutants. Strains with nonsense mutations 
in chlamydial cytotoxins, guaBA-add and a phospholipase D homolog developed 
normally in cell culture. Two of the cytotoxin mutants were less cytotoxic than 
wild-type suggesting that the cytotoxins are functional. However, none of the PZ 
nonsense mutants exhibited increased IFN-γ sensitivity in cell culture or were 
profoundly attenuated in a murine genital tract infection model. Our results 
suggest that C. muridarum PZ genes are transcribed and some may produce 
functional proteins, but are dispensable for infection of the murine genital tract. 
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2.2 Introduction  
 
 Acquisition of genetic islands encoding the machinery necessary to invade 
eukaryotic cells was a key event in the evolution of many bacterial pathogens 
from free-living ancestors. For those pathogens that subsequently lost the ability 
to replicate outside host cells, a dearth of foreign microbial genetic material and 
Muller’s ratchet may have tilted the balance of niche adaptation towards genomic 
decay. Reductive evolution appears to have played an especially pivotal role in 
niche adaptation of the obligate intracellular bacterial pathogens in the family 
Chlamydiaceae (1). Understanding why extant Chlamydia spp. retained different 
combinations of the metabolic pathways encoded by their common ancestors 
could reveal insights into chlamydial pathogenesis and cognate immune 
defenses against these intracellular pathogens. 
 Whole genome comparisons provided early clues concerning the 
importance of genomic streamlining in chlamydial evolution but less insight into 
how loss of specific genes and metabolic pathways is adaptive (2-5). What is 
clear is that the genomes of pathogenically diverse Chlamydia spp. are small, 
have limited biosynthetic capacity, and are remarkably similar. For example, the 
murine pathogen C. muridarum and pathogenically diverse C. trachomatis 
isolates share 99% gene content (4). Various hypotheses have been put forth to 
explain this paradox which was recently described as “divergence without 
difference” (6). One idea is that polymorphisms in conserved genes are key 
chlamydial virulence determinants. Some C. trachomatis trachoma strains have 
no obvious novel genes that differentiate them from genital strains (7) and some 
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trachoma strains that vary in their sensitivity to IFN-γ differ by only a few 
polymorphisms in conserved “core” genes (8) Alternately, but not exclusively, 
ORFs which have accumulated in a variable genomic region termed the plasticity 
zone “PZ” may be determinants of chlamydial pathogenic diversity (4). 
Comparative genomic and biochemical studies implicated that a partial 
tryptophan operon in the PZ of some C. trachomatis strains could reflect niche 
adaptation to immune-regulated tryptophan availability (9-12). Functionality of 
chlamydial tryptophan synthase, the product of this operon, in cell culture was 
recently confirmed using a reverse genetic strategy (13). Whether other PZ 
ORFs similarly mediate chlamydial niche adaptation, or if the PZ primarily houses 
inactive and decaying genes, remains unclear. 
 The PZ is consistently located near the region of replication termination in 
Chlamydia spp. but varies considerably in size and gene content (4). Some PZ 
ORFs have no homologs outside Chlamydia whereas others have been grouped 
into families based upon the homology of their predicted protein products to 
characterized bacterial and mammalian proteins. Some Chlamydia spp. encode 
a protein that resembles eukaryotic membrane attack complex (MAC) proteins 
and perforin (MACPF) in the PZ (4, 14). Various functions have been ascribed to 
chlamydial MACPFs including immune evasion by molecular mimicry, protein 
secretion and bacterial entry/exit (14, 15). Chlamydial MACPF is also purported 
to assist in lipid modification because of its proximity to a cluster of 
phospholipase D (PLD)-like genes (14, 16). Indirect evidence also suggests that 
PZ PLDs, like their mammalian homologs, are sensitive to primary alcohols and 
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play roles in lipid acquisition or transfer (17, 18). The C. muridarum PZ contains 
three putative cytotoxins that have similarity to the large clostridial toxins (LCTs) 
and yersinial YopT (4). The cytotoxin ORFs of C. trachomatis serovars are 
truncated, disrupted or absent altogether (2, 19, 20). A guaBA-add operon found 
in C. muridarum, but not C. trachomatis, could render the mouse pathogen less 
dependent on host nucleotides (4). These purine interconversion genes are 
replaced by trpRBA in C. trachomatis (2, 4). However, a lack of genetic tools and 
limitations of available animal models has prevented testing hypotheses 
concerning the functions of PZ ORFs in chlamydial virulence and tropism. 
Determining functions of PZ ORFs could provide insight into the molecular 
basis of chlamydial host and tissue tropism and direct design of improved animal 
models of human chlamydial disease. C. muridarum infection of the murine 
genital tract (GT) is a leading model for the study of adaptive immunity to genital 
infection because innate immunity is sufficient to clear murine genital infection 
with human strains of C. trachomatis (21). We and others have speculated that 
C. muridarum PZ genes play roles analogous to C. trachomatis tryptophan 
synthase in circumvention of niche-specific innate immune responses (4, 22). If 
correct, this also implies that specific effectors were retained by C. muridarum 
because the cognate targets are relevant barriers during the natural course of 
infection. Murine modeling of C. trachomatis human urogenital tract infection 
might be improved by use of C. muridarum PZ null mutants and mice lacking the 
corresponding target of these effectors (23). Alternately, if PZ ORFs are 
dispensable for GT infection, this would suggest that either these ORFs do not 
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encode functional proteins or that the appropriate targets of these proteins are 
not relevant during experimental GT infection. 
 In this study, we used a combination of transcriptional profiling, reverse 
genetic analysis and mouse modeling to assess if C. muridarum PZ ORFs are 
expressed and necessary for murine GT infection. Our results suggest that 
although PZ ORFs are transcribed, they are dispensable for infection of the 
murine GT. 
 
2.3 Materials and Methods 
 
2.3.1 Cell lines, chlamydial culture and infection 
 C. muridarum and C. trachomatis serovar L2 (434/Bu) were kind gifts from 
Harlan Caldwell (Rocky Mountain Laboratories, NIAID, Hamilton, MT). Chlamydia 
were routinely propagated in McCoy mouse fibroblast cells (American Type 
Culture Collection CRL-1696) and infectious elementary bodies (EB) were 
purified by density gradient centrifugation (24). McCoy cells and HeLa human 
cervical epithelial cells (American Type Culture Collection CCL-2) were 
maintained in DMEM-high glucose medium containing HEPES, glutamine and 
sodium pyruvate (Hyclone), supplemented with 10% fetal bovine serum albumin 
(Atlanta Biologicals) and 100 µM non-essential amino acids (Gibco). Infections 
were performed in tissue culture flasks or plates with appropriate dilutions of 
chlamydial stock in SPG buffer (0.25 M sucrose, 10 mmol/L phosphate, 5 mmol/L 
L-glutamic acid; pH 7.2). Flask infections were rocked for 2 h at 37°C whereas 
plate infections were centrifuged at room temperature (RT) for 1 h followed by 
rocking at 37°C for 30 min. During large-scale propagation experiments SPG was 
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replaced with fresh DMEM containing 0.5 µg/mL cycloheximide. In some 
experiments, DMEM containing 20 U/ml murine IFN-γ (R&D Systems; catalog # 
485-MI) was added to McCoy cells 24 h prior to and post infection. 
Cycloheximide was excluded from the cell culture media in experiments where 
IFN-γ was added. 
 
2.3.2 Recoverable Inclusion Forming Unit (rIFU) assays 
 McCoy cells in 24-well plates were infected with C. muridarum or PZ 
mutants at a multiplicity of infection (MOI) of 0.25. The infected cell monolayers 
were frozen in 500 µl SPG at various intervals post-infection. Upon thawing, cells 
were scraped using a pipette tip and EB were harvested by bead-beating the cell 
suspension in microfuge tubes. Inclusion forming unit (IFU) assays were 
performed using serial dilutions of the harvests to infect confluent McCoy cell 
monolayers in 96-well plates. Cells were fixed with methanol and stained with 
anti-chlamydial LPS mAB (EVIH1) followed by a secondary Alexa Fluor488-
conjugated anti-mouse IgG mAB (Life Technologies) at 24 hours post infection 
(hpi). Chlamydial inclusions were imaged and enumerated using an EVOS FL 
Auto Cell Imaging System (Life Technologies). 
 
2.3.3 RT-PCR and qRT-PCR 
 McCoy cells in six-well plates were infected with C. muridarum at an MOI 
of 1. Total RNA was extracted at 0, 6, 12, 18, 24, and 30 hpi using TRISure 
reagent (Bioline), treated with DNAse I (Qiagen) for 15 min and then purified on 
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GeneJET RNA purification columns (Thermo Scientific). RT-PCR reactions were 
performed using 100 ng of total RNA and gene-specific primers (Table 1) using 
the MyTaq one-step RT-PCR kit (Bioline). For quantitative RT-PCR (qRT-PCR) 
experiments, total RNA was converted to cDNA using the Maxima H Minus First 
strand cDNA synthesis kit (Thermo Scientific). The qRT-PCR reactions were 
performed in an Eppendorf Realplex4 thermocycler using SensiFAST SYBR No-
ROX master mix (Bioline) using gene-specific primers (Table 2). The 
amplification cycle included a 2 min step at 95°C followed by 40 cycles of 95°C 
for 5 sec, 60°C for 10 sec, and 72°C for 20 sec. Absolute transcript copy 
numbers were calculated by normalizing to standard curves of C. muridarum 
genomic DNA amplified in parallel with experimental samples. Control reactions 
lacking RT were run in parallel with all RT-PCR and qRT-PCR experiments. 
 
2.3.4 PZ Cloning and β-galactosidase assays  
 Overlapping 500 bp-1 kb regions of the C. muridarum PZ were PCR 
amplified from C. muridarum genomic DNA and were cloned upstream of the 
lacZ gene in pAC-lacZ, between the NruI and EagI sites of the vector (25). 
Sequences of the PCR primers and the genomic coordinates of the cloned PZ 
regions are in Table 3. The resulting plasmids were transformed into E. coli 
DH5α and the inserts and cloning junctions were confirmed by DNA sequencing. 
For β-galactosidase activity assays, triplicate samples from overnight cultures of 
E. coli strains carrying various PZ and control plasmids were grown in Luria-
Bertani broth containing 50 μg/ml chloramphenicol, then were diluted 1:100 in 
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fresh broth and grown at 37°C until they reached mid-log phase (OD600≈0.6). β-
galactosidase expression analysis was performed as described previously, (26, 
27) with the following modifications. Cells were diluted in a total volume of 500 μl 
Z-buffer (60 mM Na2HPO4, 40 mM NaH2PO4·H2O, 10 mM KCl, 1 mM 
MgSO4·7H2O) followed by the addition of 50 μl of chloroform and 50 μl of 0.1% 
sodium dodecyl sulfate. The solution was vortexed for 5 seconds, and the 
reactions were equilibrated by incubation at room temperature for 5 min prior to 
the addition of 100 μl of ortho-nitrophenyl-β-galactoside (4 mg/ml). The reactions 
were stopped by adding 250 μl of 1 M Na2CO3 and then were centrifuged at 
14,000 rpm for 5 min in an Eppendorf microcentrifuge to separate the cell pellet 
and the supernatant. The initial OD600 of the cells and the OD420 supernatant 
were measured and used to calculate β–galactosidase activity. 
 
2.3.5 Preparation of CEL1 endonuclease extract 
 CEL1 extract was prepared from celery as described previously (28). 
Fresh celery stalks (25 kg) were washed, chopped to remove leaves and juiced 
to yield approximately 10 L of celery juice. Subsequent steps were carried out at 
4°C. 500 mL of Buffer A containing 2 M Tris-HCl (pH 7.7) and 0.1 M 
phenylmethanesulfonyl fluoride (PMSF) was added to the celery juice and the 
solution was centrifuged to remove plant debris. Protein was precipitated from 
the supernatant by ammonium sulfate fractionation in the 25-80% saturation 
range. The protein pellet was resuspended in 100 mL Buffer B (0.1 M Tris-HCl, 
pH 7.7; 0.5 M KCl; 100 μM PMSF; 0.01% Triton X-100) and was dialyzed 
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overnight against a large volume of Buffer B. The final CEL1 extract was stored 
in small aliquots at -80°C.  
 
2.3.6 EMS mutagenesis and library construction 
 Confluent McCoy cells in a T-75 flask were infected with C. muridarum at 
an MOI of 0.5. At 16 hpi, culture media was replaced with 5 mL of DMEM 
containing 8 µg/ml ethyl methanesulfonate (EMS) (Sigma). The cells were 
exposed to EMS for 1 h and were then washed several times with 1X PBS, after 
which fresh DMEM without mutagen was added. EB were bead-harvested from 
the cells at 28 hpi and resuspended in 2 mL of SPG. An infection forming unit 
(IFU) assay estimated chlamydial survival after EMS treatment at less than 0.1% 
of untreated control. Half of the harvest was stored at -80°C and the remainder 
was used to infect a fresh T-75 flask of cells. Four rounds of EMS mutagenesis 
were performed in total and the final harvest yielded 9 x 105 EB. These EB were 
divided into small aliquots and stored at -80°C. To constuct mutant libraries, 96-
well plates of McCoy cells were infected with 10 EB per well of the mutagenized 
stock. Mutant chlamydiae were scaled up by four rounds of passaging in 96-well 
plates. Plates from the third passage were stored at -80°C to serve as the library. 
Genomic DNA was extracted from the final plates by adding 75 µl of alkaline lysis 
buffer to each well (0.2 mM EDTA, 25 mM NaOH; pH 12.0) and incubating at 
95°C for 10 min, after which the lysis buffer was neutralized by adding an equal 
volume of 40 mM Tris-HCl (pH 5.0). Genomic DNA plates were stored at 4°C.  
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2.3.7 TILLING 
 Targeting Induced Local Lesions IN Genomes (TILLING) was used to 
identify specific mutants in the library and was performed as described previously 
(13). Specific primers (Table 4) were used to amplify targeted PZ genes from 
template genomic DNA plates, which were extracted from the mutant libraries. 
These PCR products were annealed slowly (80°C, 7 seconds, 60X; decrease by 
0.3°C every cycle) then were digested with CEL1 endonuclease. Digestions were 
performed for 10 min at 45°C using an empirically determined volume of CEL1 
extract (range 0.1 to 1 µl) diluted in 1X CEL1 buffer (0.01 M MgSO4; 0.01 M 
HEPES, pH 7.5; 0.02 M KCl; 0.005% Triton X-100; 2 µg/mL bovine serum 
albumin). Digestions were stopped by adding 10 µl EDTA (0.15 M, pH 8.0). The 
digested products were separated on 2% agarose TBE gels, stained with Midori 
Green (Bulldog Bio) and visualized using a ChemiDoc XRS+ device (BioRad 
Laboratories, Inc., Hercules, CA)). 
 
2.3.8 Cytotoxicity assays 
 McCoy cells seeded on coverslips in 24-well plates were infected with C. 
trachomatis, C. muridarum or cytotoxin mutants at an MOI of 10 or 250 in the 
presence of 0.1 µg/mL rifampin. Cells were fixed in 3.7% formaldehyde at 3 hpi 
and then permeabilized with 1% Triton X-100. Following staining with AlexaFluor 
488-phalloidin and AlexaFluor 594 WGA (Invitrogen) for visualization of actin 
filaments and host plasma membrane, respectively, coverslips were mounted on 
slides using ProLong Gold antifade reagent with DAPI (Life Technologies). Cells 
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were imaged using a Nikon Eclipse Ni-E fluorescent microscope (Nikon 
Instruments, Melville, NY). 
 Lactate Dehydrogenase (LDH) assays were performed according to the 
manufacturer’s instructions (OPS Diagnostics). McCoy cells were infected with 
various strains at a range of MOI (10, 25, 100 and 500) in the presence of 
rifampin. To determine maximal LDH release, cells in control wells were lysed 
with 10% Triton X-100 10 min prior to supernatant collection. Supernatants were 
removed from wells 3 hpi after brief centrifugation of the plates to remove debris. 
25 µl of the supernatants were mixed with 75 µl of the dye/buffer solution. The 
A490 was measured after 15 min incubation at 37°C.  
 
2.3.9 Animal experiments 
 C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, 
ME). All animal experiments were approved by the Institutional Animal Care and 
Use Committees of the University of Arkansas for Medical Sciences and Indiana 
University. Female mice between 6-10 weeks old were treated with 2.5 mg Depo-
Provera diluted in 100 µl PBS at 10 and 3 days prior to infection. Prior to 
infectious challenge, the vaginal vault was swabbed to remove excess mucus.  
Mice were inoculated vaginally with C. muridarum or PZ mutants at a 
concentration of 5x104 IFU in 5 µl SPG. The infections were monitored by 
enumeration of IFU from cervical swabs collected at various time points.  
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2.3.10 Sequencing Library Construction and Whole Genome Sequencing 
 Gradient-purified EB were treated with DNase I (NEB) at 37 °C for 1 h and 
then 5 mM EDTA was added and the mixtures were incubated at 75 °C for 10 
min to halt digestion. Total DNA was extracted using the DNeasy Blood & Tissue 
kit (Qiagen) and DNA concentrations were determined using the Quant-It High 
Sensitivity dsDNA assay (Life Technologies Corp.) The dsDNA fragments were 
generated by treating 1 µg of genomic DNA with NEBNext dsDNA Fragmentase 
(NEB). DNA sequencing libraries were prepared using the TruSeq Nano DNA 
sample preparation kit according to the manufacturer’s protocols (Illumina Inc.). 
Samples were multiplexed using TruSeq Single Index sequencing primers. 
Equimolar concentrations of indexed libraries were combined into a single pool 
and submitted for Illumina HiSeq sequencing at Tufts University Genomics Core 
Facility. Paired-end 100 bp sequencing was performed on the Illumina HiSeq 
2500 platform. 
 
2.3.11 Genome assembly and sequence analysis 
 For single nucleotide polymorphisms (SNP), nucleotide insertion and 
deletion analysis (Indel), raw sequence data was mapped to the corresponding 
reference genome (GenBank: AE002160.2) using Bowtie2. Resulting SAM files 
were converted to a BAM file format and sorted. SNPs/Indels were called using a 
Samtools mpileup function. Remaining ambiguous sequences from the dataset 
and mutation calls with low quality scores were resolved by PCR and Sanger 
sequencing. 
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2.3.12 Statistics 
 Data was analyzed using Prism 6.0 software (GraphPad). For 
comparisons of multiple groups with more than one variable, two-way analysis of 
variance (ANOVA) followed by the Bonferroni posttest was used. Two-way 
ANOVA with Bonferroni posttest was also used to analyze the differences in 
chlamydial burden between groups of infected mice. Multiple comparisons for 
data with a single variable were analyzed by one-way ANOVA followed by the 
Dunnett’s posttest. Differences were considered statistically significant when P< 
0.05. 
 
2.4 Results  
2.4.1 The C. muridarum Plasticity Zone is transcriptionally active  
 The C. muridarum Plasticity Zone (PZ) is defined as the 50 kb locus 
between tc0431 (MACPF) and tc0448 (dsbB) (Fig. 2.1). The C. muridarum PZ is 
poorly characterized and the only evidence for gene activity in the region comes 
from a prior transcriptional study of the cytotoxin ORFs (tc0437 – tc0439) (19). 
To determine if and when other PZ ORFs were expressed, we examined the 
entire locus for transcriptional activity. RT-PCR analysis of RNA isolated from C. 
muridarum-infected McCoy cells at 24 hpi indicated that all the PZ genes were 
transcribed (Fig. 2.2 A). Next, we determined the transcriptional and temporal 
expression profiles of a subset of PZ ORFs (tc0431, tc0436 – tc0443) using qRT-
PCR analysis at various time points post infection. The developmentally 
regulated genes, euo, ompA and omcB were analyzed as representative 
 57 
 
chlamydial early, mid-late and late genes, respectively (19). Increased 
expression of euo was detected by 6 hpi, whereas ompA transcripts first 
increased between 6 and 12 hpi and de novo omcB expression was only 
detected at 12 hpi and did not peak until 18 hpi (Fig. 2.2 B). The expression trend 
for all of the PZ genes most closely resembled ompA, except that the absolute 
peak numbers of PZ ORF transcripts were 1 to 3 logs lower than those of ompA 
and omcB. Taken together, these results showed that expression of most PZ 
ORFs initiates mid to late developmental cycle and that they are expressed at 
low levels relative to known highly expressed chlamydial genes. 
 We next sought to identify the promoters of PZ genes. The ability of a 
series of overlapping cloned fragments of the C. muridarum PZ to drive 
expression of a promoterless lacZ gene was assayed in E. coli to identify 
promoters. Only two of the constructs exhibited strong promoter activity. One 
promoter locus (GenBank coordinates: 515330-515896) was situated near the 3’ 
end of tc0437 and was in the correct position and orientation to drive expression 
of tc0438-tc0440. The other locus (GenBank coordinates: 542868-542368) was 
located immediately upstream of guaB (Table 5). This gene is predicted to lie in 
an operon along with guaA and add. No promoter likely to drive expression of the 
predicted PZ PLD operon tc0436-tc0432 or the cytotoxin ORF tc0437 was 
identified although regions immediately upstream of tc0436 and tc0437 were 
represented in the PZ clone library (Table 5). Failure to identify other promoters 
for PZ genes whose expression was confirmed by RT-PCR could indicate that 
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some PZ promoters were not functional in E. coli or were located outside the 
regions interrogated in the assay. 
 
2.4.2 Members of three PZ gene families are dispensable for C. muridarum 
survival and proliferation in vitro 
 Since little is known about the potential functions of most PZ ORFs, we 
tested if they were dispensable using a reverse genetic approach. An EMS-
mutagenized C. muridarum library was screened by TILLING for isolates that had 
nonsense mutations in eight C. muridarum-specific PZ ORFs: tc0437, tc0438, 
tc0439, tc0440, guaA (tc0441), guaB (tc0442), add (tc0443) and MACPF 
(tc0431). (13). The TILLING library was constructed with a high mutation load to 
facilitate faster screening. To estimate the number of EMS-induced point 
mutations in a given gene that would have to be isolated in order to recover at 
least one nonsense mutation, we assumed a Poisson distribution described as P 
(x ≥ 1) = 1 – P (x = 0) = 1 – e-a where a = N·p; N is the number of mutations in 
gene X that need to be isolated and p is the probability of obtaining a nonsense 
mutation in gene X. The majority of mutations induced by EMS are GC->AT 
transitions. A total of 5 GC transitions in 4 amino acid codons (CAA, CGA, CAG, 
TGG) can yield a stop codon. We use tc0442 as an example to illustrate how we 
arrived at an approximation of screen size (N). The probability p can be 
calculated as the number of possible nonsense GC transitions in the analyzed 
region of tc0442 divided by the number of GC base pairs in the same region of 
tc0442 (p = 19/585; = 0.032). For 95% screen saturation, screen size N was 
 59 
 
determined as follows: P (x ≥ 1) = 0.95 = 1 - e-0.032N or N = 94. In other words, if 
tc0442 is not essential, there is a 95% probability that at least one of 94 isolated 
mutants is a nonsense mutant. Screen sizes for other PZ genes were calculated 
by the same method (Table 6). 
 One or more nonsense mutants in guaBA-add, the C. muridarum-specific 
PZ PLD tc0440 and the cytotoxins (tc0437 – tc0439) were isolated at anticipated 
frequencies, indicating that these ORFs are not essential for chlamydial survival 
in vitro. Despite isolating over 60 unique mutants with point mutations in tc0431 
(MACPF), none of these were nonsense (Table 6). C. abortus does not encode 
MACPF (29, 30), and the C. caviae and human C. pneumoniae MACPF genes 
contain frameshifts (5, 30, 31), so this result could indicate that MACPF plays an 
essential, species-specific role in C. muridarum.  
 
2.4.3 PZ mutants display mild in vitro growth defects  
 The PZ nonsense mutants were initially characterized using temporal 
recoverable IFU assays. Since multiple independent mutants of tc0440 and guaA 
were recovered by TILLING, we selected a representative mutant of each with a 
nonsense mutation located closest to the predicted 5’ end of these ORFs for 
further analysis. Growth kinetics of most of the PZ mutants paralleled C. 
muridarum, with the sole exception of guaB, which attained maximal EB 
production at 18 hpi as opposed to 30 hpi. None of the mutants exhibited 
dramatic growth defects, although IFU production of most of the mutants was 
significantly reduced compared to C. muridarum (Fig. 2.3). Confocal microscopy 
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also failed to reveal obvious differences between the morphology of the mutant 
and C. muridarum inclusions (data not shown). These results implied that the 
presence of nonsense mutations in PZ ORFs did not hinder the ability of C. 
muridarum to form inclusions, complete development or produce infectious EB.  
 
2.4.4 Cytotoxicity of cytotoxin nonsense mutants is reduced  
 Since none of the PZ mutants displayed pronounced growth or 
morphological defects, we focused on examining phenotypes that have been 
indirectly attributed to the chlamydial cytotoxins in previous studies. The C. 
muridarum LCT-like cytotoxins are purported to mediate multiplication-
independent cytopathic effects of C. muridarum EB to host cells at high MOI (19). 
This phenomenon, referred to as “immediate cytotoxicity” (32), resembles the 
cytoskeletal collapse observed in cultured cells treated with clostridial TcdB (19). 
 To determine if the C. muridarum cytotoxin (tc0437, tc0438 and tc0439) 
nonsense mutants were less cytotoxic, HeLa cells were infected with EB at an 
MOI of 250 in the presence of rifampin. Cells were fixed and stained with 
Phalloidin at 3 hpi and examined by fluorescent microscopy. HeLa cells infected 
with C. trachomatis serovar L2 (C. trachomatis), a cytotoxin negative strain, did 
not differ in morphology from uninfected cells. In contrast, cell rounding and 
alterations in actin filament morphology were observed in infections with C. 
muridarum and the cytotoxin mutants (Fig. 2.4 A). This implied that the single 
cytotoxin mutants retained some cytotoxic activity.  
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 Microscopy could not distinguish small variations in cytotoxicity so we 
measured LDH release at 3 hpi from cells infected with C. muridarum, C. 
trachomatis and the mutants at various MOI. As expected, C. trachomatis elicited 
minimal LDH release even at an MOI of 500. In contrast, C. muridarum caused 
cells to release significantly more LDH at high MOIs. Interestingly, the tc0437 
and tc0439 mutants elicited lower LDH release than C. muridarum at the highest 
MOI tested (Fig. 2.4 B). Wild-type cytotoxicity of the tc0438 mutant implies that 
TC0438 may not be functional, or has a function different than the other two 
cytotoxins altogether.  
 
2.4.5 IFN-γ resistance is unaltered in C. muridarum PZ mutants 
 While high multiplicity infections were important in associating a toxin-like 
activity to chlamydial EB, these doses may not be relevant in natural chlamydial 
disease. Roles for the chlamydial cytotoxins in host cell attachment, entry, 
vesicle trafficking and modification of host cell GTPases have been reported (33-
35). The C. muridarum cytotoxins have also been proposed to mediate evasion 
of the inhibitory effects of IFN-γ responses in murine cells (12). To test the latter 
hypothesis, McCoy cells were treated with IFN-γ followed by infection with C. 
trachomatis, C. muridarum or cytotoxin mutants. Chlamydial survival was 
measured by IFU (Fig. 2.5 A) and rIFU (Fig. 2.5 B) assays. C. trachomatis, but 
not C. muridarum, was dramatically inhibited by IFN-γ. IFN-γ treatment did not 
significantly affect the survival of the cytotoxin mutants compared to C. 
muridarum. Parallel experiments with other PZ nonsense mutants indicated that 
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they were also similarly resistant to IFN-γ (Fig. 5). Thus, disruption of individual 
cytotoxin or other PZ ORFs did not confer IFN-γ sensitivity to C. muridarum. 
 
2.4.6 PZ mutants retain virulence in the mouse genital tract infection model  
 Intravaginal inoculations of mice with human C. trachomatis isolates result 
in mild infections of short duration with minimal upper genital tract infection and 
pathology (36). In comparison, C. muridarum is more virulent in this model and 
the post-infection sequelae mimic human disease (37). To determine if the C. 
muridarum PZ genes were niche-specific virulence factors in mice, PZ mutants 
were analyzed in the murine genital tract infection model. Chlamydial burden in 
mice infected with the tc0439 cytotoxin mutant was significantly lower at 3 days 
post infection in comparison to animals infected with C. muridarum. Infection 
trajectories in mice inoculated with the tc0437 and tc0438 mutants also trended 
lower during the first week of infection. However, chlamydial recoveries of all 
three cytotoxin mutants appeared identical to C. muridarum infection at later time 
points (Fig. 2.6 A). We also did not observe any significant deviation in bacterial 
loads of mice infected with the tc0440 mutant compared to mice infected with C. 
muridarum (Fig. 2.6 B). Interestingly, the guaA nonsense mutant behaved 
identically to C. muridarum, whereas guaB and add mutants displayed reduced 
pathogen burdens at early data points (Fig. 2.6 C, D). The putative guaBA-add 
operon encodes products that function in the same purine biosynthetic pathway. 
Absence of phenotypes in the guaA mutant suggested that either the phenotypes 
of the guaB and add mutants were due to background mutations or that the 
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guaBA-add acts non-canonically in C. muridarum. Since none of the PZ mutants 
were completely attenuated in vivo, we conclude that these genes are 
dispensable for infection of the murine genital tract.  
 
2.4.7 PZ mutants contain multiple background mutations 
 To identify a plausible explanation for the differing phenotypes of the 
purine pathway mutants, we sequenced the genomes of the parent strain and PZ 
mutants to an average coverage of 2075x on the Illumina HiSeq platform (Tables 
7-14). Comparison to published C. muridarum genomes indicated that our parent 
most closely resembled a C. muridarum Weiss isolate that was recently 
sequenced by Ramsey et al (Table 7). On average, the PZ mutants contained 
36.4 mutations, of which 66.67% were non-synonymous substitutions. Most 
(98.43%) of the mutations were GC->AT transitions consistent with EMS induced 
changes. Several synonymous and non-synonymous mutations were shared by 
some PZ mutant strains, which was a consequence of our serial mutagenesis 
strategy. These included mutations in recA, alaS, tc0237, tc0283, tc0471, tc0490, 
rpoC, aroA, upp and tc0877 that were common to the add, tc0437 and tc0438 
mutants. The add and tc0437 mutant strains contained identical mutations in 
tc0035, tc0069, tc0438, tc0575, tc0917 and pfkA-2. The tc0438 mutant shared 
mutations in murB, tc0330 and tc0575 with the add mutant and a pmpB/C-2 
mutation with the tc0437 mutant. Finally, mutations in tc0054, tc0191, pmpD, 
tc0250, tc0290, tc0312, tc0600 and an intergenic region (GenBank genome 
position: 126188) were present in the tc0439 and the guaB mutants. 
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Interestingly, multiple mutant strains had nonsense mutations in tc0412, an 
ortholog of C. trachomatis ct135 which has been linked to virulence of C. 
trachomatis in the murine genital tract model (38). None of the tc0412 mutants 
except add were significantly attenuated in the murine GT and an identical stop 
mutation was present in the tc0437 mutant strain suggesting that attenuation of 
the add mutant was unlinked to this tc0412 allele. No common mutations were 
present in the guaB and add mutants, which is consistent with the hypothesis 
that guaB and add might function in a non-canonical pathway independent of 
guaA. 
 
 
2.5 Discussion 
 C. muridarum and C. trachomatis are genetically closely related and 
genital infection of their respective hosts, mice and humans respectively, have 
many similarities (4, 39). While T-cell immunity is critical for the resolution of 
chlamydial infection in both mice and humans, other aspects of immunity, most 
notably IFN-γ responses, appear to differ and are incompletely characterized 
(36). The results of our study suggest that although the PZ is the site of maximal 
divergence between the genomes of these pathogens, C. muridarum IFN-γ 
resistance determinants may not localize to this region. 
We show that most PZ ORFs are transcribed mid to late developmental 
cycle and are expressed at relatively low levels. Although we identified two 
promoter regions that support our RT-PCR findings, and which could provide 
plausible explanations for how some PZ ORFs are transcribed, strong promoters 
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that could drive expression of one of the cytotoxin ORFs (tc0437) and an 
adjacent operon of PZ PLD (tc0436-tc0432) that is relatively conserved in 
Chlamydia spp. were not identified. The putative start sites of tc0436 and tc0437 
are located less than 1000 bp apart in opposite strands of the C. muridarum 
genome, so perhaps our chosen cloning site disrupted two promoters in the 
same narrow region on opposing strands thus compromising their detection. 
Another possibility is that E. coli sigma factors cannot recognize the chlamydial 
promoters in this region. For example, the auxiliary C. trachomatis transcription 
factor GrgA, which is not conserved in E. coli, directs expression from some 
chlamydial σ66-dependent promoters (40). Chlamydial σ28 also cannot 
complement an E. coli σ28 mutant, indicating that even conserved E. coli and 
chlamydial sigma factors are not completely interchangeable (41). We attempted 
to identify additional promoters using RNA-seq, but low expression of PZ ORFs 
relative to other highly expressed genes yielded insufficient coverage for 
mapping transcriptional start sites in this region. As costs of deep RNA-seq 
decrease further and methods for enrichment of chlamydial from host cell 
transcripts improve, it might make sense to re-visit this approach in the future. 
Better understanding of transcriptional organization could inform subsequent 
attempts to inactivate PZ operons.  
Two of three cytotoxin mutants displayed reduced cytotoxicity in vitro, 
which suggests that these alleles are functional. The biological role of chlamydial 
cytotoxins is still largely a matter of speculation. Polymorphisms in the cytotoxins 
have been associated with differences in the ocular and genital tropisms of C. 
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trachomatis isolates (20). On the basis of their homology to LCTs and YopT, we 
have previously proposed that the cytotoxins may inactivate interferon regulated 
GTPases that inhibit C. trachomatis, but not C. muridarum, in IFN-γ-treated 
mouse cells (42). Finally, mutants of E. coli efa1, another chlamydial cytotoxin 
homolog, exhibit reduced adherence to epithelial cells and fail to colonize colonic 
tissue effectively in mice (43). The observed trend towards lower chlamydial 
burden during the first week of infection in mice inoculated with the chlamydial 
cytotoxin mutants argues for a possible role in adhesion and colonization. A 
future direction would be to evaluate IFN-γ resistance and virulence of double 
and triple cytotoxin mutants. 
One of the most surprising findings of our study was that the guaB (IMP 
dehydrogenase) and add (adenosine deaminase) mutants were moderately 
attenuated in the GT while a guaA (GMP synthase) mutant was not. Genome 
sequencing confirmed that the phenotypes of the guaB and add mutants were 
not caused by a common background mutation. Thus, if unrelated background 
mutations were not responsible for the very similar GT phenotypes, our results 
suggest C. muridarum could encode an additional cryptic GMP synthase enzyme 
or that C. muridarum purine salvage acts non-canonically. The guaBA-add 
operon has been retained by several chlamydial species that cause respiratory 
illness including C. psittaci, C. felis and human isolates of C. pneumoniae, but it 
is unknown if they are functional (31, 44, 45). guaA and guaB are known 
virulence determinants in other pathogenic organisms like B. burgdorferi and F. 
tularensis during intraperitoneal and subcutaneous infection of mice, indicating 
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that one or more purine nucleoside monoposphates are limiting in certain 
mammalian niches (46, 47). Thus, an explanation of our results could be that 
NMP levels in the murine GT are sufficient to support chlamydial growth whereas 
other tissues like the lung are starved for purine nucleotides. We hope to 
differentiate these possibilities by constructing additional guaA, guaB and add 
nonsense mutants and comparing their virulence in murine GT and lung infection 
models. 
Although we were unable to identify a role for individual PZ genes in IFN-γ 
resistance and murine genital infection, functional redundancy in the cytotoxin 
and PLD super family of proteins could have masked effects of the loss of a 
single family member. However, our data indicates that cytotoxin functions are 
not wholly redundant and true functional redundancy of these alleles is not 
consistent with the relatively low amino acid identity to one another (40-42%). 
While it would be possible to disrupt all members of the cytotoxin and guaBA-add 
operons sequentially, variable alleles including tc0412 are a practical impediment 
to constructing isogenic strains by iterative TILLING (38, 48). Another possible 
explanation for the lack of phenotype of select PZ mutants is the emergence of 
suppressor mutations. Although this possibility is difficult to exclude, the fact that 
all of the PZ mutants were isolated from pools of mutants at expected 
frequencies indicates that this is unlikely to have been a significant issue. We are 
currently investigating the possibility of disrupting the putative PZ PLD (tc0436-
432), cytotoxin (tc0437-439) and guaBA-add operons using polar transposon 
insertions by the Targetron® method developed by Fisher and colleagues (49).  
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 In summary, our results imply that all examined PZ ORFs are non-
essential for virulence in the mouse GT but we cannot rule out their importance in 
other niches. C. muridarum was originally isolated from the lungs of symptom-
free laboratory mice. Disease was only observed upon  inoculation of mice with 
serially passaged lung homogenates, indicating that very low levels of C. 
muridarum are typically present in pulmonary tissue (50). Later studies 
demonstrated that C. muridarum is transmitted through the oro-fecal route, which 
suggests that the gut is a reservoir and that small numbers of C. muridarum enter 
the lungs during feeding (51). Finally, it is notable that guaBA-add and cytotoxin 
homologs of other intracellular pathogens modulate infections of the lung and 
gastrointestinal tract, respectively (43, 46, 52). Thus, examination of C. 
muridarum PZ mutants in lung or gastrointestinal tract models of mouse 
infections is warranted. A positive implication of our study is that successful 
modeling of human disease in the murine GT does not appear to require much of 
the C. muridarum PZ. Future investigations of polymorphisms outside the PZ will 
be important in the identification of C. muridarum alleles that confer IFN-γ 
resistance and dictate virulence in the murine GT model. 
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Fig. 2.1. Map of the C. muridarum Plasticity Zone. Diagram of PZ ORFs. 
ORFs are color-coded according to functional annotation: red, MACPF; green, 
phospholipase D (PLD); yellow, cytotoxin; orange, purine nucleotide synthesis; 
gray, conserved hypothetical; blue, peptide ABC transporter; pink, dsbB. 
Locations of promoters identified by β-galactosidase assays in this study are 
shown by arrows. The genomic location and nucleotide change of nonsense 
mutations discussed in this study are indicated in the corresponding ORFs. 
Figure is not drawn to scale. 
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Fig. 2.2. Transcription of C. muridarum PZ ORFs initiates mid-late 
developmental cycle. Total RNA was isolated from C. muridarum infected 
McCoy cells at 0, 6, 12, 18, 24 and 30 hpi. A) RT-PCR at 24 hpi indicated that all 
genes in the PZ are transcribed, +/- symbols indicate amplifications performed 
with or without reverse transcriptase. B) Kinetics of transcription of select PZ 
ORFs was characterized by qRT-PCR. Transcript levels were normalized to 
standard curves of dilutions of C. muridarum chromosomes. Data represent the 
mean transcript levels (± SD) from three independent experiments. euo, ompA 
and omcB represent early, mid-late and late genes, respectively. 
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Fig. 2.3. C. muridarum PZ mutants exhibit mild growth defects. rIFU analysis 
was performed for C. muridarum WT (CM) and PZ mutants at various time 
intervals following infection of McCoy cells. Data in the panels are from 
experiments performed in parallel. Data represent the average (± SD) ratios of 
input:output IFU from three independent experiments performed in triplicate. ****, 
p < 0.0001; ***, p < 0.001; **, p < 0.01 by two-way ANOVA with Bonferroni post 
hoc test.  
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Fig. 2.4. tc0437 and tc0439 mutants have reduced cytotoxicity. (A) HeLa 
cells were infected at an MOI of 250 in the presence of rifampin and were fixed 3 
hpi. Cell morphology and actin structure were visualized by staining with 
AlexaFluor 488-phalloidin (green), DAPI (blue) and AlexaFluor 594 WGA (red). 
Overlays of fluorescent micrographs of cells that are mock-infected or infected 
with C. muridarum (CM), C. trachomatis serovar L2 (CTL), tc0437, tc0438 or 
tc0439 are depicted. Images are representative of three independent 
experiments. B) LDH in supernatants of HeLa cells infected at various MOI, 
indicated below the X axis, in the presence of rifampin. C. muridarum (black), C. 
trachomatis serovar L2 (gray), tc0437 (hatched), tc0438 (white) or tc0439 (cross-
hatched). Triton X-100 treated cells were used as positive controls for LDH 
release. Data show the mean percent of positive control (± SD) of three 
independent experiments performed in triplicate. ****, p < 0.0001; **, p < 0.01 by 
one-way ANOVA with Dunnett’s post hoc test.  
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Fig. 2.5. PZ mutants are resistant to IFN-γ. Sensitivity to IFN-γ treatment of C. 
muridarum (CM), C. trachomatis serovar L2 (CTL) and various PZ mutants was 
assessed by A) IFU assay and B) rIFU assay. Data are represented as the 
average (± SD) percent of untreated (no IFN-γ) infected controls from three 
independent experiments performed in triplicate. ***, p < 0.001; **, p < 0.01 by 
one-way ANOVA with Dunnett’s post hoc test.  
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Fig. 2.6. Mouse genital tract infections with C. muridarum PZ mutants. 
Groups of mice were challenged intravaginally with 50,000 IFU of WT C. 
muridarum (CM) or various PZ mutants. The infection curve for WT C. muridarum 
infected mice (n=30) is reproduced in each panel for comparison.  (A) Lower 
genital tract shedding of IFU by mice infected with C. muridarum (CM) differed 
significantly from that of mice infected with the tc0439 mutant (n=8) at day 3 post 
infection (p < 0.01), but not those infected with tc0437 (n=8) or tc0438 (n=8). IFU 
shedding from mice infected with CM did not vary significantly from mice infected 
with mutants of (B) t0440 (n=12) or (C) guaA (n=16).  (D) Shedding by mice 
infected with add (n=8) mutant was significantly lower than with C. muridarum at 
3 days (p < 0.0001) and 7 days (p < 0.01) post infection. IFU shedding from mice 
infected with add (n=8) mutant was also significantly reduced at 3 days (p < 
0.0001), 7 days (p < 0.05) and 10 days (p < 0.001) post infection. Data are 
presented as mean IFU (± SD) for mice per group. Statistical differences were 
analyzed by two-way ANOVA with Bonferroni post hoc test.  
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TABLE 2.1. Primers for RT-PCR 
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TABLE 2.2. Primers for qRT-PCR 
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TABLE 2.3. Primers for cloning PZ fragments into the pAC-lacZ vector 
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TABLE 2.3. Cont.  
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TABLE 2.4. Identification of promoter elements in the C. muridarum PZ 
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TABLE 2.4. Cont.  
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TABLE 2.5. Primers for TILLING 
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TABLE 2.6. Summary of TILLING screen size and isolated mutants 
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TABLE 2.7. Polymorphisms in C. muridarum parent strain  
 
 
C. muridarum Nigg isolate accession number: AE002160.2  
C. muridarum Weiss isolate accession number: ACOW00000000 
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TABLE 2.8. SNPs in C. muridarum tc0437 mutant 
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TABLE 2.9. SNPs in C. muridarum tc0438 mutant 
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TABLE 2.10. SNPs in C. muridarum tc0439 mutant 
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TABLE 2.11. SNPs in C. muridarum tc0440 mutant  
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TABLE 2.12. SNPs in C. muridarum add mutant 
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TABLE 2.13. SNPs in C. muridarum guaA mutant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
 
TABLE 2.14. SNPs in C. muridarum guaB mutant 
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CHAPTER 3 
A GENETIC SCREEN REVEALS THAT CHLAMYDIA MURIDARUM IFN-γ 
RESISTANCE IS A COMPLEX PHENOTYPE 
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3.1 Abstract 
 
 Some anti-chlamydial effector mechanisms controlled by the Th1 cytokine 
IFN-γ differ in mice and in humans and this can impact modeling of human 
chlamydial infections in mouse models. C. muridarum, a natural mouse 
pathogen, is highly resistant to IFN-γ in mice compared to C. trachomatis strains 
that infect humans. We screened a library of EMS-mutagenized C. muridarum 
strains to identify mutants sensitive to IFN-γ, with the goal being to identify and 
map C. muridarum IFN-γ resistance genes. 31 moderately to highly IFN-γ 
sensitive (igs) isolates were identified and genomes of four of these were 
sequenced. All igs strains contained multiple mutations, so revertants of igs4, the 
most sensitive mutant, were selected by serial passage in IFN-γ-treated mouse 
cells. Almost all of the revertants had intragenic suppressor mutations that were 
predicted to truncate a putative inclusion membrane protein (inc) allele of 
unknown function that was mutated in isg4. IFN-γ sensitivity of igs4 was not 
reversed by an iNOS inhibitor or a scavenger of reactive oxygen species, 
indicating that igs4 was susceptible to other IFN-γ-regulated antimicrobial effector 
pathways. igs4 suppressor mutants behaved similarly to wild-type C. muridarum 
in mice whereas igs4 was profoundly attenuated and its virulence was not 
restored in IFN-γ-/- mice. igs4 was also sensitive to IFN-β in cell culture, 
suggesting that compensatory roles played by Type I IFNs might be sufficient to 
control igs4 infection in mice. Overall, the data suggest that a gain-of-function 
missense mutation in a C. muridarum-specific Inc protein conferred IFN 
sensitivity to C. muridarum in vitro and accelerated its clearance from mice. This 
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mutant could be particularly useful in differentiating IFN-γ-dependent and 
independent pathways for control of C. trachomatis infection and disease in mice.  
3.2 Introduction 
The genus Chlamydia comprises a genetically similar, but pathogenically 
diverse, group of obligate intracellular bacterial pathogens, including the 
important human pathogen C. trachomatis. Acquisition and loss of chlamydial 
effectors that counter host immune defenses may have contributed to distinct 
host tropisms of some Chlamydia spp. (1-5). Identifying these bacterial effectors 
has been challenging because until recently, Chlamydia lacked a genetically 
tractable system (6).  
The Th1 cytokine interferon-gamma (IFN-γ) is a key determinant of 
chlamydial tropism in vitro (7-9). For example, the mouse pathogen C. 
muridarum and the sexually transmitted human pathogen C. trachomatis serovar 
D can productively infect a variety of murine and human epithelial cell lines in the 
absence of IFN-γ. If mouse oviduct epithelial cells are exposed to IFN-γ, C. 
trachomatis serovar D, but not C. muridarum, is strongly inhibited (7). IFN-γ 
inhibits both C. muridarum and C. trachomatis serovar D in human epithelial cells 
in tryptophan-limiting conditions, but only the growth of C. trachomatis can be 
restored by adding an indole intermediate to the cell culture medium (2, 8, 10). 
Thus, it appears that C. muridarum and C. trachomatis have developed different 
strategies to circumvent IFN-γ regulated defenses that are relevant in cells of 
their natural host organisms. 
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More is known about how IFN-γ controls chlamydial infections than is 
known about the cognate bacterial effectors that these pathogens use to 
counteract the effects of this cytokine. In human epithelial cells, the tryptophan 
decyclizing enzyme indoleamine 2,3 dioxygenase (IDO) appears to be the most 
important IFN-γ-regulated pathway in chlamydial inhibition (7, 8, 11-14). This is 
based upon observations that IFN-γ inhibition of C. trachomatis and C. 
muridarum can be completely reversed by adding tryptophan in some human cell 
culture models (2, 8, 15). Although p65 family interferon inducible GTPase 
proteins (p65 IRG) may not be directly antimicrobial, there is evidence that these 
proteins potentiate IFN-γ inhibition of C. trachomatis in human epithelial cells 
(16). Since IDO may not be functional in anaerobic regions of the female genital 
tract in humans (17), it is unclear if these pathways are relevant to human C. 
trachomatis genital infection. 
The role of IFN-γ in C. trachomatis infection and disease has been studied 
more extensively in mice. IFN-γ knockout mice are susceptible to C. trachomatis 
genital tract infection, and develop more severe pathology and disseminated 
infections (7, 18, 19). IDO is not regulated by IFN-γ in murine genital tract 
epithelial cells or fibroblasts (7, 8) and the course of C. trachomatis genital tract 
infection does not differ in wild type and IDO knockout mice (7). This suggests 
that different pathways control C. trachomatis infections in mice and humans. 
The role of p65 IRGs in C. trachomatis infection has not yet been evaluated in 
mice although there is evidence that some of these proteins contribute to control 
of this pathogen in murine fibroblasts (20, 21). Other IFN-γ regulated proteins and 
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pathways including inducible nitric oxide synthase (iNOS), the phagocyte oxidase 
complex (phox) and various interferon inducible p47 GTPase family members 
(p47 IRGs) clearly impact C. trachomatis infection or disease progression in 
mice. inos-/- and inos-/-/phox-/-  mice cannot efficiently clear C. trachomatis genital 
tract infections (22-25). Multiple p47 IRGs may restrict C. trachomatis growth in 
murine fibroblasts and epithelial cells (7, 26-28). Some p47 IRG knockout mice 
are more sensitive to intravenous challenge with C. trachomatis (26, 27, 29). 
Disentangling roles of the individual p47 IRGs in the murine models has proven 
challenging because loss of these proteins can trigger compensatory immune 
responses (29). It is clear however that inos-/- (7), inos-/-/phox-/-  (23) and some 
p47 IRG-/- mice (29) are less susceptible to C. trachomatis genital tract infection 
than are IFN-γ-/-  mice (7), thus suggesting that the anti-chlamydial effects of 
these pathways may be additive or could work with unidentified IFN-γ pathways. 
Discovery of chlamydial effectors that counteract IFN-γ has relied heavily 
upon genome sequencing. Comparison of C. trachomatis and C. muridarum 
genomes revealed a partial tryptophan biosynthesis operon that was only present 
in C. trachomatis (3, 30). Presence of intact tryptophan synthase genes was 
subsequently shown to separate C. trachomatis urogenital and trachoma biovar 
isolates (2, 5). Work from the McClarty group first showed that C. trachomatis 
tryptophan synthase was functional in E. coli (10) and a later reverse genetic 
study confirmed that tryptophan synthase is required for indole rescue of C. 
trachomatis in cell culture (31). It has been speculated that tryptophan synthase 
harvests indole from other urogenital microorganisms to make tryptophan and 
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circumvent tryptophan depletion mediated by host IDO (1, 2). Duplication and 
polymorphisms of tyrP, a putative tryptophan transporter, were linked to 
chlamydial IFN-γ resistance and tropism in other studies (32, 33). Even less is 
known about the genes that mediate C. muridarum IFN-γ resistance. We 
previously speculated that the C. muridarum cytotoxin family might inactivate 
IRGs based primarily on their homology to effectors of other bacteria that 
inactivate GTPases and their expansion in C. muridarum (1, 7). Some C. 
muridarum effectors that counter IFN-γ are pre-loaded in EB and may function in 
trans because metabolically inactive C. muridarum EB can partially restore C. 
trachomatis growth in IFN-γ treated mouse cells (34). The identity of these C. 
muridarum effectors is unknown. 
In this study we identified IFN-γ sensitive C. muridarum mutants using a 
genetic screen. Genome sequencing of four of these IFN-γ sensitive (igs) 
mutants revealed that they shared no common mutations and that C. muridarum 
IFN-γ resistance is a complex phenotype. We determined that IFN-γ sensitivity of 
one mutant, igs4, was likely linked to a gain-of-function mutation in the putative 
inclusion membrane protein (Inc) TC0574 using genetic analysis. Virulence of 
igs4, but not igs4 suppressor mutants, was severely attenuated in the murine 
genital tract infection model and igs4 infection only provided partial protection 
against re-infection with virulent C. muridarum in C57/B6 mice. IFN-γ sensitivity 
of igs4 was not reversed by inhibitors of iNOS and reactive oxygen species 
suggesting that it might be sensitive to IRG or other uncharacterized interferon-
regulated antimicrobial pathways. Our results provide the first molecular insights 
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into the mechanisms of C. muridarum IFN-γ resistance and a powerful set of 
mutants for identification of chlamydial genes that counteract IFN-γ regulated 
defenses. 
 
3.3 Methods 
3.3.1 Chlamydia and cell culture 
Chlamydia muridarum (C. muridarum) and Chlamydia trachomatis 
L2/434/Bu (C. trachomatis) were gifts from Dr. Harlan Caldwell (Rocky Mountain 
Laboratories, NIH-NIAID). The rifampin-resistant C. trachomatis L2/434/Bu 
isolate rifR (C. trachomatis rifR) was described previously (34). Chlamydiae were 
routinely propagated in HeLa229 (HeLa) or mouse McCoy cells and chlamydial 
elementary bodies (EB) were purified by density gradient centrifugation as 
described previously (34-36). Dulbecco's modified Eagle's medium (Hyclone) 
supplemented with 10% fetal bovine serum, sodium pyruvate (Atlanta 
Biologicals), non-essential amino acids (Gibco), and 5 µM HEPES buffer (Sigma) 
(DMEM-10) was used for cell culture and was supplemented with mouse 
recombinant IFN-γ (0.15 ng/U) (R&D systems) in some experiments. Unless 
stated otherwise, 20 U/ml IFN-γ was added to cell culture media for 24 hours 
prior to infection and to the infection media in IFN-γ treatment experiments. Cell 
culture was performed at 37°C in a 5% CO2 atmosphere. 
 
3.3.2 Chemical mutagenesis 
Confluent 150 cm2 flasks of Vero cells were infected with C. muridarum at 
a multiplicity of infection (MOI) of 2 in sucrose phosphate glutamic acid buffer 
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(0.25 M sucrose, 10 mM sodium phosphate, 5 mM L-glutamic acid, pH7.2) (SPG) 
by rocking for 1.5 h and were incubated in DMEM-10 supplemented with 100 
μg/mL cycloheximide. The monolayers were washed 16 hours post infection (hpi) 
and were then treated with 10 mL DMEM-10 supplemented with 15 mg/ml ethyl 
methanesulfonate (EMS) for 1 h to mutagenize EB as described previously (31, 
37). The monolayers were washed with phosphate buffered saline (PBS) to 
remove the mutagen and fresh DMEM-10 with cycloheximide was added. The 
media was aspirated and the infected cell monolayers were disrupted with 3 mm 
glass beads at 26 hpi in SPG. Aliquots of mutagenized EB stocks were stored at 
-80°C. 
 
3.3.3 Mutant library construction 
McCoy cell monolayers in 6-well cell culture plates were infected with 
mutagenized EB to isolate plaques (38). Well-isolated plaques were picked 10 
days post infection using plugged pipette tips and were transferred into tubes 
containing 150 µl SPG and 3 mm glass beads. EB were released by agitation at 
1400 rpm for 2 min in an Eppendorf Thermomixer (Eppendorf). Plaque lysates 
were arrayed in deep 96-well plates and archived at -80°C. 30 μL of each plaque 
isolate was used to infect McCoy cells in 96-well plates by centrifugation (168 x g 
for 1 h at room temp.) and rocking (30 min at 37°C) and the infected cells were 
frozen 26 hpi in SPG at -80°C. EB were harvested by thawing and transferred to 
96-deep-well plates for use as working stocks in mutant screens. 
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3.3.4 IFN-γ sensitive (igs) mutant screen  
McCoy cells were seeded in 96-well plates in DMEM-10 and were 
incubated until 90% confluent. The medium was then replaced with fresh DMEM-
10 +/- IFN-γ and the plates were incubated for 24 h. Equal inoculums of mutant 
working stocks were used to infect the plates as described above and fresh 
DMEM-10 +/- IFN-γ was added. The monolayers were fixed 24 hpi in methanol at 
room temp. for 5 min, washed with PBS and then blocked in PBS with 1% bovine 
serum albumin (BSA) for 1 h at room temp. Inclusions were labeled with a murine 
monoclonal antibody (mAB) against chlamydial LPS (EVIH1), a gift from Harlan 
Caldwell, followed by a secondary Alexa 488 conjugated goat anti-mouse IgG 
(Life Technologies). Inclusions were imaged using an EVOS® FL Auto cell 
imaging microscope and counted using a custom macro written in Image J (39). 
 
3.3.5 Inclusion Forming Unit Assays 
Inclusion forming unit (IFU) and recoverable IFU (rIFU) inclusion assays 
were performed in McCoy cells in 24 or 96-well cell culture plates. Infections 
were performed by centrifugation and rocking as above and IFN-γ was added in 
some experiments. For IFU experiments, cells were fixed in methanol and 
inclusions were labeled with antibodies as described above. For rIFU assays, cell 
monolayers were harvested in SPG by scraping and EB were released by bead 
agitation. Serial dilutions of these lysates were used to infect McCoy cells and 
inclusions were visualized and counted 24 hpi as described for IFU. In some rIFU 
experiments, 2 mM of the iNOS inhibitor L-NMMA (L-NG-monomethyl arginine 
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citrate, Cayman Chemical) or 15 mM of the hydroxyl radical scavenger DMTU 
(Dimethylthiourea, Cayman Chemical) or both were added simultaneously with 
IFN-γ.  
 
3.3.6 Analysis of igs mutant inclusion morphology 
McCoy cells were seeded in 24-well tissue culture plates on glass 
coverslips overnight and then were incubated an additional 24 h +/- 20 U/ml IFN-
γ. The cells were then infected with C. muridarum, C. trachomatis or igs mutants 
at an MOI of 0.1 by centrifugation and rocking and were overlaid with infection 
medium +/- 20 U/ml IFN-γ. At 24 hpi, the infected cells were fixed with methanol, 
rinsed with PBS, treated with 0.05% Evans Blue for 1 min and rinsed again with 
PBS. The fixed cells were blocked in 0.1% BSA for 1 h and then stained with the 
primary antibody EVI-H1 followed by a secondary DY488-conjugated goat anti 
mouse IgG antibody (Life Technologies). The coverslips were mounted in 
Prolong gold anti-fade reagent with DAPI (Life Technologies) and imaged using a 
Leica DMI6000B microscope with a 63X and 100X oil immersion objectives. At 
least 30 inclusions of each strain in each condition were imaged.  
Inclusion morphology of chlamydial strains in HeLa cells was similarly 
analyzed. HeLa cells were grown on coverslips in tryptophan-free DMEM (trp- 
DMEM-10) (University of California at San Francisco, Cell Culture Facility, San 
Francisco, CA) supplemented with 10% dialyzed FBS (HyClone) or in media 
containing excess tryptophan (trp+ DMEM-10) by the addition of 128 mg/L 
tryptophan to trp- DMEM-10. 20 U/mL of human recombinant IFN-γ (R&D 
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Systems) was added to culture media 24 hours prior to infection and treatment 
continued throughout infection. Infected cells were fixed at 24 hpi with methanol, 
stained with EVI-H1 and imaged as described above.  
 
3.3.7 Isolation of igs suppressor mutants 
McCoy cell monolayers were incubated for 24 h in DMEM-10 + 20 U/ml 
IFN-γ, infected with the IFN-γ sensitive C. muridarum mutant igs4 (described in 
the Results) at an MOI of 1.5 (3 x 106 total IFU) by centrifugation and rocking and 
were incubated for 24 h in DMEM-10 + 20 U/ml IFN-γ. The infections were 
harvested by scraping in SPG and EB were released by bead agitation. One-fifth 
of each harvest was used to infect a new well of IFN-γ-treated McCoy cells, and 
then the entire infection and harvest cycle was repeated 6-8 times. The number 
of chlamydia-infected cells declined to undetectable levels in most wells after 4 
passages, whereas 23/96 wells became heavily infected by passage 6. 
Suppressor mutants (S1-S9) were isolated from the latter wells and were purified 
by two rounds of plaque cloning. 
 
3.3.8 Construction of tc0574::GII(bla)  
EB from a plasmid-cured isolate of C. muridarum (108 IFU), which was a 
gift from Harlan Caldwell (40), were transformed with a modified vector pFDTT3 
containing an intron targeted to tc0574 (7 µg) which was constructed similarly to 
an incA targeting intron plasmid recently described by Johnson et al (41). The 
TargeTronTM algorithm (Sigma) was used to design tc0574-specific primers 
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(supplemental table 3) for retargeting pDFTT3 between nucleotides 44 and 45 of 
tc0574. Transformation was performed as described previously (41, 42), except 
the infections were performed by centrifugation at 550 x g for 1 h at room temp, 
and were allowed to proceed 30 h before EB were harvested by bead agitation to 
generate Passage P0. Additional passages were performed in 6-well tissue 
culture dishes, and the growth medium was supplemented with 5 µg/ml ampicillin 
from P2-P9. Clones from P9 were purified by two rounds of plaque isolation as 
described above, except that the overlay medium was supplemented with 5 
µg/ml ampicillin. Insertion of the intron in tc0574::GII(bla) was confirmed by PCR 
and Sanger sequencing. 
 
3.3.9 Co-infection rescue assays 
Co-infections of McCoy cells with C. trachomatis rifR and C. muridarum or 
igs4 was performed as described previously (34). Confluent cells in 24-well 
plates were infected with C. trachomatis rifR at an MOI of 0.5 in SPG, +/- 20 U/mL 
IFN-γ, and sufficient rifampin (0.1 µg/mL) to completely inhibit C. muridarum 
inclusion development. Some wells were co-infected with C. muridarum or igs4 
EB. Following centrifugation and rocking, SPG was replaced by DMEM-10 
containing rifampin, +/- 20 U/mL IFN-γ. Cells were harvested in SPG by scraping 
at 34 hpi and C. trachomatis rifR EB were collected by bead agitation. 
Recoverable IFU assays were performed as above except that rifampin was 
included in the infection medium and the inclusions were visualized by labeling 
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with the C. trachomatis serovar L2 MOMP-specific monoclonal antibody (mAB) 
L21-45 which was a gift from Harlan Caldwell. 
 
3.3.10 Western blot analysis of iNOS expression and Griess Assay 
 Expression of iNOS protein was analyzed by Western blot. Cells from the 
Griess assay experiments were washed with PBS and then incubated in 50 ml 
Lysis buffer (2% sodium dodecyl sulphate (SDS), 10% glycerol, 62 mM Tris, pH 
6.8) supplemented with a Protease Inhibitor mini tablet (Pierce) for 10 min on ice. 
Cells were gently scraped and denatured at 95°C for 5 min. Protein samples 
were separated in 10% SDS-polyacrylamide gels and electrophoretically 
transferred to nitrocellulose membranes. The proteins were then labeled with a 
primary rabbit anti-mouse iNOS mAb (#2982S) or a rabbit anti-murine GAPDH 
mAb (#2118S), followed by a secondary anti-rabbit horse radish peroxidase-
conjugated mAB antibody (#7074), all of which were purchased from Cell 
Signaling. Proteins were visualized by adding SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) according to the manufacturer instructions. 
 Nitrite was measured using a commercial Griess assay kit (Biotium). 24-
well plates containing uninfected or infected McCoy cells, +/- IFN-γ, were cultured 
for 24 h +/- 2 mM L-NMMA. 150 µl volumes of the culture supernatants were 
incubated with 20 µL Griess reagent (0.05% N-(1-naphthyl)ethylenediamine 
dihydrochloride, 0.5% sulfanilic acid, 2.5% phosphoric acid) in a 96-well plate for 
30 min at room temp. Absorbance was measured at 540 nm and nitrite levels 
were calculated against a sodium nitrite standard curve. 
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3.3.11 Sequencing Library Construction and Genome Sequencing 
 C. muridarum isolates were expanded in McCoy cells. Genomic DNA was 
isolated from 30% Renocal gradient-purified EB. EB were treated with DNase I 
(NEB) at 37°C for 1 hour followed by treatment with 5mM EDTA and incubated at 
75°C for 10 min to halt digestion. Total DNA was extracted from EB using the 
DNeasy Blood & Tissue kit (Qiagen) and genomic DNA was quantified using the 
Quant-It High Sensitivity dsDNA assay (Life Technologies Corp.). 1 µg aliquots of 
purified genomic DNAs were subjected to NEBNext dsDNA Fragmentase (NEB) 
treatment to generate dsDNA fragments for multiplex Illumina sequencing. The 
TruSeq Nano DNA sample preparation kit was used to prepare DNA sequencing 
libraries according to the manufacturer’s protocols (Illumina Inc.). Samples were 
multiplexed using TruSeq Single Index Sequencing primers. Equimolar 
concentrations of indexed libraries were combined into a single pool and were 
sequenced at Tufts University Genomics Core. Paired-end 100 bp sequencing 
was performed on the Illumina HiSeq 2500 platform. 
3.3.12 Genome assembly and analysis 
Single nucleotide polymorphisms (SNP), nucleotide insertions and 
deletions analysis (Indel), were mapped from raw sequence data to the 
corresponding reference genome accession number (AE002160.2) using 
Bowtie2. Resulting SAM files were converted to BAM file format and sorted. 
SNPs/Indels were called using a Samtools mpileup function. Ambiguous 
sequences and mutation calls with low quality scores were resolved by PCR and 
Sanger sequencing. 
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3.3.13 Taqman quantitative real time PCR (q-PCR) 
McCoy cells were plated at 0.5 × 106 cells per well in twenty four-well plates in 
DMEM-10 +/- IFN-γ and the plates were incubated for 24 h. Equal inoculums of 
WT and igs4 were then used to infect the plates as above and fresh DMEM-10 
+/- IFN-γ was added. Following infection, the cell monolayers were disrupted via 
cell scraping at 2, 18, 24, 30, and 36 hpi, and total DNA was extracted using the 
IBI gMax Mini Kit. The DNA was re-suspended in 50 μl of elution buffer. Taqman 
quantitative real time-PCR (q-PCR) was performed in an Eppendorf Realplex4 
thermocycler using the FastStart Taqman Probe master mix (Roche). The 
amplification cycle included 10 min at 95°C, followed by 40 cycles of 95°C for 20 
s, 60°C for 1 min and 68°C for 20 s. Taqman primer-probe sets were designed 
using PrimerQuest software (Integrated DNA Technologies). The sequences of 
the primers and probes were: 16S Forward (5’-GTAGCGGTGAAATGCGTAGA-
3’); 16S Reverse (5’-CGCCTTAGCGTCAGGTATAAA-3’); 16S Taqman probe 
(5’- / 56-FAM / ATGTGGAAG / ZEN / AACAACAGTGGCGAA / 3IABkFQ / -3’). 
Genome copy numbers were determined by comparison to standard curves of 
dilutions of a plasmid that contained a cloned copy of the C. muridarum 16S 
rRNA gene. 
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3.3.14 Reverse transcriptase PCR (RT-PCR) analysis of tc0572-tc0574 
expression  
McCoy cells were seeded in 6-well tissue culture plates and were allowed 
to adhere overnight. They were then incubated for an additional 24 h +/- 20 U/ml 
IFN-γ. The cells were infected at an MOI of 1 by centrifugation and rocking and 
were overlaid with infection medium +/- 20 U/ml IFN-γ. Total RNA was harvested 
24 hpi using TRISure reagent (Bioline). The RNA was treated with DNAseI 
(Qiagen) for 15 min and then was purified on a GeneJET RNA purification 
column (Thermo scientific). RT-PCR reactions were performed with 100 ng of 
total RNA and gene specific primers (Table 3.3) using the Mytaq one-step RT-
PCR kit (Bioline). RNA was harvested and processed similarly for semi-
quantitative RT-PCR. 1 µg of total RNA was then converted to cDNA with 
random hexamers utilizing iscript select cDNA synthesis kit (Biorad).  
 
3.3.15 In vivo pathogenicity of C. muridarum mutants 
 C. muridarum and various mutant strains were expanded in HeLa cells 
and EB were purified using Renocal gradients. 6-10 week old female C57BL/6J 
or B6.129S7-Ifnγtm1Ts/J (IFN-γ-/- mice) (Jackson laboratories, Bar Harbor, ME) 
were treated with 25 mg/mL Depo-Provera at 10 and 3 days prior to infection by 
subcutaneous injection of 100 µl (2.5 mg total) between the front shoulders. Mice 
were inoculated with C. muridarum wild-type or mutants by placing 5 µl of SPG 
containing 50,000 inclusion forming units (IFU) into the vaginal vault. At various 
time points following infectious challenge (day 3, 7, 10, 14 and weekly thereafter) 
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the vaginal vault was swabbed using a Calgiswab and the infections were 
monitored by counting IFU. 
Fifty-nine days following primary infection, mice were treated daily for 11 
days with 300 µg doxycycline/mouse given by intraperitoneal injection to assure 
infection cure, and then rested for 14 days prior to assessing protective immunity. 
To determine if primary infections induced protective immunity, mice were treated 
with Depo-Provera following the 14-day rest period, reinfected with 50,000 IFU of 
wild-type C. muridarum, and the infections were monitored as described above. 
Mice were euthanized at the termination of the secondary infection experiment 
and presence or absence of hydrosalpinx was recorded. 
Nonparametric repeated measures analysis of variance (ANOVA) models 
were used to test whether the time trends between treatment groups were 
parallel and, if they were parallel, to determine whether the groups differ with 
respect to magnitude of response. An α-level of 0.05 was used to determine the 
statistical significance of each test. No adjustments for multiple comparisons 
were made. All analyses were performed using R (version 3.0.1, R Foundation 
for Statistical Computing, Vienna, Austria). 
 
3.3.16 Treatment with IFN-β and IFNAR-1 neutralizing antibody 
 McCoy cells were incubated with 10 µM anti-mouse IFNAR-1 antibody 
(clone MAR-5A3) or an IgG1 isotype control antibody (BioLegend).  At the time of 
antibody addition, some wells were treated with 250 U/mL IFN-β (R&D Systems). 
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Cells were infected after 1 hour with C. muridarum or igs4 at an MOI of 0.5. IFN-
β ± Ab treatment continued throughout the course of infection.  
 
3.4 Results 
3.4.1 A phenotypic screen for IFN-γ sensitive C. muridarum mutants  
C. trachomatis and C. muridarum can establish productive infections in 
McCoy murine fibroblast cells (McCoy cells). However, C. trachomatis infection 
of McCoy cells is profoundly inhibited by low doses of the Th1 cytokine interferon 
gamma (IFN-γ), while C. muridarum infection is only mildly affected (8, 34). We 
reasoned that C. muridarum IFN-γ resistance in murine cells is linked to genes 
that are either absent or non-functional in C. trachomatis and that these genes 
might be dispensable for infection of McCoy cells in the absence of IFN-γ (1, 7). 
We screened a library of 2976 moderately EMS-mutagenized and plaque-cloned 
C. muridarum isolates to identify mutants that could productively infect McCoy 
cells and were sensitive to IFN-γ. 
Numbers of inclusions that the library isolates formed in IFN-γ treated (10 
U/ml 24 h pre- and post-infection) and untreated McCoy cells were counted and 
compared using an automated microscopic assay. The ratio of inclusions formed 
by the library wild type parent (C. muridarum) -/+ IFN-γ averaged 1.22 fold and 
328/2976 library clones that yielded higher ratios were selected for secondary 
screening. The secondary screen was performed in triplicate and the IFN-γ 
concentration was increased to 20 U/ml to improve specificity. The ratio of 
inclusions formed by C. muridarum in -/+ 20 U/ml IFN-γ averaged 1.26 fold and 
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31/328 isolates that yielded ratios equal to or greater than 2 fold (range 2-7) were 
selected for further characterization. These isolates were plaque-cloned and the 
phenotypes of all 31 mutants were confirmed by an additional round of screening 
(in triplicate) in 20 U/ml IFN-γ. Four interferon gamma sensitive (igs) mutants 
were expanded for characterization and genome sequencing. 
 
3.4.2 Phenotypes of igs mutants can be differentiated by inclusion forming unit 
assays and morphology 
The ability of C. muridarum and the igs mutants to infect and replicate in 
McCoy cells was compared using IFU and rIFU assays (Fig. 3.1). Infection of 
McCoy cells with C. muridarum was robust and production of infectious EB 
neared maximum by 18 hpi (Fig. 3.1 A, B). In the absence of IFN-γ, IFU 
production from 3 of the 4 igs mutants (igs1-3) was nearly indistinguishable from 
C. muridarum, whereas peak igs4 IFU production was slightly delayed (Fig. 3.1 
C-J). Quantitative PCR (q-PCR) analysis showed that igs4 genome copy number 
was reduced compared to C. muridarum at 18 hpi but was similar to C. 
muridarum by 24 hpi (Fig. 3.2). 
The defining phenotype of igs mutants was that fewer inclusions were 
observed 24 hpi in the presence of IFN-γ and inclusion size and morphology of 
the mutants and parent were similar in untreated McCoy cells. It was unclear if 
IFN-γ sensitivity of these mutants was due to formation of fewer inclusions or 
lysis of inclusions prior to 24 hpi. Ratios of inclusions versus rIFU which were 
formed by C. muridarum and the igs mutants were compared to differentiate 
 121 
 
these possibilities. An IFU/rIFU ratio was defined as (IFU+ IFN-γ/IFU- IFN-γ)/(rIFU+ 
IFN-γ/rIFU- IFN-γ) to express the results of the growth curves as a single number 
(Table 3.1). The IFU/rIFU ratio of C. muridarum ranged narrowly from 0.9 to 1.1 
at 4 time points from 12 to 30 hpi. This indicated that C. muridarum formed 
slightly fewer inclusions in the presence of IFN-γ, but that once these inclusions 
formed they produced similar numbers of infectious EB in the presence or 
absence of IFN-γ. igs3 followed a similar pattern indicating that their phenotypes 
were primarily because they initially formed fewer inclusions in the presence of 
IFN-γ (Fig. 3.1 G, H). In contrast, elevated IFU/rIFU ratios were observed in igs1 
and igs2 suggesting that inclusions of these mutants yielded fewer infectious EB 
(Fig. 3.1 C-F). Interestingly, the IFU/rIFU ratio of igs4 increased progressively 
from 0.7 at 12 hpi to 9.4 at 30 hpi indicating that this mutant not only produced 
fewer inclusions in the presence of IFN-γ, but that many of the chlamydiae failed 
to mature in the few remaining inclusions (Fig. 3.1 I, J). The genome copy 
number of igs4 also failed to increase between 18 and 24 hpi in IFN-γ treated 
cells and subsequently decreased (Fig. 3.2). These results showed that the igs 
mutants could be separated into distinct phenotypic classes. 
We previously reported that C. trachomatis is most sensitive to IFN-γ when 
the cytokine is added prior to or shortly after infection (34), so we tested if igs4 
exhibited a similar pattern. C. trachomatis and igs4 yielded similar results in 
temporal IFN-γ addition assays (Fig. 3.3). Both strains were inhibited when IFN-γ 
was added prior to or shortly after infection, but were mostly unaffected when 
IFN-γ was added 12 h or later post-infection. This implied that the effectors that 
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inhibit C. trachomatis and igs4 target nascent or early inclusions and are less 
effective against more mature inclusions. 
 
3.4.3 IFN-γ causes lysis of igs4 inclusions in mouse cells 
Inclusion morphology of the igs mutants and C. muridarum was compared 
using fluorescent microscopy (Fig. 3.4 A). Size and morphology of most of the 
inclusions formed by C. muridarum and the igs mutants were similar in McCoy 
cells in the absence of IFN-γ. Some lysed inclusions was observed in populations 
of igs1 and igs4, although these never exceeded 10% (Fig. 3.4 B). In IFN-γ 
treated McCoy cells, the morphologies of most C. muridarum and igs1-3 mutant 
inclusions were also similar, with the caveat that minor sub-populations of lysed 
inclusions were again observed with igs1 (Fig. 3.4 B). In contrast, the vast 
majority of igs4 inclusions had lysed by 24 hpi in IFN-γ treated McCoy cells (Fig. 
3.4 A, B). These results indicated that the IFN-γ sensitivity of igs4 was associated 
with premature inclusion lysis. 
 To determine if igs4 was similarly sensitive to human IFN-γ, we 
examined the inclusion morphology of igs4 and C. muridarum in HeLa cells in 
tryptophan-free DMEM (Trp- DMEM-10) -/+ 20 U/ml IFN-γ (Fig. 3.5). In untreated 
HeLa cells, no lysed inclusions were observed with igs4 and C. muridarum. In the 
presence of cytokine, neither igs4 nor C. muridarum inclusions developed due to 
tryptophan starvation. When HeLa cells were treated with IFN-γ in DMEM 
containing excess tryptophan (Trp+ DMEM-10), igs4 and C. muridarum grew 
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normally and inclusions remained intact at 24 hpi. This implied that lysis of igs4 
inclusions was caused by mechanisms that were specific to mouse cells.  
 
3.4.4 IFN-γ sensitivity is a complex phenotype  
The C. muridarum parent isolate and the igs mutants were pair-end 
sequenced to an average coverage of 1511 fold (range 815 to 2894) on the 
Illumina HiSeq platform. The igs mutants differed by an average of 12.75 
mutations (range 8 to 20) from our C. muridarum isolate and 49 of the 51 total 
mutations in the four mutants were GC-AT transitions, consistent with their being 
elicited by EMS (43).  
All 4 igs strains had mutations in tc0412, the highly polymorphic (44) 
ortholog of C. trachomatis ct135, that were predicted to truncate TC0412 (364 
amino acids, full length): a C-T mutation (tc041266(Am)) in igs1 and igs3, a T-G 
mutation (tc0412338(Op)) in igs2 and frameshift mutations leading to a premature 
stop codon (tc0412197(Oc)) in igs4 (Table 3.2). To test if tc0412 polymorphisms 
contributed to IFN-γ sensitivity, tc0412 alleles of 10 library isolates with wild-type 
IFN-γ sensitivity, and 10 uncharacterized igs isolates from the secondary screen 
were sequenced. Four and five novel tc0412 sequences were identified in the ten 
wild-type and ten igs isolates, respectively (data not shown). This suggested that 
there was no correlation between tc0412 genotype and IFN-γ sensitivity in vitro, 
consistent with a previous study of a C. trachomatis isolate with a frameshift 
mutation in ct0135 (45). The observation that no other common genes were 
 124 
 
mutated in the igs mutants showed that our screen did not reach saturation and 
that C. muridarum IFN-γ resistance is a complex phenotype. 
 
3.4.5 A gain-of-function missense mutation in TC0574 is linked to IFN-γ 
sensitivity of igs4  
Since igs4 produced few infectious EB in IFN-γ treated McCoy cells, we 
used a serial passage strategy to test if we could isolate IFN-γ resistant 
revertants. This was successful in 23 of 96 experiments in which inoculums of 3 x 
106 igs4 IFU were blindly passed 6 times in IFN-γ treated McCoy cells. 
Phenotypes of nine representative isolates (S1-S9) were characterized in single 
time point IFU and rIFU assays and two of the isolates (S1 and S5) were further 
characterized in temporal IFU and rIFU assays (Fig. 3.6). IFN-γ sensitivity of all of 
these isolates was similar to C. muridarum at 24 hpi (Fig. 3.7). Developmental 
kinetics and inclusion morphology in the presence and absence of IFN-γ were 
also similar to wild type (Fig. 3.8). 
IFN-γ resistant revertants were isolated more frequently (7.9 x 10-6) than 
was anticipated for true revertants, based upon a previous estimate of 
spontaneous mutation frequency in C. trachomatis (1.10 × 10-9 to 3.84 × 10-10) 
(46). Therefore we tested if any of the mutant alleles that were present in the igs4 
parent had reverted or accumulated intragenic suppressors. Intragenic 
suppressor mutations in tc0574 were identified in 22 of the 23 revertants, 
although only 8 unique tc0574 genotypes were detected (Fig. 3.9), indicating that 
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some of the revertants may have been siblings in the original igs4 stock. No 
mutations were identified in any of the igs4 mutant alleles in S9. 
The genomes of S1, S5 and S9 were sequenced. S1 contained no 
additional mutations aside from the missense mutation in tc0574 identified by 
Sanger sequencing (Table 3.2). S5 contained a synonymous mutation in codon 
204 of tc0673, which encodes the heat shock gene repressor HcrA. S9 had a T 
to C transition that changed the predicted start codon of tc0573, the gene 
immediately upstream of tc0574, from valine to alanine (Fig. 3.9). This ORF, like 
tc0574, is predicted to encode an Inc protein and is located immediately 
upstream of tc0574 (47). 
Five of the 9 unique igs4 suppressor mutations were predicted to truncate 
mutant TC0574 of igs4 (Fig. 3.9). A possible explanation for the phenotype of S9 
was that translation of tc0574 is coupled to tc0573, in which case the proteins 
would be transcribed from the same transcript (48). Consistent with this 
hypothesis, we determined that tc0573 and tc0574 were co-transcribed as part of 
an operon that originated upstream of tc0572 using RT-PCR. (Fig. 3.10 A, B). 
We also determined that tc0574 transcript levels were similar in C. muridarum, 
igs4 and the suppressor mutants S5 and S9 using semi-quantitative RT-PCR 
(Fig. 3.10 C). These results ruled out the alternate possibility that the phenotype 
of igs4 was linked to destabilization of the larger polycistronic transcript detected 
by RT-PCR. Many of the mutations in the igs4 suppressors were predicted to 
truncate TC0574 suggesting that the normal function of TC0574 was unrelated to 
IFN-γ resistance. To independently test this, we inserted an ~2kb intron in the 5’ 
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prime end of tc0574 to create C. muridarum tc0574::GII(bla) (41). IFN-γ 
resistance of the tc0574::GII(bla) mutant was indistinguishable from C. 
muridarum and the suppressor mutants (Fig. 3.7). Overall the results suggested 
that the IFN-γ sensitivity of igs4 is caused by mutant TC0574 protein of altered 
function and that this phenotype can be suppressed by inactivating the mutant 
protein or by blocking its expression. 
 
3.4.6 igs4 EB can rescue C. trachomatis from IFN-γ  
Productive C. trachomatis infection in IFN-γ treated mouse cells can be 
partially rescued if the cells are co-infected with C. muridarum EB (34) and this 
blocks recruitment of the IRG proteins Irgb10 and Irga6 and to C. trachomatis 
inclusions (27). Rescue does not require C. muridarum replication or metabolic 
activity. We tested if igs4 could similarly rescue C. trachomatis to differentiate if 
C. trachomatis and igs4 had defects in the same or different pathways (Fig. 
3.11). IFN-γ-treated McCoy cells were simultaneously infected with a rifampin 
resistant C. trachomatis isolate and C. muridarum or igs4 EB in the presence of 
rifampin to inhibit growth of C. muridarum. C. trachomatis infection was rescued 
by C. muridarum in a dose-dependent manner up to a C. muridarum MOI of 4. 
Higher doses were not evaluated because of the immediate cytotoxic potential of 
C. muridarum EB (34, 49). Rescue with igs4 EB was similar to C. muridarum, 
suggesting that the underlying mechanisms of IFN-γ sensitivity in igs4 and C. 
trachomatis differ. 
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3.4.7 IFN-γ sensitivity of igs4 is not reversed by inhibitors of nitric oxide or 
reactive oxygen 
We next interrogated the mechanism of igs4 sensitivity to IFN-γ from the 
perspective of the stimulated host cell. Nitric oxide (NO) produced by inducible 
nitric oxide synthase (iNOS) and reactive oxygen species from the phagosome 
oxidase pathway (Phox) have been implicated in IFN-γ-mediated control of 
chlamydial infection in mice and mouse cells (22-24, 50, 51). We tested if igs4 
activated these pathways more robustly or was more sensitive to their products. 
Levels of iNOS protein in lysates of mock-treated and Chlamydia-infected 
McCoy cells +/- IFN-γ, were compared by Western blot (Fig. 3.12 A). iNOS was 
below the limit of detection in the mock infected cells and infection with C. 
muridarum, igs4, S1 and S5 also failed to elicit detectable iNOS by 24 hpi. 
Robust iNOS expression was detected in C. trachomatis infected cells at 24 hpi. 
Similar and relatively low levels of iNOS were detected in lysates of IFN-γ treated 
cells that were infected with C. muridarum or the mutants. However, levels of 
iNOS appeared to be consistently higher in IFN-γ-treated C. trachomatis-infected 
McCoy cells. These results suggested that igs4 IFN-γ sensitivity was not linked to 
elevated expression of iNOS. 
A possible explanation for the above results was that C. muridarum and 
the suppressor mutants modulated iNOS activity, whereas igs4 did not. This was 
tested by comparing nitrite levels in supernatants using the Griess assay (Fig. 
3.12 B). Nitrite levels mirrored iNOS levels found by Western blotting. Elevated 
nitrite was almost completely reversed by addition of 2 mM L-NMMA indicating 
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that iNOS, not altered expression or activity of constitutive nitric oxide synthase 
(NOS), was the primary source of nitrite. 
We also tested if igs4 was more sensitive to nitrogen oxide radicals 
produced by NO and reactive oxygen species using the competitive iNOS 
inhibitor L-NG-monomethyl Arginine citrate (L-NMMA) (52) and the oxygen radical 
scavenger dimethylthiourea (DMTU) (53) (Fig. 3.12 C). Neither compound, 
individually or in combination, rescued C. trachomatis or igs4, although the 
compounds effectively rescued C. trachomatis in IFN-g treated RAW 264.7 
murine macrophages (Krithika Rajaram, Chapter 4). These results suggested 
that IFN-γ sensitivity of igs4 was not due to enhanced production of NO or 
increased susceptibility to reactive nitrogen species. 
 
3.4.8 igs4 is attenuated in the murine genital tract 
Growth of igs4 in cell culture was similar to its parent under normal growth 
conditions but was diminished in the presence of IFN-γ (Fig. 3.1). To determine if 
igs4 had decreased pathogenicity in vivo, we used the murine genital infection 
model. The infection course of igs4 and C. muridarum in C57BL/6 mice differed 
significantly with respect to both duration of infection and magnitude of 
chlamydiae shedding (Fig. 3.13 A, P<0.0001). Differences in the magnitude of 
chlamydiae shedding were clearly evident as early as 7-10 days post infection, 
which correlates with marked inflammation and CD4+ T cell emigration to genital 
tract tissues (54). In contrast, the infections with the suppressor mutants S1 and 
S5 were indistinguishable from C. muridarum (P>0.05). These results suggested 
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that the suppressor mutations completely reversed the effects of the tc0574 
missense mutation in their igs4 parent. 
Next we tested if the decreased pathogenicity of igs4 in mice was 
mediated by IFN-γ. Surprisingly, the course and magnitude of igs4 infection was 
similar in C57BL/6 (IFN-γ+/+) and the IFN-γ-/- animals (Fig. 3.13 A, C; p>0.05). 
This result suggested that anti-chlamydial mediators not regulated by IFN-γ were 
sufficient to control igs4 infection.  
C. muridarum infection of mice produces an adaptive immune response 
that robustly protects against reinfection (55, 56). To determine if igs4 could 
similarly elicit protective immunity, C57BL/6 that had resolved primary genital 
infection were reinfected with wild type C. muridarum. Infection with igs4 
conferred partial protection against WT challenge in C57BL/6 mice (C. 
muridarum Fig. 3.13 A vs igs4 primary infection-WT reinfection Fig. 3.13 B; 
p<0.0001), but the magnitude of immunity as measured by bacterial shedding 
and duration of infection was significantly less than that induced by primary 
infection with C. muridarum (Fig. 3.13 B; p<0.001). Also, although there was a 
significant difference in chlamydiae shedding and infection duration between C. 
muridarum and igs4 in IFN-γ-/-mice (Fig. 3.13 C; P<0.0001), the degree of 
protective immunity conferred by primary WT and igs4 infection in IFN-γ-/- mice 
was indistinguishable (Fig. 3.13 D; P>0.05). Thus, primary genital infection with 
igs4 is much attenuated compared to C. muridarum infection, but nevertheless, 
significant protective immunity is elicited. 
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The development of hydrosalpinx following murine C. muridarum genital 
infection is used as a measure of upper genital tract immunopathology.  We 
found that the proportion of C57BL/6 mice that developed hydrosalpinx following 
infection with C. muridarum, igs4, S1 or S5 and reinfected with C. muridarum 
was 9/9, 0/10, 10/10 and 7/9, respectively. Similarly, only 2/10 IFN-γ-/- mice 
infected with igs4 and reinfected with C. muridarum developed hydrosalpinx, 
whereas 4/4 IFN-γ-/- mice challenged at both primary infection and reinfection 
with C. muridarum developed hydrosalpinx. Collectively, these data suggest that 
igs4 produces an infection that is not only attenuated in chlamydial shedding and 
infection duration, but also in upper genital tract pathology as measured by 
hydrosalpinx. Furthermore, infection with igs4 conferred immunity sufficient to 
protect against hydrosalpinx when challenged with C. muridarum. 
 
3.4.9 igs4 is sensitive to IFN-β 
 The attenuated phenotype of igs4 in IFN-γ-/- mice suggested that some of 
the IFN-γ anti-chlamydial pathways might also be regulated by innate immune 
interferons. For example, the type I interferons IFN-α/β and IFN-ε are expressed 
in the murine genital tract during C. muridarum infection (57-59). To determine if 
igs4 was susceptible to type I interferons, inclusion morphology of C. muridarum 
and igs4 was examined in McCoy cells ± 250 U/mL IFN-β (Table 3.4). C. 
muridarum inclusions at 24 hpi were similar in the presence or absence of 
cytokine. However, the percent of lysed igs4 inclusions increased from 8.5% in 
untreated cells to over 80% in cells treated with IFN-β. igs4 lysis induced by IFN-
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β was reduced to basal levels (9.14%) when McCoy cells were incubated with an 
anti-IFNAR antibody. The antibody failed to significantly reduce igs4 lysis in the 
absence of exogenous cytokine, but the addition of cycloheximide prior to 
infection abolished inclusion lysis (Table 3.4 and Amanda Rhoel, personal 
communication). Collectively, these results suggested that C. muridarum 
infection of McCoy cells was sufficient to induce the production of inhibitory 
factors, and their expression could be greatly increased by the addition of 
interferons.   
 
3.5 Discussion 
Chlamydia IFN-γ resistance is both strain and host-organism specific and 
few chlamydial genes that mediate this have been identified. We believe our 
study is the first to use a forward genetic approach to directly search for IFN-γ 
resistance genes. We previously speculated that plasticity zone (PZ) genes could 
be key determinants of C. muridarum IFN-γ resistance in mice (1, 34), but 
analysis of multiple nonsense mutants of C. muridarum PZ genes revealed no 
defect in resistance to IFN-γ in vitro or dramatic attenuation in mice (Krithika 
Rajaram, Chapter 2). Since none of the four igs mutants we sequenced had 
mutations in the same genes aside of the polymorphic tc0412 ORF, our results 
imply that chlamydial IFN-γ resistance is a complex phenotype. This could reflect 
the importance of IFN-γ resistance in C. muridarum virulence, prolonged 
pathogen adaptation or the inability of a single chlamydial effector to counteract 
mechanistically distinct anti-chlamydial pathways controlled by interferons. If the 
 132 
 
last hypothesis is correct, we expect that our collection of igs mutants would 
contain isolates that are sensitive to specific IFN-γ regulated effectors, such as 
iNOS, Phox and IRGs. One of the caveats of our screen is that it would not be 
expected to identify functionally redundant resistance genes. This could be 
relevant to phospholipase D and cytotoxin genes in the PZ which are present in 
multiple copies in C. muridarum (3). Requiring that igs mutants had near wild-
type growth in the absence of IFN-γ probably also prevented identifying genes 
with crossover functions in housekeeping and IFN-γ resistance. Nonetheless, our 
results suggest that characterization of additional igs mutants could be a 
powerful approach for identification of chlamydial IFN-γ resistance genes. 
We focused initial characterization on igs4 due to the strong phenotype of 
this mutant in cells of mouse, but not human, origin. We hypothesize that the 
phenotype of igs4 is caused by a gain-of-function tc0574 allele, although we 
have not yet been able to confirm that either TC0574 or mutant TC0574 proteins 
are expressed. Gain of function is suggested by observations that 1) predicted 
missense, nonsense and frame-shift mutations throughout tc0574 completely 
reversed igs4 IFN-γ sensitivity as did 2) destruction of the predicted start codon 
of the upstream gene tc0573 and 3) insertion of an ~ 2kb intron in the 5’ prime 
end of tc0574. These results, and our observation that expression of the larger 
polycistronic transcript encoding tc0574 was unaffected in igs4 and suppressor 
mutants, rules out the possibility that the igs4 phenotype is caused by nonsense-
mediated decay of upstream genes. Confirming that the igs4 tc0574 allele is 
gain-of-function will require allele swapping which may be challenging due to a 
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lack of systems for complementation at relevant gene dosage and the likely 
possibility that the mutant tc0574 allele is dominant. Isolation of igs4 genotypic 
revertants would also be difficult because phenotypic revertants arose >1,000 
fold more frequently than would be predicted for revertants. We cannot exclude 
that tc0574 suppressors are intergenic or bypass suppressor mutations of 
another mutant allele in igs4. However, with the relatively low degree of 
mutagenesis in igs4, the possibility that a random mutation serendipitously 
located to the same 381 bp gene as did 8 of 9 suppressors is unlikely. We hope 
to differentiate these possibilities using a lateral gene transfer approach we are 
developing for crossing C. muridarum strains (Amanda Roehl, personal 
communication).  
Little can be gleaned from homology of TC0574 to other chlamydial 
proteins, although in silico structural modeling suggests how the missense 
mutation in TC0574 in igs4 might alter this protein’s function. Our results suggest 
tc0574 is expressed as part of an operon with another putative Inc tc0573 (47) 
and possibly hemC, which is flanked by radA and pknD. An orthologous operon 
in C. suis MD56 is organized similarly and encodes homologs with 47% and 55% 
amino acid identity to TC0573 and TC0574, respectively (60). CT300 of C. 
trachomatis shares 42% amino acid identity with TC0574, but the region between 
hemC and ct300 in C. trachomatis contain numerous stops in all three frames. 
Why this operon was maintained in C. muridarum and C. suis but not C. 
trachomatis is unclear but seem consistent with a niche-specific function. Phyre2 
modeling suggested that TC0574 contains two α-helices that are packed 
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together (Krithika Rajaram, Chapter 5). Interestingly, glycine 81, mutated to 
glutamate in TC0574 of igs4, is located at the interface between the helices in 
TC0574. Ronzone et al. recently reported that a core region between the two α-
helices of IncA regulates homodimer formation and can block the SNARE-
mediated fusion and homotypic inclusion fusion activities of IncA (61). Thus, we 
speculate the mutation in TC0574 might alter homo-oligomerization or 
interactions of this protein with host proteins. Instability of igs4 inclusions also 
seems consistent with known functions of other Inc proteins in maintenance of 
inclusion morphology.  
How a mutant Inc could confer IFN-γ sensitivity is unclear but our 
observation that tc0574 frameshift and nonsense mutants were normal in this 
regard suggests that TC0574 does not directly mediate IFN-γ resistance. A trivial 
explanation could be that IFN-γ resistance is an indirect effect of the slight 
reduction in growth rate we observed between 18 and 24 hpi. We think this is 
unlikely because we have identified C. muridarum mutants with more severe 
growth defects in unrelated screens that have wild type IFN-γ resistance (David 
Nelson, unpublished observation). Alternately, mutation of TC0574 could lead to 
general inclusion instability that manifests IFN-γ sensitivity, although this still 
means that some direct or indirect effect of IFN-γ exacerbates inclusion 
instability. Our observation that inhibitors of iNOS and Phox cannot facilitate 
rescue argues against sensitivity of igs4 to these IFN-γ-mediated anti-chlamydial 
mechanisms. Coers et al. reported that ectopically expressed Irgb10 inhibits 
growth of C. trachomatis and that both Iigp1 (Irg6a) and IrgB10 localize to C. 
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trachomatis, but not C. muridarum, inclusions (27, 29). Whether p47 IRG proteins 
are regulated similarly in McCoy cells is unknown, but similar experiments might 
be useful in determining if igs4 is sensitive to IRG proteins. Differentiating these 
possibilities in IRG knockout cell lines and mice could be challenging because 
the effects of loss of individual IRG proteins may be masked by other IRG 
proteins at the cellular level (20), and by compensatory T-cell responses at the 
level of the organism (29). If IFN-γ sensitivity of igs4 cannot be explained by 
susceptibility to IRG family proteins our results may indicate that Plac8 (25) or 
novel pathways not yet implicated in chlamydial IFN-γ resistance are key.  
 Our observation that igs4 virulence was not completely restored in IFN-γ-/- 
mice suggests that clearance of this mutant is not solely regulated by this 
cytokine. We observed that igs4 is sensitive to exogenous IFN-β in McCoy cells. 
Type I interferons modulate the course of C. muridarum infection and disease in 
the murine genital tract. The magnitude and duration of C. muridarum genital 
tract shedding was reduced in IFNAR-/- mice, possibly due to improved CD4 T-
cell recruitment to local lymph nodes in these animals (57). In contrast, mice that 
lack the reproductive tract-specific and constitutively-expressed type I interferon 
IFN-ε shed more C. muridarum than wild type mice and this is most pronounced 
early in infection (58). Relevant to the design of our mutant screen, IFN-ε is not 
secreted by cells of fibroblastic lineage (59). Since expression of IRG proteins 
(62, 63) and iNOS (64) is also regulated by type I interferons, an immediate 
future direction would be to test if igs4 virulence is fully restored in mice that 
cannot respond to both Type I and Type II interferons.  
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Fig. 3.1. Development of igs mutants is inhibited by IFN-γ. McCoy cells were 
infected at an MOI 1 with C. muridarum (WT) or igs mutants, +/- 20/ml IFN-γ, and 
numbers of IFU and rIFU were measured at multiple times post-infection. IFN-γ 
slightly decreased IFU and rIFU production of C. muridarum. In contrast, IFN-γ 
strongly and significantly inhibited IFU and/or rIFU production of the igs mutants 
at one or more points in the developmental cycle. The graphs show results of 
three experiments performed in triplicate. Error bars indicate standard deviation. 
IFN-γ treated specimens are indicated by squares, untreated by circles. 
Corresponding +/- IFN-γ samples were compared by two-way ANOVA with 
Bonferroni post test. *P<0.05, ***P<0.001. 
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Fig. 3.2. Genome replication of igs4 is inhibited by IFN-γ. IFN-γ treated or 
untreated McCoy cells were infected at an MOI of 1 with C. muridarum or igs4 
and DNA was harvested at various intervals post-infection. Quantitative real-time 
PCR was performed using a primer-probe set against the C. muridarum 16S 
rRNA gene and genome copy numbers were calculated by comparing the 
amplification curves to dilutions of a plasmid with a clone copy of C. muridarum 
16S rRNA. Results of a representative experiment performed in triplicate are 
shown. 
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Figure 3.3. igs4 is most sensitive to IFN-γ early in its developmental cycle. 
McCoy cells infected with C. muridarum (black bars), igs4 (white bars) or C. 
trachomatis serovar L2 (gray bars) were treated with 20 U/ml IFN-γ at different 
times relative to the start of infection. Times of IFN-γ addition are indicated on the 
Y-axis. Recoverable IFU are shown as percent of rIFU produced in the absence 
of IFN-γ. The graphs depict results of three experiments performed in triplicate. 
Error bars indicate standard deviation. 
 
 
 
 
 
 
 
 
 
 140 
 
 
 
Fig. 3.4. IFN-γ treatment elicits lysis of igs4 inclusions in McCoy cells. A) 
McCoy cell monolayers which were untreated or pre- and post-treated with 
20U/ml IFN-γ were infected with C. muridarum, C. trachomatis L2 or igs mutants 
at an MOI of 0.1, and inclusions were fixed and stained with an antibody for 
chlamydial LPS and a green secondary fluorescent antibody at 24 hpi. Nuclei 
and host cytosol were stained with DAPI (blue) and Evans Blue (red), 
respectively. Representative lysed igs4 inclusions are indicated by white arrows. 
B) Percentages of lysed inclusions, out of total inclusions, observed in the 
cultures infected with C. muridarum and igs mutants +/- IFN-γ. Lysed inclusions 
were rare except in IFN-γ-treated igs4 cultures where they were dominant. The 
results indicate the averages of two independent experiments where at least 30 
inclusions for each strain and condition were imaged. 
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Fig. 3.5. IFN-γ treatment does not elicit lysis of igs4 inclusions in HeLa 
cells. HeLa cells in Trp- DMEM-10 +/- 20U/mL IFN-γ or in Trp+ DMEM-10 with 
IFN-γ were infected with C. muridarum, C. trachomatis or igs4 at an MOI of 0.1. 
Inclusions were fixed and stained with an antibody for chlamydial LPS (green) 
and DAPI (blue). All chlamydial strains grew normally in tryptophan-free DMEM-
10 in the absence of IFN-γ, but the addition of cytokine resulted in complete 
inhibition of all three strains. In medium containing excess tryptophan, IFN-γ did 
not cause inhibition of any strain. igs4 inclusions were identical in morphology to 
those of C. muridarum. The results indicate representative images from two 
independent experiments where at least 30 inclusions for each strain and 
condition were imaged. 
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Fig. 3.6. Development of igs4 suppressor mutants is unaffected by IFN-γ. 
McCoy cells were infected at an MOI of 1 with the igs4 suppressor mutants S1 
and S5, +/- 20/ml IFN-γ, and the numbers of IFU, and rIFU was measured at 
multiple intervals post-infection. IFN-γ slightly and similarly decreased IFU and 
rIFU production of C. muridarum and the suppressor mutants (Table 3.1). The 
graphs show results of three experiments performed in triplicate. Error bars 
indicate standard deviation of the experiments. Corresponding +/- IFN-γ samples 
were compared by two-way ANOVA with Bonferroni post test. *P<0.05, 
***P<0.001. Results for C. muridarum (WT) and igs4 are reproduced from Fig. 
3.1.  
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Fig. 3.7. Suppressor mutants and a tc0574::GII(bla) mutant are IFN-γ 
resistant. IFN-γ treated and untreated McCoy cells were infected with C. 
muridarum, igs4, various suppressor mutants or C. muridarum tc0574::GII(bla) 
and the fold change of A) IFU and B) rIFU +/- 20 U/ml IFN-γ was compared at 24 
hpi. The graphs depict results of three independent experiments performed in 
triplicate. Error bars indicate standard deviation of the experiments. Values were 
compared to igs4 by one-way ANOVA with Bonferroni post test. ***P<0.001. 
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Fig. 3.8. Suppressor mutants resist IFN-γ-mediated lysis. A).  Untreated or 20 
U/ml IFN-γ pre- and post-treated McCoy cell monolayers were infected with igs4 
suppressor mutants at an MOI of 0.1 and were then fixed and labeled with EVI-
H1 and a secondary fluorescent antibody at 24 hpi (green). Nuclei (blue) and 
host cytoplasm (red) were stained with DAPI and Evans Blue, respectively. B) 
Percentages of lysed inclusions, out of total inclusions, observed in the cultures 
infected with C. muridarum, igs4 and the suppressor mutants S1, S5 and S9. 
Cross-sectional area for at least 30 inclusions per strain per condition were 
measured using ImageJ. Burst inclusions were excluded in cross-sectional area 
measurements. Graph represents cross sectional area average (µM2) with 
standard deviation bars from two independent experiments. Results for C. 
muridarum (WT) and igs4 are reproduced from Fig. 3.4 B. 
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Fig. 3.9. Diagram of igs4 suppressor mutants. Approximate location and 
predicted effects of suppressor mutations on the expression of the 127 amino 
acid TC0574. All nine suppressor mutants retained the G81E mutation (black 
circle) which was present in igs4 but not in the C. muridarum parent. Hatched 
areas indicate regions of TC0574 predicted not to be translated due to nonsense 
mutations (* asterisk in amino acid designations), out-of-frame insertions (ins) or 
single base deletions causing frame-shifts (deletions are marked by the delta 
symbol).  
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Fig.3.10. Organization and expression of tc0572-tc0574. A) Diagram of 
tc0572-tc0574 genomic region (top) and amplicons amplified by RT-PCR 
(bottom). B) Total RNA from C. muridarum (left) or igs4 (right) infected McCoy 
cells 24 hpi was reverse transcribed and then was PCR amplified with primers 
against various regions of tc0572-tc0574 (indicated by numbered lines in panel 
A) and the amplicons were separated by gel electrophoresis. Corresponding 
control PCR reactions of each amplified region with no reverse transcriptase (RT) 
are labeled with asterisks (*). PCR products spanning tc0572-tc0574 were 
detected in both C. muridarum and igs4 infected cultures indicating that these 
genes are expressed in a single transcript and that the SNP in tc0574 of igs4 did 
not alter transcription of tc0572-tc0574. C) Semi-quantitative RT-PCR analysis of 
tc0574 expression. One hundred µg of total RNA from McCoy cells infected with 
C. muridarum, igs4 or S9 at an MOI of 1 was reverse transcribed and PCR 
amplified as above with primers against tc0574 and 16S rRNA, except that the 
PCR products were analyzed by gel electrophoresis after various numbers of 
PCR cycles (indicated above the gel lanes). Similar quantities of tc0574 
transcripts were detected in C. muridarum, igs4 and S9 infected McCoy cells. 
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Fig. 3.11. C. muridarum and igs4 can rescue C. trachomatis from IFN-γ. IFN-
γ treated McCoy cells were co-infected with a rifampin-resistant C. trachomatis 
isolate at an MOI 1 and C. muridarum or igs4 EB at an MOI of 2 or 4. The 
infection medium was supplemented with rifampin to inhibit the C. muridarum 
strains, and C. trachomatis rIFU were counted 24 hpi. C. trachomatis growth was 
inhibited in IFN-γ-treated cells but was partially and similarly restored by C. 
muridarum or igs4 co-infection. The graphs depict results of three experiments 
performed in triplicate and the error bars indicate standard deviation. Values 
were compared to IFN-γ treated sample by one-way ANOVA with  Bonferroni 
post test. ***P<0.001. 
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Fig. 3.12. igs4 IFN-γ sensitivity is unrelated to iNOS or Phox. A) McCoy cells 
treated with IFN-γ and untreated controls were infected with C. muridarum (WT), 
C. trachomatis L2 (CT) or various mutant strains at an MOI of 1 and were 
harvested at 24 hpi. Equal amounts of protein from the samples were separated 
by SDS-PAGE and were immunoblotted with primary antibodies to the loading 
control GAPDH or iNOS. C. muridarum, igs4 and the igs suppressor strains 
elicited similar levels of iNOS protein expression. B) McCoy cells treated with 
IFN-γ, IFN-γ and L-NAME, or untreated controls were infected with C. muridarum 
(black bars), C. trachomatis L2 (white bars), igs4 (gray bars), S1 (hatched bars) 
or S5 (cross-hatched bars) at an MOI of 1. Nitrite in the cell culture supernatants 
was measured at 24 hpi by Griess assay. C. muridarum, igs4 and igs suppressor 
mutants elicited similar levels of nitrite production. P-values were calculated by 
comparison to C. muridarum by two-way ANOVA with Bonferroni post test. 
**P<0.01, ***P<0.001.  C). McCoy cells treated with IFN-γ (black bars), IFN-γ and 
L-NAME (white bars), IFN-γ and DMTU (hatched bars), IFN-γ L-NAME and 
DMTU (gray bars) or untreated controls were infected with C. muridarum (WT), 
C. trachomatis L2 (CT), igs4 or the suppressor mutants S1 and S5 at an MOI of 1 
(indicated below X-axis). The infections were harvested at 24 hpi and the rIFU 
produced by each strain in the various treatment conditions was compared to the 
control rIFU produced in untreated McCoy cells (Y axis). Inhibitors of iNOS and 
oxidative radicals did not reverse IFN-γ sensitivity of C. trachomatis or igs4. 
Western blotting experiments shown in panel A were performed multiple times 
and results of a single representative experiment are depicted. Experiments in 
panels B and C were repeated three times in triplicate and the error bars indicate 
standard deviation of the experiments.  
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Figure 3.13. igs4 is attenuated in the murine genital infection model. The 
course of primary genital infection (A, C) and reinfection (B, D) in female 
C57BL/6 (A, B) and IFN-γ-/- (C, D) mice was evaluated. For primary infections, 
mice were challenged intra-vaginally with 50,000 IFU of WT C. muridarum 
(C57BL/6 mice n=9; IFN-γ-/- mice n=4), igs4 (C57BL/6 mice n=10; IFN-γ-/- mice 
n=10), S1 (C57BL/6 mice n=10) or S5 (C57BL/6 mice n=9). Immunity to 
reinfection was assessed following the resolution of primary infection by 
challenging mice with 50,000 IFU of WT. Infection was followed by enumerating 
IFU recovered from cervico-vaginal swabs. Data are presented as mean (log10) 
IFU + standard deviation. Data were analyzed by ANOVA (see Materials and 
Methods) and P values for various comparisons are noted in the Results. 
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TABLE 3.1. IFU/rIFU ratios of C. muridarum and igs mutants 
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TABLE 3.2. Genome sequences of igs and igs4 suppressor mutants 
 
 
 
 
Strain Gene ID Chromosomal Position Mutation Amino Acid Change
igs 1 TC004 3413 CCT--> TCT P--> S
igs 1 TC0090 108613 CTC--> TTC L--> F
igs 1 TC0180 214411 TTG--> TTA L--> L
igs 1 Intergenic 227381 G--> A Substitution
igs 1 TC0243 281925 GAT--> AAT D--> N
igs 1 TC0256 299426 CCC--> CCT P--> P
igs 1 TC0271 325196 ATG--> ATA M--> I
igs 1 TC0320 377362 ACT--> ATT T--> I
igs 1 TC0412 472952 CAG--> TAG Q--> Stop
igs 1 TC0439 532334 GCT--> GTT A--> V
igs 1 TC0851 987831 GCT--> GTT A--> V
igs 1 TC0862 997718 CGT--> TGT R--> C
igs 1 TC0868 1005383 GGG--> AGG G--> R
igs 2 TC008 13782 CTG--> TTG L--> L
igs 2 TC052 58829 AAA--> GAA K--> E
igs 2 TC056 66042 GTA--> ATA V--> I
igs 2 TC0197 230212 CAG--> CAA Q to Q
igs 2 TC0412 473769 TTA--> TGA L--> Stop
igs 2 TC0476 577763 AGT--> AAT S--> N
igs 2 TC0481 585522 TTC--> TTT F--> F
igs 2 TC0496 603314 AGC--> AGT S--> R
igs 2 TC0671 800632 TCA--> TTA S--> L
igs 2 TC0726 864375 GGA--> AGA G--> R
igs 2 TC0820 952912 GAA--> AAA E--> K
igs 3 TC0090 108613 CTC--> TTC L--> F
igs 3 TC0143 174709 TCG--> TTG S--> L
igs 3 TC0243 281925 GAT--> AAT D--> N
igs 3 TC0303 361136 AAC--> AAT N--> N
igs 3 TC0412 472952 CAG--> TAG Q--> Stop
igs 3 TC0414 474871 GTT--> ATT V--> I
igs 3 TC0476 578503 CAG--> TAG Q--> Stop
igs 3 TC0799 940807 GTG--> GTA V--> V
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Note: Only  novel mutations in suppressor mutants are listed 
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TABLE 3.3. Primers 
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TABLE 3.4 igs4 inclusions are susceptible to IFN-β 
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CHAPTER 4 
CHLAMYDIA MURIDARUM INFECTION OF RAW 264.7 MACROPHAGES 
ELICITS BACTERICIDAL NITRIC OXIDE PRODUCTION VIA REACTIVE 
OXYGEN SPECIES AND CATHEPSIN B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscript in preparation: Krithika Rajaram and David E. Nelson*. Chlamydia 
muridarum infection of RAW 264.7 macrophages elicits bactericidal nitric oxide 
production via reactive oxygen species and cathepsin B. 
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4.1 Abstract 
 The ability of certain species of Chlamydia to inhibit the biogenesis of 
phagolysosomes permits their survival and replication within macrophages. 
Survival of macrophage-adapted chlamydiae correlates with the multiplicity of 
infection (MOI). Optimal chlamydial growth in macrophages occurs at MOI ≤ 1 
while an MOI of 100 or higher induces “immediate cytotoxicity” resulting in the 
death of both the macrophage and pathogen. In this study, we examined the 
replicative capacity of Chlamydia muridarum in the RAW 264.7 murine 
macrophage cell line at different MOIs. C. muridarum productively infected these 
macrophages at low MOI but yielded few viable in EB when macrophages were 
infected at moderate (10) or high (100) MOI. While high MOIs caused cytotoxicity 
and host cell death, macrophages infected at the moderate MOI did not show 
signs of cytotoxicity until late in the infectious cycle. Inhibition of host protein 
synthesis rescued C. muridarum in macrophages infected at a moderate MOI, 
implying that chlamydial growth was blocked by activated defense mechanisms. 
Conditioned medium from these macrophages was anti-chlamydial and 
contained elevated levels of IL-1β, IL-6, IL-10 and IFN-β. Macrophage activation 
depended on TLR2 signaling and required live, transcriptionally active 
chlamydiae. A hydroxyl radical scavenger and inhibitors of iNOS and cathepsin B 
also reversed chlamydial killing. High levels of reactive oxygen species (ROS) 
led to an increase in cathepsin B activity, and pharmacological inhibition of ROS 
and cathepsin B reduced iNOS expression. Our results reveal a novel role for 
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cathepsin B in enhancing nitric oxide production and chlamydial inhibition in 
activated RAW 264.7 macrophages. 
 
4.2 Introduction 
 Infection of host epithelia by Chlamydia spp. sets in motion a cascade of 
signaling events that recruit multiple innate immune effectors to the impacted 
site. Upon recognition of chlamydial pathogen-associated molecular patterns 
(PAMPs) and host danger signals, infiltrating leukocytes undergo transcriptional 
reprogramming to amplify the immune response by producing several cytokines 
and anti-microbial factors. The subsequent inflammatory process aids in bacterial 
clearance and primes elements of adaptive immunity while also contributing to 
the damaging pathology associated with chlamydial disease (1, 2).  
 Cells of the monocyte-macrophage lineage play critical roles in innate and 
adaptive immunity against chlamydial infections. Depletion of macrophages from 
mice prior to infection results in increased morbidity and pathogen burden (3, 4). 
Adoptive transfer of macrophages to IFN-γ-deficient mice has been shown to be 
sufficient for the control of Chlamydia pneumoniae in lung models of infection 
even in the absence of T and B cell responses (5). Some species of Chlamydia 
can survive and replicate in isolated macrophages. Studies examining 
intracellular survival of C. trachomatis strains determined that lymphogranuloma 
venereum (LGV) biovar, but not oculogenital, strains could productively infect 
macrophages (6-8). C. pneumoniae and C. psittaci have been similarly shown to 
replicate in macrophages by preventing maturation of the phagosome (9, 10). 
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Chlamydial persistence or replication within phagocytic cells correlates with 
infection resolution and disease outcome. For instance, LGV strains are highly 
invasive and cause systemic infections by dissemination through the lymphatic 
system (11). These strains also require a longer antibiotic regimen for effective 
treatment as compared to non-LGV C. trachomatis biovars (12).  Persistent 
infection of macrophages by C. pneumoniae in several tissues has been 
associated with chronic inflammatory conditions including atherosclerosis, 
reactive arthritis and asthma (13, 14).  
 Intracellular replication of chlamydiae within macrophages in vitro is less 
efficient than in epithelial cells and is limited by the constitutive expression of 
perforin-2 in macrophages (15). Productive infection also appears to be 
contingent upon the macrophage activation state and multiplicity of infection 
(MOI). Macrophages “classically activated” by IFN-γ and LPS or other microbial 
PAMPs switch to an M1 polarized state. This correlates with increased bacterial 
killing via pro-inflammatory cytokines, production of reactive oxygen species 
(ROS) and upregulation of inducible nitric oxide synthase (iNOS) (16). Multiple 
types of immune cells secrete IFN-γ in response to chlamydial infection, likely 
favoring M1 polarization (17). M2 anti-inflammatory macrophages are activated 
by IL-4 or IL-10 and participate in wound-healing and fibrosis (16). All evaluated 
chlamydial species fail to survive in M1 macrophages in vitro, but whether they 
selectively replicate in M2 or resting macrophage (M0) reservoirs as opposed to 
M1 in vivo is unknown (18-21). Interestingly, a virulent strain of C. psittaci 6BC 
recruits M0 instead of activated macrophages in mice and this correlates with 
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increased morbidity (3). Other chlamydial species may also modulate 
macrophage activation state or possess alternative macrophage subversion 
strategies.  
  Early work with macrophages isolated from various hosts and tissues 
indicated that recovery of chlamydial infectious particles is also dictated by MOI 
(6, 10, 22). Optimal recoveries were obtained when macrophages were infected 
at an MOI of 1 or less. MOI in the order of 10 to 250 of C. psittaci and C. 
trachomatis L2/434/Bu led to decreased EB recovery, and this was attributed to 
host cell cytotoxicity occurring within the first 6 to 10 hours of infection.  
 In this study, we examined chlamydial recoveries from cells of the murine 
RAW 264.7 macrophage line (RAW) infected with the mouse pathogen C. 
muridarum at a range of MOI from 0.5 and 100. We observed a decrease in 
chlamydial survival with increasing MOI, consistent with previous studies (10, 
22). Interestingly, a majority of cells infected at an MOI of 10 remained healthy 
but failed to support chlamydial development. However, these cells produced 
high levels of pro-inflammatory cytokines, iNOS-derived nitric oxide (NO) and 
ROS, indicative of M1 polarization. Induction of iNOS expression depended on 
an increase in cathepsin B activity and ROS accumulation. Blocking iNOS, ROS 
or cathepsin B restored chlamydial growth in moderately infected macrophages. 
Together, our results indicate a novel ROS and cathepsin B-dependent pathway 
for NO production and control of C. muridarum infection in RAW macrophages. 
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4.3 Materials and Methods 
4.3.1 Cell lines and chlamydial propagation 
 The murine RAW 264.7 macrophage (RAW) cell line was a kind gift from 
Cheng Kao  (Indiana University, Bloomington). RAW cells were maintained in 
low-adhesion 10 cm bacterial petri dishes (VWR) in RPMI-1640 medium 
containing 2 mM L-glutamine (Life Technologies), supplemented with 10% fetal 
bovine serum albumin (FBS) (Atlanta Biologicals), 10 mM HEPES (Gibco) and 1 
mM sodium pyruvate. Only low passage macrophages (≤ 4) were used for 
experiments.  C. muridarum (a generous gift from Harlan Caldwell, NIAID, NIH) 
was  propagated in McCoy mouse fibroblast cells (American Type Culture 
Collection CRL-1696) and elementary bodies (EB) were purified as previously 
described (23). McCoy cells were cultured in DMEM-high glucose medium 
containing  4 mM L-glutamine and 110 mg/L sodium pyruvate (Hyclone) and 
supplemented with 10% FBS, 10 mM HEPES and 100 µM non-essential amino 
acids (Gibco).  
 
4.3.2 Recoverable Inclusion Forming Unit (rIFU) assays 
 RAW cells were seeded in 24-well cell culture plates (Thermo Scientific) 
48 h prior to infection. Chlamydial infections were performed on confluent 
monolayers in sucrose phosphate glutamic acid (SPG) buffer and infections were 
performed by centrifugation at 168 × g at room temperature (RT) for 1 h. 
Following infection, SPG was replaced with fresh culture medium and the plates 
were incubated at 37°C in 5% CO2. In some recoverable infection forming unit 
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(rIFU) experiments, RAW cells were treated at 30 minutes prior to infection with 
one or more of the following reagents: 1 mM L-NG-monomethyl Arginine citrate 
(L-NMMA) (Cayman Chemical), 2 mM L-NG-Nitroarginine methyl ester (L-NAME) 
(Cayman Chemical), 15 mM N,N′-Dimethylthiourea (DMTU) (Acros Organics), 50 
or 100 ng/mL IL-1Ra (Peprotech), 25 µM Ac-YVAD-CHO (Peprotech), 25 µM Z-
WEHD-FMK and 25 µM CA-074 Me (kind gifts of Stanley Spinola, Indiana 
University School of Medicine). Treatment continued throughout the course of 
infection. Infected monolayers were frozen in 500 µl SPG at 24 hours post 
infection (hpi). Upon thawing, cells were scraped from the wells and were 
agitated with 3 mm glass beads to harvest EB. An IFU assay was then performed 
by infecting McCoy cells in 96-well plates (Thermo Fisher) with serial dilutions of 
the harvests. At 24 hpi, cells were fixed with methanol and stained with mouse 
anti-chlamydial LPS mAB (EVIH1) followed by a secondary Alexa Fluor488-
conjugated mAB (Life Technologies). Chlamydial inclusions were imaged and 
counted using an EVOS FL Auto Cell Imaging System (Life Technologies).  
 
4.3.3 Cytotoxicity assay 
 Lactate Dehydrogenase (LDH) assays were performed according to the 
manufacturer’s instructions (OPS Diagnostics). RAW cells were infected with C. 
muridarum at an MOI of 0.5, 10 or 100. Maximal LDH release was determined by 
treating cells in control wells with 10% Triton X-100 10 minutes prior to the assay. 
Supernatants were removed from wells at the indicated time points after a brief 
spin to remove debris. In a 96-well plate, 25 µl of the supernatants were mixed 
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with 75 µl of the dye/buffer solution. Following incubation at 37°C for 15 minutes, 
absorbance was measured at 490 nm.  
 
4.3.4 Immunofluorescence Microscopy 
 RAW macrophages were grown on glass coverslips in 24-well plates. 
Cells were infected by centrifugation, fixed at 2 hpi with 4% formaldehyde and 
were then permeabilized with 0.05% Saponin. Cells were blocked in PBS 
containing 0.1% Bovine Serum Albumin (BSA) for 1 h and chlamydial inclusions 
were then stained with primary mAB EVIH1 followed by an anti-mouse Alexa 
Fluor488 secondary antibody (Life Technologies). The coverslips were mounted 
on glass slides using ProLong Gold antifade reagent with DAPI (Life 
Technologies) and images were captured using a Leica DMI6000 B inverted 
microscope with a 63X oil immersion objective. 
 
4.3.5 TLR2 and TLR4 neutralization experiments 
 RAW macrophages were incubated for 1 h with antibody (10-30 µg/mL) 
and were stimulated with either C. muridarum (MOI 10) or 0.5 ng/mL E. coli LPS 
and C. muridarum EB (MOI 0.5). Anti-TLR4-MD2 (clone MTS510), anti-TLR2 
(clone T2.5) and isotype-matched antibodies IgG2A and IgG1 were purchased 
from BioLegend (San Diego, CA). Supernatants were assayed for IFN-β levels at 
24  hpi, and the cells were harvested for rIFU assays. 
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4.3.6 C. muridarum EB heat and UV inactivation 
 Heat-inactivated EB were prepared by incubating concentrated C. 
muridarum stocks at 56°C for 30 minutes. UV-inactivated EB were made by 
diluting stocks in SPG at a 1:10 ratio. Diluted EB solutions were pipetted onto a 
petri dish and exposed to 1,200 J/cm2 twice in a UV-cross-linking cabinet 
(Spectralinker; Spectronics Corporation) (24, 25). Efficacy of the UV and heat 
treatments was confirmed by IFU assays.  
 
4.3.7 Cytokine analysis 
 Culture supernatants were collected from infected RAW macrophages at 
indicated times and were centrifuged briefly to remove debris. The supernatants 
were assayed for IL-1β, IL-6, 1L-10, IL-12p40, TNF-α and IFN-γ (Milliplex) at the 
Bio-Plex core (IUPUI, Indianapolis) according to manufacturer’s instructions. IFN-
β levels were determined using a mouse IFN-β ELISA Kit according to 
manufacturer’s instructions (BioLegend, San Diego, CA).  
 
4.3.8 Griess assay 
 Nitrite concentrations in culture media were measured by a commercial 
Griess assay kit (Biotium). 150 µl of culture supernatant was removed from 
infected monolayers at 6, 12 and 24 hpi. The samples were incubated with 20 µL 
Griess reagent (0.05% N-(1-naphthyl) ethylenediamine dihydrochloride; 0.5% 
sulfanilic acid; 2.5% phosphoric acid) in a 96-well plate at room temperature for 
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30 minutes. Absorbance was measured at 540 nm and nitrite levels were 
calculated from a sodium nitrite standard curve.  
 
4.3.9 Western blot analysis 
 RAW cells were treated with various reagents and were infected at an 
MOI of 0.5 or 10. Cells were washed with PBS at 6, 12 or 24 hpi and were then 
incubated in 50 µl Lysis buffer (2% sodium dodecyl sulphate (SDS); 10% 
glycerol; 62 mM Tris, pH 6.8) containing a Protease Inhibitor mini tablet (Pierce) 
for 10 minutes on ice. Cell lysates were boiled for 5 minutes. Protein samples 
were separated by SDS-PAGE and transferred to nitrocellulose membranes. 
Membranes were incubated at 4°C overnight with rabbit iNOS mAb or rabbit 
GAPDH mAb followed by incubation with a secondary anti-rabbit horse radish 
peroxidase conjugate for 1 h. Antibodies were purchased from Cell Signaling 
Technology (Danvers, MA). Proteins were visualized using SuperSignal West 
Dura Chemiluminescent Substrate (Pierce) according to the manufacturer’s 
instructions.  
 
4.3.10 ROS assay 
 ROS production from infected RAW cells in 96-well clear bottom black 
plates (Corning) was assayed using the fluorogenic dye 2’, 7’-dichlorofluorescein 
diacetate (DCFDA) (Abcam). At indicated times, 20 µM DCFDA was mixed with 
culture media 45 minutes prior to measurement of fluorescence intensity 
(excitation/emission wavelengths: 485 nm/535 nm).  
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4.3.11 Assay for cathepsin B activity  
 RAW macrophages were cultured on coverslips in 24-well plates. 
Infections and pharmacological treatments of RAW macrophages were 
performed. At 10 hpi, reconstituted Magic Red cathepsin B substrate reagent 
MR-(RR) 2 (Immunochemistry Technologies) was added directly to the culture 
media in wells. After 30 minutes of treatment, nuclei were counterstained with 
Hoechst 33342 for 10 minutes. Coverslips were analyzed for cathepsin B activity 
by fluorescence microscopy (Leica DMI6000 B; 63X oil immersion objective). 
Fluorescence intensities were quantified from ten images obtained from each of 
three independent experiments using ImageJ software (26).  
 
4.3.12 Statistics 
Data was analyzed using Prism 6.0 software (GraphPad). For comparisons of 
multiple groups with two or more variables, data was subjected to log 
transformation and two-way analysis of variance (ANOVA) followed by the 
Bonferroni posttest was used. Multiple comparisons for data with a single 
variable were analyzed by one-way ANOVA followed by the Dunnett’s posttest. 
Differences in values between two different groups were determined using 
Student’s t test. Differences were considered statistically significant when p < 
0.05.  
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4.4 Results 
4.4.1 Productive C. muridarum infection of RAW macrophages is dependent on 
multiplicity of infection 
 The effects of multiplicity of infection (MOI) on C. muridarum infection 
forming unit (IFU) production were examined in RAW macrophages (Fig. 4.1 A). 
At the lowest MOI (0.5), we observed a 2-fold increase in IFU recovery over 
input, which is in agreement with previous reports (22). Maximal IFU recovery 
occurred when macrophages were infected at an MOI of 1. IFU recovery 
decreased at MOIs of 3 and higher. At moderate (10) and high (100) MOIs, IFU 
recoveries were approximately .001% and .0001% of input, respectively.  
 To determine if reduced IFU recovery at moderate and high MOIs could 
be explained by host cell death, infected macrophages were examined by light 
microscopy (Fig. 4.1 B-G). Cells infected at an MOI of 100 exhibited rounding 
and cytotoxicity (Fig. 4.1 G). However, most cells infected at an MOI of 10 had 
normal morphologies (Fig. 4.1 F). These macrophages also released basal levels 
of LDH until late in the chlamydial developmental cycle (Fig. 4.2). To test if low 
IFU recovery could be explained by reduced EB entry into macrophages, 
internalized EB were quantified by fluorescence microscopy at 2 hpi. The 
numbers of cytosolic EB correlated with input MOI (Fig. 4.1 H). Overall, these 
findings suggested that moderate MOI infection triggered macrophage activation 
which inhibited chlamydial EB production.  
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4.4.2 Chlamydial inhibition in RAW macrophages requires de-novo host protein 
synthesis 
 To elucidate the mechanism of C. muridarum inhibition in RAW 
macrophages, we initially tested if the anti-chlamydial factors were pre-formed. 
Infected macrophages were treated with cycloheximide to block protein 
synthesis. Cycloheximide increased IFU production of macrophages infected at 
an MOI of 0.5 by 3-fold, but did not increase IFU production of macrophages 
infected at an MOI of 100 (Fig. 4.2). In contrast, cycloheximide treatment 
increased IFU production of macrophages infected at an MOI of 10 by more than 
10,000-fold. These results implied that moderate MOI of C. muridarum induced 
macrophage defenses, whereas higher MOIs caused macrophage death. 
 
4.4.3 Supernatants from RAW macrophages contain heat-sensitive anti-
chlamydial factors 
 Activated macrophages release cytokines that can stimulate neighboring 
cells (27) so we tested if conditioned supernatants from infected macrophages 
could inhibit C. muridarum infection of newly infected macrophages. Conditioned 
supernatants from RAW cells, infected at low or moderate MOIs, were collected 
at various intervals post infection. The fresh supernatants were then transferred 
onto macrophages that had just been infected with C. muridarum at an MOI of 
0.5 by centrifugation. Supernatants from the MOI 0.5 infections failed to inhibit 
chlamydial growth (Fig. 4.4). In contrast, supernatants from the MOI 10 infections 
inhibited rIFU production. The degree of this inhibition varied from 4-fold with 4 
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hpi supernatants, to 1000-fold with 24 hpi supernatants and was completely 
abolished if the supernatants were heated at 95°C for 5 minutes.  
 
4.4.4 Multiple chlamydial antigens are required for induction of macrophage 
inhibitory responses 
 Killed and viable EB elicit dissimilar cytokine responses (28, 29). We 
tested if the anti-chlamydial responses of macrophages that we had observed 
could be triggered by heat and UV-killed EB using co-infection assays. 
Macrophages were co-infected with live EB at an MOI of 0.5, and UV or heat-
killed EB at MOIs of 9.5 (total MOI =10). To differentiate if chlamydial 
transcription was required to elicit cytokine responses, similar co-infection 
experiments were performed with rifampin-resistant C. muridarum EB at an MOI 
of 0.5, and wild type C. muridarum EB at an MOI of 9.5, in the presence of 
sufficient rifampin to block growth of the wild type C. muridarum. Heat-inactivated 
EB did not inhibit IFU production in the co-infection experiments (Fig. 4.5 A). In 
contrast, UV-inactivated EB (Fig. 4.5 A) and transcriptionally inactive EB (Fig. 4.5 
B) dramatically reduced IFU production of C. muridarum and CMRifR, respectively. 
This suggested that the chlamydial antigen(s) that stimulated the macrophage 
antimicrobial responses was present in EB and was not damaged by UV 
treatment. Failure of heat-inactivated EB to block chlamydial growth might be 
explained by reduced uptake of these EB by macrophages or destruction of the 
relevant antigens by heat (30). 
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 Macrophages were also infected with wild-type EB in the presence of 
rifampin, or UV/heat-inactivated EB at an MOI of 10. Supernatants from these 
infections were collected 24 hpi and were transferred onto macrophages that had 
been infected at an MOI of 0.5 with CMRifR or wild-type EB, respectively. None of 
the supernatants inhibited IFU production (Fig. 4.5 C, D). Collectively, the results 
of the co-infection and conditioned supernatant transfer experiments suggested 
that two anti-chlamydial pathways were activated by transcriptionally active 
chlamydiae: an endogenous pathway, and an exogenous pathway mediated by a 
trans-acting heat-labile factor. 
 
4.4.5 Cytokine secretion from RAW macrophages varies with C. muridarum EB 
dose and treatment 
 To attempt to identify the trans-acting factor, we assayed cytokines in the 
conditioned supernatants of macrophages which had been infected at various 
MOI. Levels of most of most of the cytokines produced by moderately infected 
macrophages peaked by 3 hpi and were higher than those produced by the lowly 
infected macrophages (Fig. 4.6 A). High levels of TNF-α were detected at both 
MOI but this cytokine peaked earlier in supernatants from the macrophages 
infected at the higher MOI (Fig. 4.6 A). Cytokines in supernatants from 
macrophages which were infected with non-replicating chlamydia at MOIs of 10 
(wild-type EB+rifampin or UV-inactivated) were also assayed. With the exception 
of TNF-α, cytokine levels were substantially lower than observed in experiments 
with viable C. muridarum (Fig. 4.6 B). Overall, the results of these experiments 
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suggested that most cytokine secretion required an antigen not present in EB 
and which was synthesized by C. muridarum in the host cell. 
 
4.4.6 Anti-chlamydial activity of RAW macrophages is mediated by TLR2 but not 
TLR4 
 Chlamydial cell wall antigens and heat shock proteins induce Toll-like 
receptor 2 (TLR2), and to a lesser extent TLR4, signaling in phagocytes and 
epithelial cells (31, 32). To determine if TLR2 or TLR4 activation stimulated 
macrophage anti-chlamydial responses, we used mAbs to specifically block 
TLR2 (anti-TLR2) and TLR4 (anti-TLR4) responses. The neutralizing efficacy of 
anti-TLR2 was first determined by pre-treating macrophages with mAb followed 
by infection with C. muridarum at an MOI of 10. Anti-TLR2 treatment reduced 
IFN-β production of C. muridarum-infected RAW cells in a dose dependent 
manner (Fig. 4. 7 A). Anti-TLR4 increased rIFU production by 1000 fold in RAW 
macrophages that were infected with C. muridarum at an MOI of 0.5 and co-
treated with E. coli LPS. These preliminary experiments established that both 
antibodies effectively blocked cognate TLR function. However, only anti-TLR2 
partially restored C. muridarum IFU production in macrophages infected at an 
MOI of 10 (Fig. 4.7 C, D). This indicated that the anti-chlamydial response of 
macrophage infected at moderate MOIs is primarily mediated by TLR2. 
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4.4.7 Chlamydial inhibition at moderate MOIs is mediated by iNOS and ROS 
 Pro-inflammatory cytokines and bacterial products can upregulate 
expression of inducible nitric oxide synthase (iNOS), an enzyme which catalyzes 
nitric oxide (NO) formation (33-36). Activated leukocytes can also accumulate 
high levels of reactive oxygen species (ROS) via the phagocyte NADPH oxidase 
complex (phox) or damaged mitochondria.  
To determine if iNOS was induced in RAW macrophages by C. muridarum 
infection we measured the quantity of nitrites in culture supernatants. Higher 
nitrite levels were observed in supernatants from macrophages infected at 
moderate MOI  compared to macrophages infected at low MOI (Fig. 4.8 A). 
Levels of iNOS protein measured by Western blot correlated with these 
supernatant nitrite levels (Fig. 4.8 B). While iNOS was not detected in cells 
infected at low MOI, iNOS was detected by 6 hpi in macrophages infected at 
moderate MOI.  
 Macrophage ROS response was assessed by incubating infected cells 
with the fluorogenic dye 2’, 7’-dichlorofluorescin diacetate (DCFDA). ROS 
production of mock-infected and low MOI infected macrophages was low and 
similar (Fig. 4.8 C). However, macrophages infected at moderate MOI produced 
strong fluorescence which was mostly reversed by the addition of the hydroxyl 
radical scavenger dimethylthiourea (DMTU).  
 To evaluate the chlamydicidal potential of macrophage-derived NO and 
ROS, infected macrophages were treated with the iNOS inhibitors L-NMMA and 
L-NAME or the hydroxyl radical scavenger DMTU. None of these compounds 
 184 
 
affected chlamydiae recovery in low MOI infections (Fig. 4.8 D). However, both of 
the iNOS inhibitors and DMTU increased IFU production in the moderate MOI 
infected macrophages (39, 40). These results indicated that moderate MOI 
infections of RAW macrophages stimulated production of NO and reactive 
oxygen species that inhibited C. muridarum.  
 
4.4.8 Ca-074Me, a cathepsin B inhibitor, rescues C. muridarum from anti-
chlamydial macrophage responses 
 Macrophage IL-1β can stimulate caspase-1 dependent iNOS expression 
(35, 41) (42). We evaluated the roles of IL-1β and caspase-1 in chlamydial 
inhibition in macrophages using various inhibitors. Pre-treatment of the 
macrophages with IL-1Ra, an IL-1β antagonist, did not influence chlamydial 
recovery (Fig. 4.9 A). The caspase-1 inhibitor Ac-YVAD-CHO also failed to alter 
IFU production. However, the less specific caspase-1 inhibitor Z-WEHD-FMK 
increased IFU recovery in moderately infected macrophages approximately 10-
fold. Z-WEHD-FMK can also inhibit lysosomal cathepsins (43), so we treated 
macrophages infected with the selective cathepsin B inhibitor Ca-074Me. Ca-
074Me increased IFU production by 1000 fold in moderately infected 
macrophages (Fig. 4.9 B). Cathepsin B activity was also monitored in the 
infected cells using the fluorogenic substrate CV-(RR) 2. Analysis at 10 hpi 
indicated no difference in fluorescence intensity between mock-infected and low 
MOI infected cells (Fig. 4.9 C, D; Fig. 4.10). In contrast, cathepsin B activity was 
significantly increased in the moderate MOI-infected macrophages and this was 
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reversed by the addition of Ca-074Me (Fig. 4.9 E, F; Fig. 4.10). Together, these 
results indicated that cathepsin B activity influences chlamydial IFU production in 
RAW macrophages.  
 
4.4.9 ROS and cathepsin B activity are necessary for maximal iNOS induction in 
C. muridarum-infected RAW macrophages 
 Pharmacological inhibition of ROS, iNOS and cathepsin B led to equal but 
non-additive chlamydial recoveries, suggesting that they functioned in the same 
inhibitory pathway or that they played cooperative roles in chlamydial killing (Fig. 
4.11 A). To distinguish between these possibilities, we first analyzed iNOS 
protein and nitrite levels in moderately infected macrophages treated with L-
NAME, DMTU or Ca-074Me. L-NAME interferes with iNOS activity, but not 
expression. Western blots showed equal quantities of iNOS protein in samples 
that were and were not treated with L-NAME, but that nitrite levels were reduced 
in the  L-NAME treated cells (Fig. 4.11 B; Fig. 4.12). However, iNOS and nitrite 
levels were also substantially lower in cells treated with DMTU or Ca-074Me. 
This indicated that ROS and cathepsin B controlled iNOS expression.  
 We next investigated if ROS modulated cathepsin B activity or vice versa. 
Addition of DMTU to macrophages infected at an MOI of 10 decreased cathepsin 
B activity to levels lower than that of mock-infected cells (Fig. 4.11 C-E; Fig.4.13). 
Inhibition of cathepsin B with Ca-074Me in similarly infected macrophages also 
caused a small decrease in ROS levels (Fig. 4.14). The DCFDA probe can also 
detect peroxynitrite. Since nitric oxide production was inhibited in cells treated 
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with Ca-074Me, the slight reduction in DCFDA fluorescence could be due to an 
absence of nitrite intermediates. Indeed, the quantity of ROS did not differ in Ca-
074Me and L-NMMA treated macrophages (Fig. 4.14). In summary, these results 
suggested that ROS production increased cathepsin B activity, which 
upregulated iNOS expression. 
 
4.5 Discussion 
 Members of the family Chlamydiaceae differ in their capacity to survive 
within macrophages and this is largely dictated by the pathogen’s ability to avoid 
phagolysosomal fusion inside these cells (10). The capacity to survive and 
replicate in macrophages has been linked to chlamydial dissemination leading to 
systemic disease, as well as persistence which can cause chronic inflammation 
and a delayed response to antibiotic treatment (11, 12). Thus, understanding the 
mechanisms that promote chlamydial survival in mononuclear phagocytes could 
have implications for the development of therapeutic strategies. 
  Chlamydial species that can evade phagosome-lysosome fusion within 
macrophages appear to do so only when host cells are infected at an optimal 
MOI. Several groups have reported reduced chlamydial recoveries from 
macrophages infected at MOIs of 100 or greater (10, 22). This correlated with 
immediate damage to the host cells and fusion of lysosomes with EB-containing 
phagosomes. In this study, we characterized the interactions of RAW 264.7 
macrophages with C. muridarum and demonstrated that three different outcomes 
could be achieved in response to different MOIs. At an MOI of 1 or lower, RAW 
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cells supported chlamydial replication. An MOI of 100 conferred immediate 
cytotoxicity to the macrophages and few infectious chlamydial particles were 
recovered. Inhibition of host protein synthesis did not prevent chlamydial or host 
cell death. These results were consistent with findings from previous studies. 
However, when RAW macrophages were infected at an intermediate MOI of 10, 
they did not succumb to early death and cleared C. muridarum infection by a 
process that could be reversed by cycloheximide.  
 Consistent with previous studies, we found that macrophage activation 
and subsequent clearance of C. muridarum was predominantly mediated by 
TLR2 (44, 45). The cognate chlamydial ligands for TLR2 have not been 
identified, but several candidates have been proposed in recent years. 
Recombinant chlamydial MIP-like protein can induce cytokine production via 
TLR2/TLR1/TLR6 and CD14 in human macrophages (46). Chlamydial LPS is 
less active than classic endotoxins but can elicit TLR2 signaling in vitro (47). 
Chlamydial Hsp60 induces inflammatory responses in mice in a TLR2- and 
TLR4-dependent fashion (31). Plasmid-deficient strains of C. trachomatis and C. 
muridarum exhibit impaired TLR2 responses, implying that one or more TLR2 
antigens are either encoded or regulated by the plasmid (48, 49). Signaling via 
TLR2 in epithelial cells also requires infection with live, transcriptionally active 
chlamydiae, indicating that the antigen is not present in EB (29). Our experiments 
with inactive EB demonstrated that more than one chlamydial antigen was 
necessary to elicit chlamydicidal responses of RAW macrophages. An EB 
antigen required for endogenous inhibition of chlamydiae was unaffected by UV 
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treatment. Interestingly, the inhibitory potential of conditioned supernatants from 
macrophage cultures depended on an antigen present in transcriptionally active 
chlamydiae but not in heat- or UV-inactivated EB.  
 Binding of microbial PAMPs to TLRs or other cytosolic PRRs triggers a 
series of cellular signals that culminate in the activation of NFκB, mitogen-
activated protein kinase (MAPK) or IRF3 pathways (50, 51). These in turn 
regulate the expression of genes that encode pro-inflammatory cytokines and 
iNOS. Aside from the direct induction of iNOS by PRR signaling, several 
cytokines can also regulate iNOS expression. Protective effects of nitric oxide in 
chlamydial infections have been well documented. Nitric oxide promotes IFN-γ-
mediated eradication of chlamydiae and protects mice from the development of 
hydrosalphinx and infertility (52). Interestingly, TLR2/4 double-deficient mice do 
not resolve C. pneumoniae lung infections because of their inability to induce 
iNOS in spite of elevated IFN-γ secretion in these animals (53). This suggests 
that nitric oxide production relies on signaling via TLR2/4 in the murine lung 
model of infection. We observed that moderately infected RAW macrophages 
produced more iNOS and nitrite compared to cells infected an MOI of 0.5 and 
that this negatively impacted chlamydial survival. Our results are reminiscent of a 
study by Huang et al. in which the outcome of low and high doses of intranasally 
inoculated chlamydiae in C57BL/6 mice was evaluated (54). Animals infected 
with higher numbers of C. psittaci remained healthy as opposed to those that 
were infected at low doses, and the accelerated bacterial clearance in heavily 
infected mice was linked to an increased NO production by macrophages. 
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Comparable observations have been reported with C. muridarum infections of 
the murine genital tract, where high infectious doses result in less disease 
severity and fewer viable organisms in the oviducts (55). We speculate that 
similar macrophage activation programs control NO production in response to 
higher doses of infectious chlamydiae in both mice and in cell culture.  
 We determined that iNOS induction in RAW macrophages was mediated 
by an increase in the production of ROS. Modulation of iNOS expression by ROS 
is not without precedent. High MOI infection of macrophages with 
Propionibacterium acnes increases ROS levels which in turn upregulate iNOS via 
NFκB/AP-1 activation (56). Similar dependence on ROS for nitric oxide 
production has also been observed in mouse endothelial cells stimulated with 
IFN-γ and LPS (57). Multiple sources of ROS exist within mammalian cells 
including the NADPH oxidase complex and mitochondria. If ROS generated by 
RAW macrophages in our study was mitochondria- or NADPH oxidase-derived 
was not determined. Several groups have reported a loss of mitochondrial 
membrane potential and integrity in cells invaded by pathogens (58). The 
subsequent mitochondrial ROS release can cause lysosomal membrane 
permeabilization (LMP) leading to the leakage of active lysosomal cathepsins 
into the cytosol. In agreement with these studies, we noted increased cathepsin 
B activity in moderately infected RAW cells that was abolished by an ROS 
scavenger. However, a significant proportion of this cathepsin B activity at 10 hpi 
appeared to localize to large vesicular structures. Labeling with specific markers 
will be required to determine if these vesicles are lysosomes or also include EB-
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containing phagosomes that fused with lysosomes. Whether lysosomal cathepsin 
B leaks into the cytosol at later times due to ROS-mediated LMP requires further 
investigation. What is certain is that ROS affects cathepsin B activity in RAW 
macrophages. Surprisingly, the inhibition of cathepsin B led to a substantial 
decrease in iNOS and nitrite levels while also enabling chlamydial rescue. 
Pharmacological inhibition of iNOS did not greatly affect ROS levels or cathepsin 
B (Fig. 4. 10 and unpublished observations), indicating that chlamydial survival in 
RAW cells was dictated by the presence or absence of NO. We cannot rule out a 
direct role for ROS and cathepsin B in chlamydial inhibition because chlamydiae 
damaged by reactive nitrogen species might show increased susceptibility to 
lysosomal fusion and processing by cathepsin B.  
 In summary, we report that iNOS-derived nitric oxide leads to the inhibition 
of C. muridarum in RAW macrophages in an MOI-dependent manner. Elevated 
levels of reactive oxygen species and cathepsin B activity in moderately infected 
cells modulate iNOS expression to facilitate C. muridarum clearance. Future 
experiments will involve confirming these observations in primary macrophages 
isolated from wild-type and cathepsin B-knockout mice.  
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Fig. 4.1. C. muridarum is inhibited in RAW macrophages infected at high 
MOI.  Macrophages were infected with C. muridarum at MOIs from 0.5 to 100. 
(A) Recoverable IFU (rIFU) assays performed at 24 hpi showed that EB recovery 
was decreased from macrophages infected at MOI 3 and higher. (B-G) Light 
microscopy at 18 hpi revealed that the infected macrophages exhibited normal 
cell morphology at all MOIs with the exception of MOI 100. (B) Mock-infected (C) 
MOI 0.5 (D) MOI 3 (E) MOI 5 (F) MOI 10 (G) MOI 100. (H) Immunofluorescence 
microscopy of infected RAW cells at 2hpi showed that chlamydial EB invasion of 
macrophages was not hindered at an MOI of 10.  
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Fig. 4.2. High MOI induces macrophage cytotoxicity. Macrophages were 
infected at an MOI of 0.5, 10 or 100. An LDH assay for cytotoxicity demonstrated 
that macrophages infected at an MOI of 10 (gray bars) released low amounts of 
LDH comparable to macrophages infected at an MOI of 0.5 up to 18 hpi. At 24 
and 30 hpi, LDH release increased significantly in supernatants of macrophages 
infected at an MOI of 10, indicating delayed cell death. RAW macrophages 
infected at an MOI of 100 exhibited cytotoxicity as early as 6 hpi. Error bars 
represent mean ± standard deviations (SD). (****, P < 0.0001; ***, P < 0.001; **, 
P < 0.01).  P values were determined by two-way ANOVA with Bonferroni post 
hoc test.  
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Fig. 4.3. Inhibition of host protein synthesis rescues chlamydial growth in 
moderately infected macrophages. RAW macrophages were treated with 0.5 
µg/mL cycloheximide four hours prior to or at the time of infection. rIFU assays 
were performed at 24 hpi. Cycloheximide addition improved infectious EB 
recovery from macrophages infected at an MOI of 0.5 and completely reversed 
chlamydial inhibition in cells infected at an MOI of 10 but had no effect on 
chlamydial recovery from cells infected at an MOI of 100 (black bars, untreated; 
white bars, cycloheximide addition at -4 hpi; gray bars, cycloheximide addition at 
0 hpi). Error bars represent mean ± SD. ****, (P < 0.0001; ***, P < 0.001; **, P < 
0.01). P values were determined by two-way ANOVA with Bonferroni post hoc 
test.  
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Fig. 4.4. Supernatants from moderately infected macrophages contain anti-
chlamydial factors. RAW macrophages were infected with C. muridarum at an 
MOI of 0.5 or 10. Culture media was removed at 4, 8, 12 or 24 hpi and 
centrifuged briefly to remove debris. A new 24-well plate of macrophages was 
infected at an MOI of 0.5. At 1.5 hpi, the conditioned supernatants were 
transferred onto the newly infected cells. Some supernatants were heated at 
95°C for 5 minutes prior to transfer. rIFU assays performed on the supernatant-
treated macrophages at 24 hpi revealed that media from cells infected at an MOI 
of 0.5 (white bars, unheated;  striped bars, heated) had no effect on rIFU when 
compared to mock-treated cells (black bars). In contrast, media from MOI 10-
infected cells inhibited chlamydial recovery (gray bars). The inhibitory effect of 
supernatants from heavily infected macrophages increased with time and was 
abolished upon heat treatment (hatched bars). Error bars represent mean ± SD. 
(****, P < 0.0001; ***, P < 0.001; *, P < 0.05). P values were determined by two-
way ANOVA with Bonferroni post hoc test. 
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Fig. 4.5. RAW macrophage inhibitory response is mediated by at least two 
chlamydial antigens. rIFU was performed at 24 hpi from macrophages infected 
with live or inactive EB. (A) RAW macrophages were infected with C. muridarum 
(CM) at an MOI of 0.5 (black bars) or 10 (white bars). Some wells infected at an 
MOI of 0.5 were also incubated with heat-inactivated (HI) EB (hatched bars) or 
UV-inactivated EB (gray bars) at an MOI of 9.5. (B) Supernatants were collected 
at 24 hpi from RAW cells infected at an MOI of 0.5 (black bars) or 10 with live 
(white bars), HI (gray bars) or HI (hatched bars) EB. After a brief spin, 
supernatants were transferred to macrophages freshly infected with CM at an 
MOI of 0.5. (C) RAW cells were treated with 0.1 µg/mL rifampin and infected with 
C. muridarumRifR (CMRifR) at an MOI of 0.5 with or without CM at an MOI of 9.5. 
(D) Supernatants were collected from rifampin-treated cells that had been 
infected with CM at an MOI of 0.5 or 10 at 24 hpi. These were then transferred to 
macrophages freshly infected with CMRifR at an MOI of 0.5. Error bars represent 
mean ± SD. (****, P < 0.0001). P values were determined by one-way ANOVA 
with Dunnett’s post hoc test. 
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Fig. 4.6. Cytokine profiles from infected macrophages. (A) RAW 
macrophages were infected at an MOI of 0.5 (black bars) or 10 (gray bars). 
Supernatants were collected at 3, 6, 12, 18 and 24 hpi and assayed for 
cytokines. Levels of IL-1β, IL-6, L-10 and IFN-β were significantly higher in 
supernatants from MOI 10-infected cells at all time points. TNF-α amounts were 
low at 3 hpi in supernatants from MOI 0.5-infected macrophages but reached 
maximal levels between 6-12 hpi. (B) Supernatants were collected at 24 hpi from 
RAW cells infected at an MOI of 0.5 or 10 with live EB in the absence or 
presence of rifampin (RIF 10) or UV EB (UV 10). Cytokine analysis indicated that 
levels of IL-1β, IL-6, IL-10 and IFN-β were significantly lower in supernatants 
from UV 10- and RIF 10-infected cells vs cells infected with live EB at an MOI of 
10. TNF-α levels were similar in all analyzed supernatants. Error bars represent 
mean ± SD. (****, P < 0.0001). P values were determined by one-way ANOVA 
with Dunnett’s post hoc test. 
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Fig. 4.7. TLR2, but not TLR4, mediates macrophage inhibition of C. 
muridarum at intermediate MOI. (A) Macrophages that were untreated or pre-
treated with anti-TLR2 or isotype control Ab (IgG1) were infected at an MOI of 
0.5 (black bars) or 10 (gray bars). ELISA measurement of IFN-β in supernatants 
collected from cells at 24 hpi showed significantly lower cytokine levels from 
moderately infected macrophages in the presence of anti-TLR2. (B) 
Macrophages infected with C. muridarum at an MOI of 0.5 produced significantly 
fewer rIFU when co-treated with E. coli LPS. Anti-TLR4, but not an isotype 
control Ab (IgG2A), completely reversed LPS-mediated inhibition. (C) Anti-TLR2 
treatment (30 µg/mL) significantly increased rIFU yield from MOI 10-infected 
macrophages. (D) Anti-TLR4 did not prevent chlamydial inhibition in 
macrophages infected at an MOI of 10. Error bars represent mean ± SD. (****, P 
< 0.0001). P values were determined by one-way ANOVA with Dunnett’s post 
hoc test for (A), (C) and (D), and by two-way ANOVA with Bonferroni post hoc 
test for (B). 
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Fig. 4.8. Moderately infected RAW macrophages inhibit C. muridarum by 
producing nitric oxide and reactive oxygen species. (A) Supernatants were 
collected at 6, 12 or 24 hpi from RAW cells infected at an MOI of 0.5 (black bars) 
or 10 (gray bars). Nitrite levels were quantified by Griess assay. (B) Western blot 
for iNOS indicated that protein was absent from mock- or MOI 0.5-infected cells, 
but expressed at all analyzed time points in MOI 10-infected cells. (C) RAW cells 
infected at an MOI of 0.5 (black bars), 10 (gray bars) or 10 with DMTU (white 
bars) were assayed for ROS production at 1, 3, 6, 12, 18 and 24 hpi. ROS 
started to accumulate in cells infected at an MOI of 10 at 6 hpi. ROS levels 
decreased in the presence of the hydroxyl radical scavenger DMTU. (D) RAW 
cells infected at an MOI of 0.5 or 10 were left untreated (black bars) or treated 
with L-NMMA (white bars), L-NAME (gray bars) or DMTU (hatched bars). rIFU 
assay at 24 hpi revealed that inhibitors rescued chlamydial inhibition in 
moderately infected cells. Error bars represent mean ± SD. (****, P < 0.0001; **, 
P < 0.01; *, P < 0.05). P values were determined by two-way ANOVA with 
Bonferroni post hoc test. 
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Fig. 4.9. Ca-074Me, a cathepsin B inhibitor, rescues C. muridarum from 
macrophage inhibition. (A) RAW macrophages were infected at an MOI of 0.5 
(black bar) or 10 (gray bar). Some MOI 10-infected cells were treated with IL-1Ra 
at 50 µg/mL (white bar) or 100 µg/mL (cross-hatched bar), Ac-YVAD-CHO 
(striped bar) or Z-WEHD-FMK (hatched bar). Z-WEHD-FMK addition led to a 
partial increase in chlamydial output. Error bars represent mean ± SD. (****, P < 
0.0001; ***, P < 0.001). P values were determined by one-way ANOVA with 
Dunnett’s post hoc test. (B) Treatment of MOI 10-infected macrophages with CA-
074Me blocked macrophage inhibition. Panels C-F represent live microscopy 
images of cells at 10 hpi treated with the cathepsin B indicator dye MR-(RR)2 
(red channel) and nuclear stain Hoechst 33342 (blue channel). (C) Mock-infected 
(D) MOI 0.5 (E) MOI 10 (F) MOI 10 with Ca-074Me.  
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Fig. 4.10. Cathepsin B activity increases in moderately infected RAW 
macrophages. Mean red fluorescence intensity of activated cathepsin B in cells 
infected at an MOI of 0.5 or 10 was calculated from ten microscopy images 
obtained from three independent experiments. Intensity was normalized to mock-
infected control. Cathepsin B activity significantly increased in cells infected at an 
MOI of 10 and was dramatically reduced in cells treated with Ca-074Me. Error 
bars represent mean ± SD. (***, P < 0.001). P values were determined by one-
way ANOVA with Dunnett’s post hoc test. 
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Fig. 4.11. iNOS expression in moderately infected macrophages is 
regulated by ROS and cathepsin B. (A) RAW macrophages were infected at an 
MOI of 10 and treated with one of more of the following chemicals: L-NAME, 
DMTU and Ca-074Me. All drugs and combinations rescued chlamydiae from 
macrophage inhibition to the same extent. Error bars represent mean ± SD. (****, 
P < 0.0001). P values were determined by one-way ANOVA with Dunnett’s post 
hoc test. (B) Western blot for iNOS at 24 hpi from cells. (1) mock-infected (2) 
MOI 0.5 (3) MOI 10 (4) MOI 10 with L-NAME (5) MOI 10 with DMTU (6) MOI 10 
with Ca-074Me. Panels C-E represent live microscopy images of cells at 10 hpi 
treated with the cathepsin B indicator dye MR-(RR)2 (red channel) and nuclear 
stain Hoechst 33342 (blue channel). (C) Mock-infected (D) MOI 10 (E) MOI 10 
with DMTU.  
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Fig. 4.12. Nitrite levels in supernatants of moderately infected macrophages 
are reduced by DMTU and Ca-074Me. RAW macrophages were infected at an 
MOI of 0.5 or 10. Some wells infected at an MOI of 10 were pre-treated with L-
NAME, DMTU or Ca-074Me. Supernatant nitrite levels were measured at 24 hpi. 
All three compounds significantly decreased the amount of nitrites produced by 
moderately infected macrophages. Error bars represent mean ± SD. (****, P < 
0.0001). P values were determined by one-way ANOVA with Dunnett’s post hoc 
test. 
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Fig. 4.13. Cathepsin B activity is regulated by reactive oxygen species.  
Mean red fluorescence intensity of activated cathepsin B in cells infected at an 
MOI of 10 was calculated from ten microscopy images obtained from three 
independent experiments. Intensity was normalized to mock-infected control. The 
high level of cathepsin B activity in macrophages infected at an MOI of 10 was 
significantly reduced in DMTU-treated cells. Error bars represent mean ± SD. 
(***, P < 0.001). P values were determined by unpaired t-test.  
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Fig. 4.14. Evaluation of DCFDA fluorescence in moderately infected 
macrophages. Untreated RAW cells or cells treated with DMTU, L-NAME or 
Ca074-Me were infected at an MOI of 0.5 or 10. Macrophages were incubated 
with DCFDA to measure ROS levels at 24 hpi. Low fluorescence intensity was 
recorded from cells infected at an MOI of 0.5 and was not significantly affected in 
the presence of inhibitors. Macrophages infected at an MOI of 10 displayed 
strong DCFDA fluorescence that was dramatically reduced by the addition of 
DMTU and moderately affected by L-NAME and Ca-074Me. Error bars represent 
mean ± SD. (****, P < 0.0001; *, P < 0.05). P values were determined by two-way 
ANOVA with Bonferroni post hoc test. 
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CHAPTER 5 
DISCUSSION 
 
 A recurring theme in the evolutionary trajectories of intracellular pathogens 
is the degradation of the genome accompanied by niche restriction. A 
combination of host homeostasis and conserved host defense mechanisms have 
created relatively stable, predictable environments for obligate intracellular 
chlamydiae. So well-tuned are these bacteria to their respective hosts that 
human-adapted Chlamydia trachomatis, for instance, cannot survive in mice in 
spite of near-identity with the mouse pathogen C. muridarum. Much of this host-
pathogen incompatibility appears to arise from the fact that the primary host 
immune mediator IFN-γ elicits different responses in humans and mice to 
chlamydial infection (Fig. 5.1) (1).  
 It is well established that tryptophan depletion in human cells is the basis 
of the antimicrobial effect of IFN-γ against many intracellular pathogens including 
Toxoplasma and Chlamydia (2). Work from several groups has revealed how 
genital serovars of C. trachomatis have evolved to overcome tryptophan 
starvation in human cells. C. trachomatis contains a tryptophan biosynthesis (trp) 
operon that it utilizes along with imported indole to make its own tryptophan, 
thereby no longer relying on the host for this essential amino acid (3-5). The trp 
operon of C. trachomatis is located in the Plasticity Zone (PZ) which is a highly 
variable locus between otherwise conserved chlamydial genomes (6, 7). The C. 
muridarum PZ lacks the trp operon, making the mouse pathogen extremely 
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susceptible to IFN-γ in human cells (8). However, C. muridarum can survive in 
mice without the trp gene cluster because IFN-γ does not induce tryptophan 
starvation in murine cells. Instead, it upregulates a family of murine GTPases that 
specifically localize to C. trachomatis inclusions but not to those of C. muridarum 
(9). The GTPases recruit autophagic machinery to the C. trachomatis inclusions 
which results in their eventual destruction (10). The factors that C. muridarum 
employs to block these immunity GPTases from docking on to its inclusions have 
not been identified. A clue as to the location and expression of these chlamydial 
IFN-γ resistance factors (IRF) was provided when Nelson et al. showed that 
inactive C. muridarum EB could partially rescue C. trachomatis from GTPase-
mediated clearance (11). This implied that the C. muridarum IRF are pre-
packaged into EB and are either surface-exposed or released into the host cell 
upon chlamydial invasion. Since the trp operon in the C. trachomatis PZ 
contributes to immune evasion, we asked if the C. muridarum PZ also conferred 
protection by harboring IRF genes.  
 
 We examined the C. muridarum PZ in Chapter 2 by employing a reverse 
genetic technique called Targeting Induced Local Lesions in Genomes (TILLING) 
adapted for chlamydial mutational analysis (5). We screened a C. muridarum 
mutant library generated by several rounds of EMS mutagenesis for nonsense 
mutations in select PZ genes (Fig. 5.2). Aside from orf tc0431, all other targeted 
genes were found to be non-essential. tc0431 encodes a membrane attack 
complex/perforin (MACPF) domain-containing protein (8). MACPF has been 
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retained by only certain species of Chlamydia, and our inability to recover a C. 
muridarum MACPF nonsense mutant could indicate that the protein performs an 
essential function in the mouse pathogen (12). However, TILLING has its 
limitations in that very sick mutants may be lost from the EMS library. Thus, the 
indispensability of C. muridarum MACPF needs to be validated by other 
methods. Recent advances in chlamydial genetics now make it possible to 
transform chlamydiae and insertionally inactivate genes (13, 14). A technology 
called TargeTron, made commercially available by Sigma-Aldrich (St. Louis, MO) 
employs an intronII-based platform to insert mobile introns into specific sites 
within a target gene. Attempts will be made in the future to disrupt C. muridarum 
MACPF by TargeTron. 
 C. muridarum PZ genes that were found to be non-essential include 
putative cytotoxin orfs tc0437 – tc0439, a phospholipase D gene tc0440 and a 
guaBA – add nucleotide synthesis operon tc0443 – tc0441. All isolated PZ 
mutants displayed mild growth defects, but whether these defects were caused 
by mutations in the PZ as opposed to background mutations could not be 
distinguished. Previous studies have suggested that cytotoxin orfs encode IFN-γ 
resistance factors and are also responsible for the cytotoxicity associated with C. 
muridarum EB at high multiplicities of infection (11, 15). An examination of the 
cytotoxic potential of the toxin mutants revealed that tc0437 – and tc0439 – did in 
fact induce less cell damage than the C. muridarum wild-type parent. However, 
none of the toxin mutants displayed any sensitivity to IFN-γ in murine cells. Other 
PZ mutants also retained wild-type resistance to the cytokine, implying that the 
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IRF were likely encoded by genes outside the PZ. The reduced cytotoxicity 
associated with tc0437 – and tc0439 – strongly indicate that these orfs are 
functional and induce cytopathic damage. Whether tc0438 is non-functional or 
plays an unrelated role in chlamydial infection needs to be evaluated. Since 
infection with tc0437 –  and tc0439 –caused some cytotoxicity, whether the 
chlamydial cytotoxins have additive roles will need to be assessed by creating a 
mutant lacking all three toxins.  
 Infection of the mouse genital tract (GT) with C. muridarum PZ mutants 
revealed no dramatic differences in terms of infectious burden or duration of 
infection. These results, combined with the retention of resistance to IFN-γ in 
vitro, suggests that individual PZ genes do not confer survival advantages to C. 
muridarum in the GT. This does not necessarily imply that C. muridarum PZ 
genes are non-functional. Assuming they encode proteins with niche-specific 
roles, they might function only in the relevant host tissue. The C. muridarum 
mouse GT model is an artificial system that has been employed because of its 
close resemblance to human chlamydial disease (16). However, C. muridarum 
was originally isolated from mice lungs and studies suggest that it might be a gut 
pathogen (17, 18). Future work will involve the analysis of PZ mutants for their 
ability to infect and colonize the mouse lung and gut. Since we know that PZ 
genes are dispensable, PZ-null mutants will be generated by TargeTron to avoid 
the complication of EMS-induced background mutations.  
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 Since the PZ genes targeted by TILLING did not appear to encode C. 
muridarum IRF, we embarked on a forward genetic screen described in Chapter 
3 to identify putative IRF genes. 31 mutants with varying degrees of sensitivity to 
murine IFN-γ were isolated from an EMS-derived C. muridarum mutant library. 
Whole genome sequencing of four selected IFN-γ-sensitive mutants (igs1 – igs4) 
revealed multiple mutations in each strain. All four strains were found to carry 
inactivating mutations in tc0412; however, the gene was discovered to be 
polymorphic in the population. We therefore focused our efforts on igs4 since it 
displayed the greatest sensitivity to IFN-γ. A suppressor screen yielded multiple 
revertants that restored IFN-γ resistance to igs4. Sequence analysis indicated 
that most revertants contained additional mutations in tc0574 aside from the 
original missense mutation in igs4. Interestingly, many of the suppressor 
mutations were predicted to inactivate TC0574. This suggested that the original 
tc0574 missense mutation in igs4 was a deleterious gain-of-function mutation 
and that loss of the protein in the revertants allowed them to overcome IFN-γ-
mediated inhibition.  
 As mentioned previously, IRF present in inactive C. muridarum wild-type 
EB can rescue C. trachomatis from IFN-γ responses in murine cells (11). Since 
ig45 was nearly as sensitive to IFN-γ as C. trachomatis, we hypothesized that 
igs4 EB would be unable to rescue C. trachomatis from inhibition in IFN-γ-treated 
murine cells. However, co-infection of inactive igs4 EB with C. trachomatis 
caused a significant increase in C. trachomatis infectious yield that was 
comparable to the rescue observed with wild-type C. muridarum EB. This 
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indicates that igs4 contains some intact IRF but is still sensitive to IFN-γ. These 
results imply that the IFN-γ resistance phenotype is more complex than 
previously envisioned. That no other sequenced igs mutant (igs1 – ig3) contained 
mutations in tc0574 also supports the notion that multiple independent effectors 
contribute to C. muridarum IFN-γ resistance. Efforts are underway to conduct a 
saturating screen for additional chlamydial factors that mediate resistance to IFN-
γ. 
 Examination of igs4 infection course and duration in the mouse GT 
revealed severe attenuation of the mutant in comparison to wild-type C. 
muridarum. Shedding from mice infected with igs4 revertants was similar to that 
from mice inoculated with wild-type C. muridarum, confirming that the in vitro 
suppressors also restored virulence to the igs4 mutant in vivo. Surprisingly, igs4 
remained attenuated in IFN-γ –/– mice, implying that other host effectors were 
sufficient to control igs4 infection in mice. That resolution of igs4 occurs rapidly in 
mice suggests that IFN-γ-independent innate mechanisms may be sufficient for 
the clearance of igs4. Epithelial cells in the female urogenital tract produce type-1 
interferons including IFN-β and IFN-ε that share the regulation of many pathways 
with IFN-γ (19-21). We found that igs4 was equally sensitive to IFN-β in McCoy 
cells. Whether type-1 interferons are responsible for igs4 attenuation in mice will 
be tested by infecting mice that are incapable of responding to both type I and 
type II interferons. 
 The mutated gene tc0574 that confers IFN-γ sensitivity to igs4 is predicted 
to lie in an operon with tc0573, and RT-PCR analysis in Chapter 4 indicated that 
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orfs tc0572 – tc0574 are expressed as part of a single transcript. Interestingly, an 
igs4 revertant was found to contain a missense mutation in tc0573 that abolished 
the start codon. Two possibilities exist to explain how a mutation that prevents 
tc0573 translation affects the expression of tc0574: 
1) Rho-dependent termination of RNA polymerase transcription:  
 If a large segment of mRNA remains unbound by ribosomes, a Rho factor 
can bind to rut (rho utilization) sites in the region. Upon binding, Rho uses its 
ATPase activity to move along the RNA until it subsequently catches up with 
RNA polymerase to terminate transcription.  
2) Translational coupling: 
 When genes are translationally coupled, the translational efficiency of one 
gene is interdependent on another. While the exact mechanism is not well 
understood, a widely accepted theory is that when a gene is not being actively 
translated, it allows the formation of secondary mRNA structures that inhibit 
ribosomal binding to the downstream gene mRNA.  
 In the scenario of Rho-dependent termination, the mutation in tc0573 
would result in decreased levels of tc0574 mRNA. However, we did not find any 
differences in tc0574 mRNA levels between wild-type C. muridarum, igs4 and the 
tc0573 revertant. This suggests that tc0573 and tc0574 are translationally 
coupled. To confirm this, a comparison of TC0574 protein levels in wild-type, igs4 
and the tc0573 revertant by western blotting is required.    
 TC0573 and TC0574 are predicted to contain Inc domains that would 
result in their localization to the chlamydial inclusion membrane (22). While no 
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function has been attributed to these proteins, our results indicate that TC0574 is 
not essential for growth in cell culture and virulence in mice. Interestingly, some 
igs4 inclusions ruptured early during infection even in the absence of IFN-γ, and 
the addition of the cytotokine dramatically exacerbated this phenotype. This 
observation, combined with its dispensability, leads us to propose that wild-type 
TC0574 has a redundant function at the inclusion membrane, but the mutated 
protein in igs4 leads to inclusion membrane instability, perhaps due to a 
conformational change. Interestingly, a BLAST search for homologous proteins in 
other species of Chlamydia returned only two proteins with very low identity 
scores, one found in C. trachomatis and the other in C. caviae. A Phyre2 
structure prediction for TC0574 and the C. trachomatis serovar D homolog 
generated models where both proteins contained two α-helices in different spatial 
arrangements (23). The helices in TC0574 are packed together, with the glycine 
residue that is mutated in igs4 located at the interacting surface. The glycine ⇒ 
glutamate substitution in igs4 could cause the protein to adopt a conformation 
that is similar to the C. trachomatis protein. How these different predicted 
conformations alter protein function needs to be determined.   
 Future studies will focus on identifying the mechanism that contributes to 
the IFN-γ sensitivity displayed by igs4. It will also be important to confirm that 
tc0574 is expressed and if it localizes to the inclusion membrane. We have 
determined the mutant is not sensitive to IFN-γ-induced nitric oxide or reactive 
oxygen species, but whether it can actively block the localization of IFN-γ-
regulated GTPases to its inclusions requires investigation.  
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 While IFN-γ-dependent adaptive cellular immunity is crucial for resolving 
chlamydial disease, innate phagocytic cells (neutrophils and macrophages) act 
as first responders at the site of infection and orchestrate the immune response 
against Chlamydia. Surprisingly, some species of Chlamydia are capable of 
survival and limited replication within the hostile environment of macrophages, a 
property that correlates with invasive disease and chronic inflammation. The 
parameters that contribute to chlamydial growth or persistence within 
macrophages have not been well defined.  
 Chapter 4 was born out of the observation that the survival of C. 
muridarum in RAW 264.7 macrophages depends on the multiplicity of infection 
(MOI). An MOI of 2 or lower was optimal for a productive infection; however, 
MOIs ranging from 3 to 100 resulted in a corresponding decrease in chlamydial 
yield from macrophages. C. muridarum could not be recovered from cells 
infected at an MOI of 100 because these high infectious doses resulted in 
immediate macrophage death. In contrast, chlamydial inhibition by macrophages 
infected at more moderate doses was found to occur because of macrophage 
activation. Activated RAW cells expressed high levels of inducible nitric oxide 
synthase (iNOS) and secreted inhibitory factors into culture supernatants.  
Accordingly, an inhibitor of iNOS fully restored chlamydial growth in infected 
cells. We found that TLR2, but not TLR4, was required for the activation of 
macrophages by C. muridarum; however, the cognate chlamydial antigen has not 
been identified. Complete chlamydial inhibition by macrophages required the 
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presence of live, transcriptionally active C. muridarum, indicating that at least one 
antigen was present only in replicating chlamydiae.  
 A new pathway of iNOS regulation was discovered in RAW macrophages 
when an inhibitor of cathepsin B and a hydoxyl radical scavenger were found to 
rescue C. muridarum by blocking iNOS induction. Further investigation revealed 
that reactive oxygen species (ROS) controlled cathepsin B activation. Our current 
model of chlamydial inhibition in RAW macrophages can be described as follows: 
an intermediate multiplicity of infection is not immediately cytotoxic, but instead 
provides enough chlamydial antigen for macrophage activation. Once activated, 
increased accumulation of macrophage ROS either directly or indirectly 
enhances lysosomal cathepsin B activity. Active cathepsin B, in turn, upregulates 
iNOS expression. The resulting production of nitric oxide effectively eradicates 
intracellular chlamydiae.  
 Several questions regarding macrophage chlamydial inhibition need to be 
addressed. Firstly, is the described mechanism of iNOS regulation in infected 
RAW cells conserved in primary macrophages? Second, what are the 
intermediate steps between ROS production, cathepsin B activation and iNOS 
induction? Finally, can this observation in macrophages be extrapolated to  
chlamydial infection in mice and humans? Past research has indicated that 
disease outcome in murine and lung models of chlamydial infection is linked to 
the inoculating dose and the quantity of nitric oxide released by macrophages, 
thus lending support to our in vitro findings.  
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 In summary, our genetic and immunological studies have examined 
important host immune mechanisms that control chlamydial infection in cell 
culture and mice. We find that both host and pathogen have evolved multiple 
defense strategies that allow coexistence. Further genetic investigation on the 
biology of chlamydiae will reveal new adaptive mechanisms to assist in the 
design of  effective therapeutics against these pathogens.  
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Fig. 5.1. C. trachomatis and C. muridarum behave dissimilarly in mice.  
(A) C. muridarum (MoPn) infection of IFN-γ knockout mice (B6.IFN-γ-/-) does not 
significantly differ from MoPn infection in wild-type C57BL/6 mice. (B) C. 
trachomatis serovar D is cleared from C57BL/6 mice at around 10 days post 
inoculation. Course of infection in B6.IFN-γ-/- of serovar D is more similar to that 
of MoPn.  
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Fig. 5.2. Targeting Induced Local Lesions IN Genomes. Schematic 
description of the TILLING mutagenesis protocol.  
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Fig. 5.3. Phyre2 modeling of C. muridarum TC0574 and its C. trachomatis 
homolog. C. muridarum TC0574 (left) contains two predicted α-helices. The 
mutated glycine residue in igs4 and interacting neighboring residues are colored 
using PyMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC). The 
α-helices in the C. trachomatis serovar D TC0574 homolog (right) are positioned 
away from each other.  (N, N-terminal; C, C-terminal).  
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